Mathematical modelling of the effectiveness of two training interventions on infectious diseases in Uganda by Ssebuliba, Doreen
Mathematical Modelling of the Effectiveness of Two
Training Interventions on Infectious Diseases in
Uganda
by
Doreen Ssebuliba
Supervisor: Dr. Rachid Ouifki
Dissertation presented at the University of
Stellenbosch for the degree of
Doctor of Philosophy
Department of Mathematical Sciences
University of Stellenbosch
December 2013
Declaration
I, the undersigned, hereby declare that the work contained in this thesis is my own
original work and has not previously, in its entirety or in part, been submitted at any
university for a degree.
- - - - - - - - - - - - - - - - - - - - - - -
Doreen Ssebuliba Date
Copyright ©2013 Stellenbosch University
All rights reserved
Stellenbosch University  http://scholar.sun.ac.za
Abstract
Nurses, midwives and clinical officers referred to as Mid-level Practioners (MLPs) play
an important role in the health care system especially in rural Africa. With particular
reference to rural Uganda, due to the large shortage of doctors, MLPs handle most of
the duties usually meant for doctors, at health centre IV(s). From 2009 to 2011, two
training interventions of MLPs were performed at 36 sites in Uganda by the Integrated
Infectious Disease Capacity Building Evaluation (IDCAP). The two interventions were:
Integrated Management of Infectious Diseases (IMID) and On-site Support Services (OSS)
which aimed at improving MLPs’ case management for four diseases: HIV, TB, pneumonia
and malaria. In this thesis, we have developed three mathematical models to investigate
the effect of the two training interventions on these infectious diseases. All the models
are formulated using systems of ordinary differential equations which are structured in
three age groups: [0, 5), [5, 14) and [14, 50). We explored the effect of the two training
interventions in the context of malaria-pneumonia, HIV-TB co-infections and the four
diseases together. Our analysis shows that: i) For malaria-pneumonia, both IMID and
the combination of IMID and OSS reduce the number of cases, deaths and prevalence of
disease but have no effect on the incident episodes of disease. ii) Results from the HIV-
TB model propose that HIV and TB testing are important steps in quality of health care
and are capable of offsetting slightly negative effects of reduction in ART enrollment and
provision of treatment. iii) The HIV-TB-malaria-pneumonia (HTMP) model concurs with
the results of the first two models and its results demonstrate that high coverage levels
of the training interventions increase the positive effects that the interventions have on
mortality and morbidity. Overall, our results suggest that training of MLPs is much more
effective for the short term duration diseases such as malaria and pneumonia, where the
baseline values for most of the performance indicators are ≥ 0.6, but not so much for
long term duration diseases such as HIV and TB, whose baseline values for most of the
performance indicators are < 0.6. The results further highlight that problems such as case
detection and drug stock-outs need to be addressed in order for training to have substantial
impact, especially in instances where the performance indicator proportions are low.
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Opsomming
Verpleegsters, vroedvroue en kliniese beamptes wat gesamentlik na verwys word as mid-
vlak praktisyns (MVPs) , speel n belangrike rol in die gesondheidsorg sisteem, veral in
landelike dele van Afrika. Met spesifieke verwysing na gesondheid sentrums in Uganda,
waar daar te min dokters is, hanteer MVPs die meeste van die pligte wat eintlik deur
dokters verrig moet word. Vanaf 2009 tot 2011 is twee opleidingsprogramme vir MVPs by
36 fasiliteite in Uganda deur die Integrated Infectious Disease Capacity Building Evalu-
ation (IDCAP) organisasie aangebied. Die twee programme staan bekend as: Integrated
Management of Infectious Diseases (IMID) and On-site Support Services (OSS). Beide die
programme stel ten doel om die MVPs se pasint bestuur vir die siektes MIV, tuberkulose
(TB), longontsteking en malaria te verbeter. Drie wiskundige modelle word in hierdie tesis
ontwikkel om die effek van die opleidingsprogramme op hierdie oordraagbare siektes te
ondersoek. Al die modelle word geformuleer deur gebruik te maak van stelsels van gewone
differensiaal vergelykings wat gestruktureer is in drie ouderdomsgroepe: [0, 5), [5, 14) en
[14, 50). Die effek van die opleidings programme word in die konteks van longontsteking-
malaria mede-infeksie, MIV- TB mede-infeksie en al vier siektes gelyk, ondersoek. Die
analise wys dat: i) Vir longontsteking-malaria mede-infeksie het beide IMID en die kombi-
nasie van IMID en OSS die aantal siekte-gevalle, sterftes en die prevalensie van die siektes
verminder, maar het geen effek op die insidensie van siekte-gevalle nie. ii) Resultate van
die MIV-TB model dui aan dat MIV en TB toetsing n belangrike aspek van die gehalte
van sorg is en dat dit die effense negatiewe effek van die afname in ART inskrywing en
voorsiening van behandeling, teenstaan. iii) Die MIV-TB-longontsteking-malaria model
(HTMP) stem ooreen met die resultate van die bogenoemde twee modelle en demonstreer
dat ho dekking van die opleidingsprogramme die positiewe effek van die programme op
mortaliteit en morbiditeit verhoog. In geheel stel die resultate van hierdie studie voor
dat die opleiding van MVPs baie meer effektief is vir die korttermyn siektes soos malaria
en longontsteking waarvoor die meeste van die beginwaardes van die prestasie-aanwysers
≥ 0.6 is, maar nie soveel vir lang-termyn siektes soos MIV en TB waarvoor die meeste
van die beginwaarde van die prestasie-aanwysers < 0.6 is. Die resultate dui verder aan dat
opleiding nie voldoende is wanneer die prestasie-aanwysers < 0.6 is nie en dat probleme
soos die opsporing van siekte-gevalle en n gebrek aan medisyne by die klinieke aangespreek
moet word vir opleiding om aansienlike impak te he.
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Chapter 1
Introduction
1.1 Background: Infectious diseases
In this world that is faced with disease, the need to develop and strengthen existing health
systems is necessary. This has been done mainly through provision of equipment and drugs,
capacity building and advances in technology. Moreover, in developing countries such as
Uganda, the need to increase manpower and build capacity to handle infectious diseases
has been noted.
Infectious diseases are caused by micro-organisms such as bacteria, fungi, viruses or para-
sites. They are transmitted directly or indirectly from one person to another. Direct trans-
mission may be through contact with droplets from an infected individual by coughing,
sneezing, talking, singing, kissing as is the case with TB and pneumonia. Other diseases
such as infection with HIV are spread mostly through sexual intercourse. Transmission
may also be indirect by involving a vector as is the case with malaria.
1.1.1 Malaria
Malaria is a vector-borne disease that is transmitted by the female anopheles mosquito
and caused by a parasite, plasmodium. There are four different species leading to malaria
infection and disease among humans. These are: plasmodium falciparum, plasmodium
vivax, plasmodium malariae and plasmodium ovale. Plasmodium falciparum is the most
1
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common and life threatening.
In 2009, World Health Organisation (WHO) [201] estimated that the number of malaria
cases were 225 million and the number of deaths were 781, 000. In 2008, malaria accounted
for 8% of all deaths in children less than five years of age globally and 27% of all deaths
in children less than five years of age in Africa [201].
Malaria life cycle starts with plasmodium parasites entering the human blood stream in
the form of sporozoites that are injected by infected female anopheles mosquitoes while
taking a blood meal. After infection, most of the sporozoites migrate to the liver where
they invade the liver cells and multiply forming merozoites. The merozoites are released
into the blood stream, they attack the red blood cells and lead to the development of
the asexual multiplication cycle. A proportion of the merozoites develop into gametocytes
which are the transmissible form of the parasite to the mosquito. These are ingested by
mosquitoes and go on into the mid gut of the mosquito after developing into oocysts. They
are then taken into the salivary glands as sporozoites waiting to be injected into a human
and the cycle continues as before.
1.1.2 Pneumonia
Pneumonia is an inflammatory condition of the lung. It affects the alveoli mostly and
is associated with fever, rapid respiratory rate, difficulty in breathing, chest in-drawing,
abnormal chest sounds and a lack of air space on a chest X-ray. It results from infection
by bacteria, viruses, fungi and parasites and these can be acquired outside of health care
settings or in a health care setting.
While there are a number of pathogens that cause pneumonia, infection by Streptococcus
pneumoniae (S. pneumoniae) is the most common cause. The different kinds of pneumonia
derive their names from the pathogen of infection or from the setting in which they are
acquired.
Thus there is bacterial pneumonia (mostly occurs after bacteraemia -presence of bacteria
in blood), viral pneumonia, community-acquired pneumonia, hospital-acquired pneumonia,
to mention but a few. Pneumonia is also classified as an Acute Respiratory Infection (ARI).
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Globally, it is estimated that over two million children under five die from pneumonia per
year [119, 161]. WHO also estimates that up to one million of these deaths are caused by
Streptococcus pneumoniae and over 90% of these deaths occur in developing countries.
Pneumonia occurs because of a weakening of the host defences, invasion by virulent organ-
ism or invasion by a large inoculum of infectious agent [116].
It mostly follows an upper respiratory tract illness that permits invasion of the lower respi-
ratory tract by bacteria, viruses, or other pathogens that trigger an immune response and
produce inflammation [116]. The agents that cause lower respiratory tract infection are
most often transmitted by droplet spread resulting from close contact with a source case.
Most bacterial pneumonias are the result of initial colonization of the nasopharynx followed
by aspiration or inhalation of organisms [116].
Invasive disease most commonly occurs upon acquisition of a new serotype of the organism
with which the patient has not had previous experience, typically after an incubation period
of one to three days.
1.1.3 Human Immunodeficiency Virus (HIV)
HIV is the causative agent of AIDS. It targets the immune system of the infected individual
and weakens it making the individual incapable of resisting attack from a wide range of
infections such as TB, Kaposis Sarcoma, malaria and pneumonia.
Transmission of HIV occurs via exchange of body fluids such as blood, breast milk, semen
and vaginal secretions from the infected individual to the uninfected one.
Following infection with HIV, development of AIDS in infected individuals may take 2 to
15 years [202] and it is characterised by development of certain cancers such as Kaposis
Sarcoma and other diseases such as active TB.
WHO estimated that there were approximately 34 million people living with HIV in 2011
with Sub-Saharan Africa (SSA) being the most affected region with almost one in every
20 adults living with HIV [202].
Currently, there is no cure for HIV infection but there exists effective treatment with
antiretroviral drugs that can control the virus such that individuals can have healthy and
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productive lives.
In 2011, WHO estimated that more than 8 million people living with HIV were receiving
Antiretroviral Therapy (ART) in low and middle-income countries [202]. By the end of
2011, 54% of the people eligible for treatment were receiving ART.
1.1.4 Tuberculosis (TB)
TB is an airborne infection caused by Mycobacterium Tuberculosis (MTB). It typically
attacks the lungs but can also affect other parts of the body. TB infection occurs when
droplet nuclei containing tubercle bacilli are inhaled into the lungs and deposited in the
alveoli. It is spread when individuals with active TB disease cough, sneeze, laugh or sing.
Most of the infections are latent and about 10% of these latent infections progress to active
disease. However, in those with HIV, the risk of developing active TB increases to nearly
10% per year [10, 33].
In 2009, WHO estimated that there were 9.4 million incident cases of TB and 1.3 million
deaths due to TB among HIV-negative cases globally [200]. With HIV-TB coinfected
individuals considered, there were 1.7 million deaths due to TB globally.
1.2 Control of infectious diseases
Over 9.5 million deaths annually are attributable to infectious diseases and nearly all of
them occur in developing countries [196]. In Uganda, over 70% of years of life lost are due
to infectious diseases [204].
Control and management of the spread of infectious diseases can be done through various
interventions such as case detection and treatment for TB, use of bed-nets, mosquito
spraying, use of antimalarials for malaria, use of antibiotics for pneumonia and use of
condoms, cotrimoxazole prophylaxis use and ART roll out for HIV.
Though such interventions are in existence, many people, especially in rural Africa, with
particular reference to Uganda, lack access to needed preventive and treatment care. This
is worsened by the poor and weak health systems characterised by lack of appropriate
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infrastructure, insufficiently trained personnel, drug stock outs, to mention but a few [100,
135, 155].
Improvement is needed in all areas of the health system and it is important that human
capacity is built to handle the rising demand of health services. Moreover, due to the
shortage of doctors, it has been noted that Mid-Level Practitioners (MLPs) are taking on
duties that are meant for doctors even though, in some cases they are not well equipped
to handle those duties. This calls for training initiatives to facilitate and equip MLPs.
1.3 Training interventions
These have been disease specific for the most part and have evaluated the quality of care
through intermediate outcomes such as proportion of patients who are referred for labo-
ratory testing and those who are prescribed appropriate medication [143, 180]. Though
there is evidence that shows improvement in case management with disease specific train-
ing [143, 180], some studies have shown that it may worsen quality of care for another
disease that is not being considered [154, 158].
Moreover, training methods have largely been classroom based with little or no follow-up
reinforcement and no supervision, even though existing evidence suggests that knowledge
gained through classroom training is not applied when the trainee returns to his/her real
world clinical setting [42], and that on-site training and supervision [146, 147] can have a
positive effect on clinical practice [155]. In addition, little work has been done on evaluating
training methods, and training approaches differ in both course content and delivery.
With the global health community being geared towards training a considerable number
of health workers as was evidenced by the President’s Emergency Plan For AIDS Relief
(PEPFAR)’s reauthorisation bill of 2008, there is a need to know which training approaches
yield the best and most lasting results.
It is in this regard that Integrated Infectious Disease Capacity-Building Evaluation (ID-
CAP) carried out a study at 36 sites in Uganda to evaluate the effectiveness of two training
approaches: Integrated Management of Infectious Diseases (IMID) and On-site Support
Services (OSS) [62, 122]. It built on the already existing WHO’s Integrated Management
of Childhood Illness (IMCI) and Integrated Management of Adult Illness (IMAI) training
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programs.
1.4 Motivation of project
The shortage of doctors in sub-Saharan Africa (SSA) has led to a shift in handling of health
tasks. Duties that were conventionally carried out by doctors are now being handled by
MLPs. Moreover, MLPs report that they lack enough training to carry out such activities
[112] and other studies have noted that MLPs do not have adequate skills and knowledge
for integrated management of diseases [139, 153].
Besides, the effect of training of MLPs has focused on intermediate outcomes on the qual-
ity of care [132, 143, 180] and little on final outcomes such as morbidity and mortality.
The reason for this being that statistical analysis of data is limited since it only shows
the impact of the interventions on the intermediate outcomes, and deals with one disease
at a time. Moreover, it is hypothesised that if demonstrated effectiveness of training is
maintained and the intervention is expanded to achieve sufficient coverage levels, it could
result in considerable impact on population health [155]. It is in this regard that use of
a mathematical model is helpful in providing information about the incidence, prevalence
and mortality of disease in the population.
A mathematical model provides a framework for synthesizing all available information (de-
mographical, epidemiological and programmatic (IMID and OSS)) and producing quanti-
tative results. It can be used for short term and long term projections of the impact of the
interventions being studied and also investigate insightful scenarios. Furthermore, it can
be used in an integrated framework of two or more diseases.
It is for this reason that we employ the use of mathematical models in this thesis which
will help in quantifying the effects of the two training interventions that were carried out
by IDCAP at 36 sites in Uganda. Addressing this gap in knowledge is very important and
we are thus motivated to do this work due to the impact it can have on health policy in
Uganda and Africa at large.
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1.5 Objectives of the study
The main goals of the study are:
1. To review literature on the four infectious diseases of malaria, pneumonia, TB and
HIV and on training interventions.
2. To develop mathematical models of malaria-pneumonia co-infection, HIV-TB co-
infection and co-infection of the four diseases.
3. To link data on case management of disease to transmission dynamics of the diseases.
4. To investigate whether training interventions have an impact on mortality, prevalence
and incidence of disease.
1.6 Description of project
The primary purpose of this research project is to formulate mathematical models that
help to quantitatively study the effect of two training interventions on management of
infectious diseases. The training interventions (IMID and OSS) were implemented at 36
sites in Uganda. The sites were grouped into 2 Arms, Arm A and Arm B with 18 sites
each. Both Arms received IMID and Arm A was given OSS. Data were collected and we
fitted our models to these data using an optimization tool built in Matlab. More on the
IDCAP project is given in Chapter 3.
We formulated three mathematical models, the third being a combination of the first two.
⋆ The first model deals with malaria and pneumonia coinfection. We use the model
to assess the effect of IMID and the combination intervention of IMID and OSS on
health outcomes such as morbidity and mortality. We also estimate the incremental
impact of OSS and investigate the scenario of only doing triage of severe disease
cases.
⋆ The second model considers the coinfection of HIV and TB. It is used to explore the
effect of the two training interventions on the management of HIV and TB in terms
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of ART enrollment, TB case management and health outcomes such as deaths. We
conclude by predicting the effectiveness of IMID and OSS for five more years.
⋆ Model three is a combination of model one and model two. It is an integrated model
that considers all the four diseases together, that is HIV, TB, malaria and pneumonia.
It is used to investigate the effect of IMID and IMID+OSS in line with an integrated
approach of managing all the four diseases. The effectiveness of the interventions is
measured in terms of considering the number of deaths that occur with and without
the interventions. We also run numerical simulations to determine the effectiveness of
the two interventions with a 25% effect on performance indicators and high coverage
levels.
1.7 Project outline
In Chapter 2, we present a literature review on mathematical modelling of infectious dis-
eases, HIV, TB, malaria and pneumonia and also literature on training interventions.
Chapter 3 gives the IDCAP data and describes the parameters that were obtained from
the IDCAP project. In Chapter 4, we look at the model of malaria and pneumonia coinfec-
tion and the effect of IMID and combination of IMID and OSS on malaria and pneumonia
case management. Chapter 5 is devoted to the modelling of HIV and TB coinfection and
also explores the effect of training on management of TB and HIV cases. We then get an
overview of an integrated model of the four infections, HIV, TB, malaria and pneumonia
and examination of the effect of training with regards to managing these four diseases in
Chapter 6. We conclude in Chapter 7 with some recommendations and ideas for future
research.
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Literature Review
2.1 Introduction
In this chapter, we will review some mathematical models of malaria, pneumonia, TB,
HIV, HIV-TB coinfection and literature on training interventions on infectious diseases.
There is a considerable amount of literature on these diseases and many models have been
developed for their transmission dynamics. We focus on models which incorporate inter-
ventions and are important for our study.
Most commonly used words in this chapter are: susceptibles (individuals who are not in-
fected), latent (infected but not infectious), asymptomatic (infected, can transmit infection
but lack symptoms), infectious (infected and can transmit the infection) and symptomatic
(infectious with symptoms).
2.2 Malaria models
In this section, we review mathematical models of malaria that are most relevant to our
work. We consider compartmental and deterministic models of ordinary and partial dif-
ferential equations. Starting from the basic Ross model, we work our way to malaria
models which incorporate age structure, immunity and interventions and we discuss how
our malaria model relates to the already known and published models.
9
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Basic models
In his early work on malaria, Ross proved the role of certain mosquitoes in the transmission
of malaria [8, 160]. He built mathematical models to explain his theory that control of
malaria could be done by reducing the number of mosquitoes. He also sought answers to
why the disease varied from place to place and even in the same place, from season to
season or from year to year [160]. Ross considered two differential equations [8, 115], one
for the number of infected humans with malaria and another for the number of infected
mosquitoes. His conclusions from this study were that the increase or decrease of malaria
depended on a certain threshold in the number of mosquitoes and it was not necessary to
eliminate all the mosquitoes in order to eradicate malaria. This model was later modified
by Macdonald by considering proportions of infected mosquitoes and humans instead of
numbers and is popularly known as the Ross-Macdonald model [115].
Macdonald extended the model by Ross to account for the latency period of the parasite
in mosquitoes [96, 115] by introducing the latent class for mosquitoes and this model was
later extended by Anderson and May [5] to include a latent class in humans as well. This
idea of latency showed that survival of the adult female mosquito was very important in the
spread of malaria and this provided the rationale for a campaign by WHO to use insecticide
DDT to kill mosquitoes. Furthermore, these models focused on studying the parameters of
the mosquitoes such as biting rate, the death rate and the ratio of mosquitoes to humans
to explain how spread of malaria could be controlled.
There are other factors such as age and immunity of an individual, climate and environment
of an area that influence malaria that were not incorporated in the first four models we
reviewed. For the case of age and immunity, malaria infection depends on an individual’s
age and individuals tend to gain immunity as they grow older. Immunity can be described
in a number of responses such as: loss of infectivity, increase in recovery rate, loss of
detectability and decrease in susceptibility [46, 59].
Age structure
Anderson and May included age structure in the Ross model by considering the population
of humans as a function of time and age [5, 115]. This improved on the basic Ross model
but its predictions did not match the data well which made it clear that the interaction
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between age and immunity should be modelled explicitly.
Immunity
The model by Dietz et al. [46] used non linear difference equations to define the dynamics
of the human population. Immunity was assumed as being in the form that a vector which
bites a non-immune host is more infectious than a vector that bites an immune host. Three
aspects of immunity were considered, loss of infectivity, increase in recovery and decrease
in detectability. The model was fitted to data and there was some agreement between the
observed data and the model values.
In [26], Boni et al. used a model that considered the concept of semi-immunity to study the
effect of multiple first line therapies in presence of resistance evolution in strains of malaria
parasites. The model had three major classes: susceptible class, asymptomatic class and
symptomatic class. The concept of immunity was summarised in the way individuals re-
sponded to malaria infection and their infectiousness potential. Individuals who were naive
easily developed symptoms after infection while semi-immune hosts rarely developed symp-
toms after infection. Both naive and semi-immune hosts in asymptomatic class progressed
to symptomatic disease with naive individuals developing clinical disease more often than
semi-immune hosts. Semi-immune hosts were considered to be less infectious than naive
hosts.
Age and Immunity
Filipe et al. [59] used a model of a system of partial differential equations of age and time. It
examined the development and acquisition of immunity to malaria. In the model, acquired
immunity was represented by three immunity functions which are responses to malaria.
These were: reducing the likelihood that an infected person develops symptomatic disease,
increasing the rate at which infection is cleared and also increasing the duration of low-level
infections. The model suggested that immunity to symptomatic disease lasts for at least
5 years, and develops faster if there are higher levels of infection in the population, and
increases with age. Immunity to clear infection lasts longer (it can last for 20 years or
more), develops later in life, and does not depend on the amount of transmission in the
population. On the other hand, the clearance of low-level infections was not important in
explaining the epidemiological trends observed.
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Okell et al. [151], developed a deterministic age-structured mathematical model with five
states: susceptibles, latent, infectious and untreated, infectious and treated, and protected,
to study the impact of Artemisinin Combination Therapy (ACT) on malaria transmission
intensity. Immunity was modelled by incorporating age-dependency in the probability that
an infectious bite develops into a blood stage infection, the proportion of infections which
become symptomatic, the rate at which infection progress to the final low-level infection
stage and the infectiousness to mosquitoes. Data from a survey in Tanzania was used to
characterise rates of infection, symptomatic episodes and use of antimalarials before the
introduction of ACT. The results from the model suggested that ACTs have the potential
to reduce transmission to levels approaching those achieved by insecticide-treated nets in
lower transmission settings.
Seasonality
Bacae¨r [7] gave an approximate formula involving two terms for the basic reproduction
number, R0 of a vector-borne disease when the vector population has small seasonal fluc-
tuations of a periodic nature. The basic reproduction number R0 is defined through the
spectral radius of a linear integral operator and numerical methods for the computation of
R0 are given.
Dembele et al. [44] studied a malaria model with periodic mosquito birth and death rates.
They used periodic coefficients in the system of one-dimensional equations and these ac-
counted for the seasonal variations (wet and dry seasons) in the mosquito birth and death
rates. An R0 is defined for periodic coefficients and it is shown that the disease goes ex-
tinct if R0 is less than unity and it is endemic if it is greater than unity and may even be
periodic.
Chitnis et al. [37], developed and analysed a periodically-forced difference equation of
model for malaria in mosquitoes that captured the effects of seasonality and allowed the
mosquitoes to feed on an heterogeneous population of hosts. Their numerical results showed
the existence of a unique globally asymptotically stable periodic orbit and periodic orbits of
field-measurable quantities that measure malaria transmission. They also used the model
to compare the effects of insecticide-treated nets and indoor residual spraying on malaria
transmission, prevalence and incidence and it was found that insecticide-treated nets were
more effective in reducing malaria transmission and prevalence than indoor residual spray-
Stellenbosch University  http://scholar.sun.ac.za
Chapter 2. Literature Review 13
ing but indoor residual spraying takes less time to eradicate malaria. The results showed
that the interventions’ reduction in malaria transmission is offset with an increase in clinical
malaria.
Though our mosquito birth rate is time dependent and accounts for the effects of season-
ality, it is not periodic. The articles we have reviewed helped us in understanding the
importance of seasonality and how this may be modelled in mathematical models.
Case management
Tediosi et al. [186], developed a dynamic model that incorporated case management of
malaria into it. Their argument was that most models of cost-effectiveness of malaria
control interventions assume that incidence of illness and transmission of disease are inde-
pendent of the case management system, yet the management of disease in the health care
system has potential impact on malaria transmission and incidence. Their model compares
outcomes of different case management regimens in different transmission settings and it
considers asymptomatic malaria, symptomatic malaria and severe malaria. Though it dif-
fers from our model in that it is a combination of dynamic model of stochastic simulation
with decision tree analysis and it was constructed to look at cost-effectiveness, it raises the
importance of incorporating transmission dynamics of disease with the health care system.
In summary, the Ross and Ross-Macdonald [8, 115, 160] models motivated our development
of a relatively simple model, since their model involved only two equations (for infected
humans and infected mosquitoes) with no latent classes, and yet still yielded valuable in-
sight into the control of malaria.
The study of parameters to explain how malaria could be controlled through use of in-
terventions also informed our own work as we considered certain parameters such as the
recovery rate to study the effect of training interventions.
Models with concepts of age and immunity [26, 46, 59, 115, 151], and those with seasonal-
ity were also important for our study when we were considering how to incorporate these
concepts in our models.
Where as Boni et al [26] and Tediosi et al. [186] had a class of asymptomatic individuals,
they did not integrate the asymptomatic and susceptibles together as we have done with
our models. Moreover, none of the other models we reviewed and that we know of have
considered a class of both susceptibles and asymptomatic individuals together.
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Lastly, it is important to point out that none of these earlier malaria models studied the
effect of training interventions, and our work addresses this gap.
2.3 Models of pneumonia
We review some models of pneumonia, both mathematical and statistical. Our focus is on
models that provided estimates of parameters that we used when simulating our models in
later chapters. We also deal with models that included interventions such as vaccination
and treatment.
Smith et al. [176], used a stochastic model to estimate the acquisition and invasiveness of
different serotypes of S. pneumoniae by fitting the stochastic model to longitudinal carriage
data in children from Papua New Guinea. Frequent invasion was associated with a high
acquisition rate and high frequency and prolonged duration of carriage. Parameters of
acquisition and invasiveness from this study informed the parameter values in our model.
In [120], Melegaro et al. considered a stochastic model of pneumococcal carriage. It had
two groups, children and adults and the states considered were susceptible and infected.
Invasiveness of disease and death from disease was not considered. Probabilities of tran-
sition from susceptible to infected and vice versa were calculated. Parameters such as
clearance, community acquisition rate were estimated from carriage data. It was noted
that children had higher pneumococcal carriage prevalence as compared to adults, which
was a valuable insight. Results further showed that household acquired transmission made
a major contribution to pneumococcal carriage transmission in families.
Temime et al. [187], developed a mathematical model of selection for S. pneumoniae re-
sistance to penicillin G in an age structured population. The model considered three age
classes, that is, [0, 2) years, [2, 15) years and 15+ years. The model incorporated vaccina-
tion and sought to understand the epidemiological characteristics of S. pneumoniae in a
vaccinated population and also the distribution of resistance levels in children and adult
carriers after introduction of vaccination. The results suggested that because of serotype
replacement, the effects of vaccination observed at a particular instant would not be sus-
tained in the long run. The insight gained from this model was its use of age structure
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and incorporation of vaccination as an intervention.
Huang et al. [80] developed a transmission model to evaluate the risks of attending child-
care centres (CCC) and associating with play mates who attend CCCs. The parameters
of the model were based on data from a multicommunity study. The model explained
the marked differences in carriage across communities. The model was made up of two
states, noncolonised and colonised with S. pneumoniae in children. This was then extended
to include two classes of children, attendees of CCCs and non-attendees. The effect of
CCCs on pneumococcal carriage was established in these communities and parameters of
transmission, clearance were estimated using the data collected in the communities and
these informed some of the parameter values that we used in our model.
Sutton et al. [184] developed a mathematical model for pneumococcal infection with vacci-
nation. It was made up of partial differential equations with time and age as independent
variables, though in the analysis these were reduced to differential equations. The model
was used to evaluate the impact of vaccines at population level and parameters were esti-
mated using data. Use of vaccination as an intervention, age dependence and estimation
of parameters were important aspects that informed our work.
Snedecor et al. [177] developed an age structured transmission dynamic model to quantify
the direct and indirect benefits of infant PCV7 vaccination. The model simulated the
acquisition of asymptomatic carriage of S. pneumoniae and the development of fatal and
non-fatal invasive pneumococcal disease. It was parametrised using US data. This model
is similar to ours in that it considered asymptomatic carriage of S. pneumoniae.
In [51], Effelterre et al. developed a dynamic model of pneumococcal infection to study the
implications for prevention of infection through vaccination. The study highlighted that
the effects of vaccination on colonisation of S. pneumoniae determined the overall benefits
in the population.
The models of pneumonia that we have reviewed have aspects of age dependence, coloni-
sation to cause asymptomatic infection, and vaccination as an intervention. These models
informed our parameter values and gave us insight in our own model development. How-
ever, it is important to note that none of them had a class of symptomatic disease and
they did not have an integrated class of susceptibles and asymptomatic individuals. Fur-
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thermore, our model also sheds light on the effect of training interventions on pneumonia
which is not considered in these reviewed models.
2.4 Malaria-pneumonia coinfection
A number of observational clinical studies have shown evidence of individuals having symp-
toms of both malaria and pneumonia. Here, we review some studies related to the occur-
rence of malaria-pneumonia coinfection with particular focus on the proportions of indi-
viduals with malaria who have pneumonia, the proportions of those with pneumonia who
have malaria, and the effect of malaria-pneumonia coinfection on morbidity and mortality.
Berkley et al. [20] reviewed clinical and laboratory data of Kenyan children whose primary
diagnosis was malaria. They wanted to find out what the incidence and clinical importance
of bacteraemia (pneumonia) in severe malaria were. The overall incidence of bacteraemia
in severe malaria was 7.8% but it was 12.0% in children under 30 months of age. There
was a 3-fold increase in mortality with bacteraemia present in children with severe malaria.
Their conclusion was that bacteraemia may contribute to the severity of malaria and thus
recommended that children with severe malaria should be treated with both antimalarials
and antibiotics.
Evans et al. [54] carried out a study where 12% of malaria patients had bacteraemia.
Though severe malaria and bacteraemia were not positively associated, patients who where
smear positive for malaria and those smear negative for it could not be distinguished on
the basis of symptoms alone. The recommendation from this study was that infants with
symptoms of severe malaria but smear negative for it should be given antibiotics.
In [99], Ka¨llander et al. carried out IMCI at health facilities to determine the extent of
overlap of symptoms of malaria and pneumonia. IMCI is presumptive considering fever
for malaria and cough and fast breathing for pneumonia. 3671 children under five years of
age were evaluated at 14 health centres in Uganda. 30% of these had symptoms for both
malaria and pneumonia. Moreover, 37% of 2944 malaria cases also had pneumonia. It is
important to note that this study was observational and not laboratory based.
An observational study reported by Berkley et al. [19] used clinical syndromes to decide on
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giving children antibiotics. Children under five years of age were considered. 4.0%− 8.8%
of malaria film positive patients had an invasive bacterial infection and it was concluded
that having malaria parasitaemia should not lead to withholding of antibiotics.
Bassat et al. [16] carried out a study which found that 5.4% of children with severe malaria
also had bacteraemia and case fatality rate rose when bacteraemia was involved. The death
rate of individuals with malaria-pneumonia coinfection was higher than that for individuals
with one of the diseases. The case fatality of severe malaria cases who also had bacteraemia
was 22.0% yet that of severe malaria cases only was 4%.
In this subsection, we have reviewed studies of coinfection of malaria and pneumonia. It is
a common occurrence most especially in children less than 5 years of age and it warrants
modelling in order to quantify the prevalence of malaria and pneumonia coinfection in a
particular setting. Our model address this gap since, to the best of our knowledge, there
is no mathematical model that investigates malaria-pneumonia coinfection.
2.5 HIV models
Numerous models for the dynamics of HIV infection and AIDS disease have been developed.
Early models concentrated on the transmission dynamics of the disease and recent models
have focused on interventions for control of the disease. With the era of ART, some models
have incorporated the use of ART and have investigated the potential impact of increase in
the numbers of people receiving ART [11, 23, 64]. Others have incorporated age structure
and have time dependent parameters [11, 71].
To the best of our knowledge, no mathematical model has explicitly modelled CTX. The
only model that we know of is the the cost-effectiveness model by Pitter et al. [157] which
used cohort data and developed four screening algorithms to put HIV infected individuals
onto CTX. Their results showed that CTX was highly cost-effective in rural Uganda.
Though we are not doing a cost-effectiveness study, the model by Pitter et al. [157] has
some useful information that we took note of in our study.
Models have suggested that the presence of PMTCT reduces the number of children who get
infected at birth and those that get infected through breastfeeding. An extensive model
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for paediatric HIV that considered the importance of PMTCT was developed by Leigh
Johnson [90]. It used population projections from the ASSA2003 AIDS and Demographic
model (a model for the South African HIV epidemic) to give the number of births by HIV
positive women. Our model formulation is simpler than this as we consider a constant
number of HIV positive births.
Gupte et al. [74] modelled HIV transmission through breastfeeding in presence of an imper-
fect test using a statistical methodology. We gained some insights such as the fact that, for
populations in rural Africa where breastfeeding is the norm and duration of breastfeeding
is long, it is important to know the transmission probabilities due to breastfeeding.
An early article by Garnett and Herderson [64] on ART examined the effect of HIV trans-
mission with the introduction of ART, considering the fraction of HIV infected individuals
receiving ART. Two mathematical models were used.
The first model dealt with the rate at which susceptibles entered into the sexually ac-
tive class, and also studied the duration of sexual activity and the time when treatment
started after infection. It considered that a proportion of the infected individuals is treated,
and assumed that AIDS individuals did not take part in the transmission. It allowed for
transmission dynamics and parameters such as partner rate turn over and transmission
probability.
The second mathematical model explored heterogeneity in sexual groups and allowed for
a difference in CD4+ cell density. Depending on the scenario chosen, ART could reduce
the burden of disease or increase it. Similarly we also consider the fraction of HIV infected
individuals receiving ART.
A model by Blower et al. [23] investigated the impact of ART among Men who have Sex
with Men (MSMs), the emergence of drug resistance and increase in risky behaviour. The
transmission model also incorporated a statistical approach that helped to show the high
uncertainty of the effects of ART. The fraction of individuals taking ART per year was
calculated as the rate at which individuals go onto ART divided by a summation of the
rate at which individuals die if not on ART, and the natural death rate, and the rate at
which they go onto treatment. We also used a similar formulation to calculate the fraction
of individuals taking ART. The difference of this model with ours is that we considered
testing of HIV positive individuals which was not done in this model.
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Bacae¨ et al [11], used an age structured model is used to model the HIV epidemic in
South Africa. It has a time dependent force of infection and it considers annual testing
of individuals for HIV and ART enrollment. Itse results suggested that the high levels of
reported condom use would be able to cause a long-term decline of HIV. Similarly, we also
used a time dependent force of infection and also considered testing of HIV individuals and
used their formulation of ART enrollment.
Of crucial importance is the fact that there is no model that we know of that models
the effectiveness of training interventions on HIV and our model is novel in this area.
In addition, most of the models did not consider testing of HIV positive individuals and
neither did they consider use of CTX. In this regard, our model addresses gaps in regard
to these three issues.
2.6 TB models
Most basic models of TB consist of three classes: susceptible, latent and active TB and the
complex ones build onto these by adding more classes such as the treated and recovered
classes or by differentiating latent individuals into those who progress slowly to TB disease
and those that progress very fast [10, 24, 31, 32]. They can also include interventions such
as vaccination and TB treatment.
Blower et al. [24] formulated two models beginning with a simple model and then a
detailed one. The first model comprised susceptible class, latent class and the infectious
class. Susceptible individuals are infected and move directly into active class which is called
fast progression or they move into the latent class which is known as slow progression and
those from the latent class progress to active class later.
In the more detailed model, two active classes were presented, one infectious and one non-
infectious, as well as the recovered class. Active TB individuals recover and move into the
recovered class.
Castillo-Chavez and Feng [31] presented a model made up of susceptible class, latent class
and active class. There was no progression from active class to latent class and there was
recovery from the active class and latent class to the susceptible class. In comparison to
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our model, the recovery of TB individuals leads them back to the susceptible class which
has the latent class embedded in it.
Vynnycky and Fine [192] developed an age-structured model of TB. It dealt with time
since infection and the importance of age in the transmission dynamics of TB. There was
also some discussion on exogenous reinfection and its contribution to TB prevalence.
In [205], Williams et al. developed a two states TB model with a TB free state and TB
disease state. It is similar to ours in that two classes are used but different in that instead
of a TB free class, we have a class containing both latent and fully susceptible individuals.
Nevertheless, it is not unusual to use two classes to describe TB dynamics.
We gained useful information from these TB models which we used for our own model
formulation. None of these TB models considered the concept of having a class of suscep-
tibles together with latent individuals divided into proportions and we did not find any
that we know of. It is important to note that none of these models considered the impact
of training interventions.
2.7 HIV-TB coinfection
Oluwaseun et al. [172], presented a model of HIV-TB coinfection and discussed the effect
of using different treatment strategies: treating TB only, treating HIV only, by use of
antiretrovirals or treating both of the diseases. Their study concluded that, in resource
limited countries, treating one of the diseases reduces the number of individuals coinfected
with HIV and TB more than if the coinfected individuals are treated.
In [10], Bacae¨r et al. modelled HIV-TB coinfection in a South African township and
used data to estimate certain parameters and to investigate the impact of two TB control
measures: increased TB detection and TB treatment as well as HIV interventions such as
condom promotion and antiretroviral treatment. The first three mentioned were positively
effective and ART was effective depending on how much it reduced the infectiousness of
individuals who were HIV-positive. The model also suggested that use of ART greatly
reduces the TB notification rate.
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Bhunu et al. [21], discussed a model of HIV-TB coinfection. It considered ART for HIV and
treatment of all the different forms of TB, latent and active. The model was mathematically
analysed without any intervention strategy. From their study, ART reduces the number of
individuals progressing to active TB, and the number of active TB individuals whose TB
treatment is delayed, progressing to AIDS disease.
Both studies in [10] and [21] concluded that the effect of ART on TB (and on HIV) depends
greatly on the reduction in HIV transmission that it results in.
In [86], Roeger et al. formulated a model of HIV-TB coinfection. They determined the
basic reproductive number and analysed mathematically the model’s behaviour. They
noted that the increased progression rate from latent to active TB may have an important
part to play in the increase of TB prevalence. The model did not consider ART.
All these HIV-TB mathematical models gave us insight in our own model formulation. It is
crucial to note that none of the models that included interventions considered the impact
of training and our work addresses this gap in knowledge.
2.8 Models with two time scales
Given the mathematical and numerical challenges faced with models of two time scales
(fast and slow dynamics), there is limited literature on them. We review some of the ones
we found.
Smith et al. [107] studied a model of Sexually Transmitted Disease (STD) where they
considered that the model had two time scales; the fast paring dynamics where single
individuals form partnerships and the slow dynamics where population of susceptibles
interacts with that infected individuals. A time scale approximation known as the quasi-
steady state approximation was used for the fast dynamics.
In [14], a model of malaria and HIV was considered and also the quasi-steady state approx-
imation was used by considering that the malaria dynamics are at a faster time scale than
the HIV dynamics. It was noted that it was not necessary to model the vector mosquito
population explicitly.
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We did not find any models of malaria with TB, pneumonia with TB or HIV and pneumonia
in our literature search. However, the few articles that we reviewed on the subject of two
time scales gave us useful information.
2.9 Training
Training of MLPs is an important aspect in health care. In a recent study carried out
in Uganda [112], a training needs assessment among clinicians was done to identify task
shifting that had occurred from doctors to clinical officers, nurses and midwives. The
study noted that some of the clinicians who prescribed ART to HIV patients did not have
enough overall knowledge about it. It was then concluded that training of MLPs should
be incorporated in the health care system if task shifting is to be successful.
Some earlier studies [143, 180] had been carried out to examine the effect of training on
the management of malaria.
One study on case management of malaria [180] found that after a team based training,
there was an increase in the proportion of malaria suspects referred for blood smears and
a decrease in the proportion of patients with negative blood smears prescribed medication.
Another study done in Tanzania [143] also found that there was a decrease in prescription
of malarial drugs at health centres where health workers were trained in microscopy based
diagnosis.
Both these studies showed that there was some benefit to training of health workers even
though they were disease specific and ignored the important effect that a disease can have
on other diseases and their management.
Studies that have incorporated integrated management of infectious diseases are IMCI
studies that were carried out in in five countries: Uganda, Tanzania, Bangladesh, Peru
and Brazil [28, 132, 155]. These focused on evaluating the impact of IMCI on health of
children under five years of age.
In the Tanzanian IMCI study [132], it was noted that children under five in IMCI districts
received better care than children in districts where IMCI was not implemented. It was
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also noted that IMCI was likely to result in gains in child survival and improvement in
quality of care if sufficient coverage levels could be achieved and maintained.
The Ugandan IMCI study [155] assessed the effects of scaling up of IMCI on the quality
of care. Results revealed that health workers trained in IMCI provided better care than
those who were not. It was noted that achieving training coverage alone was not sufficient
to improve and sustain quality of care, and other factors such as training quality, effective
supervision, drug availability, equipment and government policy were important.
One study in [34], showed that basic health workers were able to correctly case manage
sick children and it highlighted that that there should be follow up sessions after the initial
training, and regular and frequent follow up by supervisors is important. Provision of
supplies such as drugs are necessary for better practice of training in IMCI.
All these studies highlighted the importance of training of MLPs. Moreover, some also
mentioned that training in integrated management of infectious diseases is crucial. These
studies have combined to give us insight into the effect of training of MLPs.
2.10 Summary
In this Chapter, we gave an overview of the biology and epidemiology of malaria, pneu-
monia, HIV and TB. We also presented a literature review on mathematical models of
malaria, pneumonia, HIV and TB and some literature on training interventions. We noted
that there are no models devoted to malaria-pneumonia coinfection and that no models
have considered the impact of training interventions, especially for more than one disease.
The ideas provided by the models and training literature we reviewed were useful and
informative in our research. We gained lots of insight on how to model all the diseases
that we considered.
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IDCAP Data and Performance
Indicators
3.1 Introduction
Integrated Infectious Disease Capacity-Building Evaluation (IDCAP) program started in
2009 at 36 sites throughout Uganda. Its focus was to provide an integrated package of
infectious disease capacity-building activities at the sites, consisting of a core curriculum
of integrated infectious disease training for mid-level practitioners and on-site support for
multidisciplinary teams at the clinic level. The aim of the program was to evaluate the
impact of training on individual and clinic performance, and to test whether the incremen-
tal impact of practical training at the site relative to classroom training alone could be
cost-effective.
In this regard, IDCAP carried out two training interventions: Integrated Management of
Infectious Diseases (IMID) and On-Site Support Services (OSS), at 36 sites throughout
Uganda to improve diagnosis and treatment of infectious diseases [62, 122]. The diseases
considered were: malaria, pneumonia, HIV and TB. The sites were grouped into two study
arms: Arm A and Arm B. All the sites received IMID and OSS was implemented at Arm
A sites for the intervention period.
IMID was classroom based and was given at IDI. OSS was given as a two day practical
training at the site every month for a period of nine months. More about the project design
and implementation is in [62], IMID and OSS have been described in [122] and TABLE
24
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3.1 gives the sites where the study was carried out.
TABLE. 3.1. Arm A and Arm B sites
Arm A sites Subcounty population Arm B sites Subcounty population
Mukuju 33000 Yumbe 65000
Rugazi 42900 Maracha 27100
Buyinja 57500 Rubaya 35100
Nsinze 23100 Koboko 44500
Kiwangala 46900 Pajule 29000
Kitwe 52300 Mulanda 32300
Rubare 30300 Bukwo 14100
Pakwach 20800 Rukunyu 59400
Midigo 69100 Pallisa 29600
Madi-opei 13300 Kiyunga 35500
Karugutu 21500 Omugo 38100
Ishongororo 44400 Shuuku 23800
Kityerera 75900 Busiu 30800
Butebo 23300 Apapai 31500
Kigezi 16100 Nyimbwa 32700
Mparo 25800 Kojja 66300
Rugarama 11600 Kasangati 74000
Magale 48300 Kisubi 76500
IDCAP evaluated the impact of training of Mid-Level Practitioners (MLPs) using per-
fomance indicators such as proportion of patients tested, proportion of patients that are
prescribed appropriate treatment and those that receive appropriate medication. All the
performance indicators are given in subsection 3.2.2.
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3.2 IDCAP data and parameters
Data were collected on the performance indicators and on malaria and pneumonia disease
cases before the intervention (baseline) and after the intervention (IMID and OSS).
3.2.1 Malaria and pneumonia data
Data on malaria and pneumonia cases were collected from all the 36 sites at baseline for
five months and 18 months for IMID and OSS. In our work, we used the average number
of malaria and pneumonia cases for an average site considering Arm A sites.
FIG. 3.1(a), FIG. 3.1(b) and FIG. 3.1(c) show the number of malaria cases for the age
groups [0, 5), [5, 14) and [14, 50) at baseline and for the two interventions of IMID and
combination of IMID and OSS. These are malaria predictions obtained using a linear
regression equation and data on number of malaria cases collected from Arm A sites.
The number of pneumonia cases do not change with time and the baseline value of pneu-
monia cases for the three age groups, [0, 5), [5, 14) and [14, 50) are given in TABLE. 3.2.
TABLE. 3.2 also has proportions of individuals that have severe malaria, severe pneumonia
and severe coinfection, and the proportions of symptomatic malaria-pneumonia individuals
that recover from malaria-pneumonia coinfection, pneumonia and malaria.
TABLE. 3.2. Number of pneumonia cases at baseline, proportions of individuals with
severe malaria-pneumonia coinfection, q, severe pneumonia, q1 and severe malaria, q2 and
proportion of symptomatic malaria-pneumonia coinfected individuals that recover from
malaria-pneumonia coinfection, z, pneumonia, z1 and malaria, z2.
Age group Pneumonia cases q, q1, q2
< 5 53 0.279, 0.075, 0.646
5− < 14 6 0.03, 0.04, 0.93
>= 14 24 0.018, 0.066, 0.916
Proportion
z = 0.2, z1 = 0.4, z2 = 0.4
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(a) (b)
(c)
FIG. 3.1. Unpublished data: malaria cases for baseline, IMID combined with OSS for age
groups [0, 5), [5, 14) and [14, 50) from Arm A
3.2.2 IDCAP performance indicators
The interventions were evaluated by using performance indicators that focused on patient
assessment and screening, treatment, prevention and referral and follow up [62]. TABLE
3.3 presents the performance indicators that were considered for malaria, pneumonia, HIV
and TB.
3.2.3 Parameters related with the interventions
IDCAP interventions dealt with improvement in patient assessment, patient triage and
appropriate drug prescription for patients and this has an effect on the rate of recovery
and the rate out of emergency. Thus the parameters that are related to the interventions
are: the recovery rate and rate out of emergency.
We describe the general form of the recovery rate in FIG. 3.2.
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TABLE. 3.3. IDCAP performance indicators for malaria and pneumonia
Performance indicator
Uncomplicated disease (malaria and pneumonia)
Proportion who were prescribed and received appropriate treatment
Severe disease (malaria and pneumonia)
Proportion triaged
Proportion who were prescribed and received appropriate treatment
HIV
Proportion with an HIV test result
Proportion on ART
Proportion on Cotrimoxazole (CTX)
Proportion of pregnant woment who receive ART on delivery
Proportion of HIV-exposed babies who receive ART on delivery
TB
Proportion who are tested
Proportion who initiated treatment
Proportion that complete treatment
HIV and TB
Proportion with an HIV test result
Proportion on Cotrimoxazole (CTX)
Proportion on ART
Recovery rate
This applies to individuals with uncomplicated disease. It has been divided into six terms
based on FIG. 3.2.
Individuals seen at the health centres are the ones that report. The others that do not
report may use traditional medicine or may recover naturally. There is evidence that shows
that some individuals clear their infection without treatment [144, 145]. We assume that
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cases
report do not report
Assessed/tested
Not assessed/ not tested
appropriate prescription
unappropriate prescription
receive unappropriate medication
do not receive medication
receive appropriate medication
do not receive medication
FIG. 3.2. General recovery term
untreated symptomatic infections are cleared in 180 days [26, 59, 151]. We also assume
that all individuals with appropriate medication recover and only 62% of those who receive
unappropriate medication (assuming 38% resistance to chloroquine [65, 141]), recover from
symptomatic malaria.
The terms making up the average recovery term, r are given as
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r
1
= proportion reporting to clinic × proportion assessed/tested ×
proportion with appropriate prescription × proportion that receive medication
×
1
duration of symptomatic disease with appropriate medication
r
2
= proportion reporting to clinic × proportion assessed/tested ×
proportion with appropriate prescription × (1− proportion that receive medication)
×
1
duration of symptomatic disease with no medication
r
3
= proportion reporting to clinic × proportion assessed/tested ×
(1− proportion with appropriate prescription) × proportion that receive medication
×
1
duration of symptomatic disease with inappropriate medication
r
4
= proportion reporting to clinic × proportion assessed/tested ×
(1− proportion with appropriate prescription) × (1− proportion that receive medication)
×
1
duration of symptomatic disease with appropriate medication
r
5
= proportion reporting to clinic × proportion not assessed/not tested
×
1
duration of symptomatic disease with no medication
r
6
= proportion not reporting to clinic ×
1
duration of symptomatic disease with no medication
r = r
1
+ r
2
+ r
3
+ r
4
+ r
5
+ r
6
r gives the general recovery rate.
For the recovery rate of malaria, r
M
, we do not consider the assessment or tested term.
This is because, almost all individuals presenting with fever are presumed to be having
malaria and are given malaria medication whether they are tested or not. Thus r
M
will
contain only five terms.
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The recovery rate of pneumonia, r
P
also has five terms because we do not consider the
assessment term since almost all individuals who present with cough and cold are given
antibiotics.
The recovery rate of TB, r
TB
has all the six terms and in addition to those, the proportion
of TB patients who complete treatment is also considered. The proportion of active TB
individuals who report to the clinic is very small because there is no active case finding.
Moreover, TB patients report to health centres after four months of illness [167, 168]. In
[200], the the case detection rate for all TB cases was 38% to 44% from 1995 to 2009. For
our model simulations, we take the proportion of TB active individuals reporting as 35%
for the [0, 5) age group and 33% for the [5, 14) and [14, 50) age groups.
Rate out of emergency class
This applies to individuals in severe disease class. It depends on the proportion of individu-
als triaged, those that are prescribed and receive appropriate medication. We assume that
if a patient with severe disease fails to access treatment, the patient dies. It is documented
that individuals and children with severe malaria or severe pneumonia die within 24 to 48
hours [18, 81, 82, 140, 189]. We take the duration of being an emergency case to be 2 days
and we define the rate out of emergency as
= proportion reporting to clinic × proportion triaged ×
proportion prescribed appropriate treatment × proportion who receive treatment
×
1
duration as an emergency case
.
3.3 Impact of IMID and OSS
To calculate the impact of IMID and the combined intervention of IMID and OSS, we
make use of the following formula:
Indicator after intervention = Indicator before intervention × (1 + (Coverage of intervention
× Impact of intervention on indicator))
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Suppose that the coverage of the intervention is 100%, the impact of the intervention on
the indicator will be given as:
Impact of intervention on indicator =
Indicator after intervention
Indicator before intervention
− 1.
The impact of the performance indicators are given in TABLE 3.4 for malaria and pneu-
monia, TABLE 3.5 for TB and TABLE 3.6 for HIV.
3.3.1 Effect of IMID and OSS
To obtain the effect of IMID, combined intervention of IMID and OSS and the incremental
impact of OSS on number of cases, prevalence, incidence and deaths, we put in mind that
for a positive effect, there would be a decline in cases, prevalence, incidence and deaths
with reference to baseline. Thus for the effect of IMID and IMID+OSS, we calculated
the difference between IMID or IMID with OSS values and baseline values and divided by
baseline values. The incremental impact of OSS was found by subtracting the IMID with
OSS values from IMID ones and dividing by IMID values. The formulas are:
Effect of IMID = (Baseline − IMID)/Baseline
Effect of IMID+OSS = (Baseline − IMID+OSS)/Baseline (3.1)
Incremental impact of OSS = (IMID− IMID+OSS)/IMID
However, for indicators such as the number of individuals who are enrolled onto ART and
the number of TB patients that recover, there would be an increase in these numbers
during the period of the interventions, if we are to have a positive effect. Thus to find the
effect of IMID and IMID+OSS, we would reverse equations in 3.1 as:
Effect of IMID = (IMID− Baseline)/IMID
Effect of IMID+OSS = (IMID+OSS− Baseline)/IMID+OSS
Incremental impact of OSS = (IMID+OSS− IMID)/IMID+OSS
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TABLE. 3.4. Impact of IMID and OSS on malaria and pneumonia indicators as compared
to baseline
Indicator Baseline IMID Impact IMID+OSS Impact
Coverage of intervention 26% Estimated
Non-severe malaria
< 5 years
Proportion treated appropri-
ately
0.49 0.529 0.0796 0.746 0.522
>= 5 years
Proportion treated appropri-
ately
0.41 0.443 0.08 0.624 0.522
Non-severe pneumonia
< 5 years
Proportion treated appropri-
ately
0.56 0.627 0.12 0.533 −0.048
>= 5 years
Proportion treated appropri-
ately
0.51 0.571 0.12 0.486 −0.047
Severe disease
< 5 years
Proportion triaged 0.26 0.335 0.288 0.53 1.038
Proportion treated appropri-
ately
0.45 0.432 −0.04 0.795 0.77
>= 5 years
Proportion triaged 0.27 0.348 0.289 0.55 1.037
Proportion treated appropri-
ately
0.27 0.259 −0.041 0.477 0.77
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TABLE. 3.5. Impact of IMID and OSS on parameters for indicators of TB
Indicator Baseline IMID Impact IMID+OSS Impact
Coverage of intervention 26% 58%
< 14 years
Proportion who are tested 0.01 0.012 0.2 0.013 0.3
Proportion who initiated
treatment
0.4 0.324 −0.19 0.522 0.305
Proportion that complete
treatment
0.41 0.136 −0.668 0.142 −0.654
>= 14 years
Proportion who are tested 0.15 0.18 0.2 0.196 0.307
Proportion who initiated
treatment
0.4 0.324 −0.19 0.522 0.305
Proportion that complete
treatment
0.41 0.136 −0.668 0.142 −0.654
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TABLE. 3.6. Impact of IMID and OSS on HIV indicators
Indicator Baseline IMID Impact IMID+OSS Impact
Coverage of intervention 26% 58%
< 14 years
Proportion with an HIV test
result
0.019 0.019 0.0 0.021 0.105
>= 14 years
Proportion with an HIV test
result
0.072 0.071 −0.014 0.077 0.069
Pregnant women
Proportion with an HIV test
result
0.67 0.657 −0.019 0.716 0.069
Proportion enrolled into HIV
care
0.33 0.406 0.23 0.52 0.576
Proportion eligible on ART 0.9 0.891 −0.01 0.855 −0.05
Proportion on Cotrimoxazole
(CTX)
0.91 0.9 −0.011 0.91 0.0
Proportion who receive ART
on delivery
0.28 0.266 −0.05 0.25 −0.107
Proportion of HIV-exposed
babies who receive ART on de-
livery
0.75 0.713 −0.049 0.67 −0.107
Proportion of infants enrolled
into HIV care
0.44 0.541 0.23 0.693 0.575
Proportion of eligible infants
on ART
0.22 0.218 −0.009 0.209 −0.05
TB patients
Proportion with an HIV test
result
0.9 0.954 0.06 0.944 0.049
Proportion enrolled into HIV
care
0.3 0.369 0.23 0.472 0.573
Proportion on Cotrimoxazole
(CTX)
1.0 0.99 −0.01 1.0 0.0
Proportion eligible on ART 0.72 0.713 −0.01 0.684 −0.05
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3.4 Summary
This chapter gives information about IDCAP, the data collected and the performance
indicators used to evaluate the two training interventions, IMID and OSS. The impact of
the two training interventions on the indicators was calculated and the formula to calculate
their effect on cases, deaths, incidence and prevalence was also given. The information in
this chapter will be used in later chapters.
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Malaria-Pneumonia Coinfection
4.1 Introduction
In this chapter, we formulate and use a malaria-pneumonia coinfection model to investigate
the effect of two training interventions on malaria and pneumonia case management.
The reason for using such a model being that individuals with malaria and pneumonia have
overlapping symptoms when severe state and diagnosis of either malaria or pneumonia is
difficult. Thus integrated management of both diseases is carried out. The points of interest
in the management of malaria and pneumonia cases are appropriate diagnosis, prescription
and receiving of treatment.
IDCAP evaluated the effect of IMID and OSS on indicators such as the proportion of
malaria and pneumonia patients prescribed appropriate medication, proportion who re-
ceived appropriate treatment and proportion of patients who were triaged. Using these
effects to provide information on incidence, prevalence and mortality of malaria and pneu-
monia, requires mathematical modelling.
Thus in this chapter, we develop a mathematical model that accounts for the transmission
dynamics of malaria and pneumonia for three age groups [0, 5), [5, 14) and [14, 50) and
investigate the effectiveness of IMID and OSS on management of both diseases.
Because this model uses new malaria and pneumonia sub-models, we will start by for-
mulating these two sub-models and their underlying assumptions. We will also perform
mathematical analyses of their dynamical behaviour. Finally, we will merge the two sub-
37
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models into one coinfection model, to which we will add age structure.
4.2 Malaria model
We describe a model of malaria with no age structure. In this model, the population
is divided into three classes: susceptibles (S), non-severe symptomatic malaria (M) -
uncomplicated malaria with symptoms that are easily manageable and severe malaria (M˜)
- complicated malaria with advanced symptoms (emergency).
We make the following assumptions in the model:
1. We assume that a constant proportion, m of susceptibles always has asymptomatic
infection.
2. Deaths of malaria occur only in severe malaria (emergency) class.
In the model, individuals are recruited into the susceptible class at a constant rate, B.
Susceptible individuals either move (through infection, reinfection or reactivation) to the
non-severe class (at a rate λ
vh
+ ϑ) or die at a rate µ. Individuals in the non-severe
symptomatic class either recover (at a rate r
M
), move to severe class at a rate α
M
or die
at a rate µ. Severe malaria individuals either move out of the emergency class at a rate
θ
M
or die at a rate µ
M˜
.
We also have mosquito dynamics with the population of mosquitoes being made up of
susceptible, Sv and infected mosquitoes, Iv . Susceptible mosquitoes are recruited into the
population at a rate, bv, are infected with malaria at a rate λhv and die at rate, µv . Infected
mosquitoes also die at a rate, µv .
Equations (4.1a)–(4.1c) represent the human population and equations (4.1d)–(4.1e) are
for the mosquito population. The model diagram is given by FIG. 4.1 and TABLE 4.1
gives the descriptions of the model variables and parameters.
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FIG. 4.1. Malaria model
dS
dt
= B + r
M
M − (λ
vh
m′ +mϑ+ µ)S, (4.1a)
dM
dt
= (λ
vh
m′ +mϑ)S + θ
M
M˜ − (r
M
+ α
M
+ µ)M, (4.1b)
dM˜
dt
= α
M
M − (θ
M
+ µ
M˜
)M˜, (4.1c)
dSv
dt
= bv − λhvSv − µvSv , (4.1d)
dIv
dt
= λ
hv
S
v
− µ
v
I
v
, (4.1e)
where:
(i) λ
vh
= β
vh
Iv/N . βvh is the rate at which a vector (mosquito) infects a human, Iv is
the infected vector (mosquito) population and N is the human population.
(ii) m′ = m1(1 − m) + m2m. m1 and m2 are the proportions of new infections and
reinfections that progress to symptomatic disease respectively.
(iii) λ
hv
= β
hv
(I
M
/N). β
hv
is the rate at which a vector (mosquito) becomes infected
by biting an infected human. I
M
= M + M˜ + ζmmS is the population of humans
with malaria infection where ζ
m
is the reduction in infectiousness of individuals with
asymptomatic malaria.
The biological feasibility of model system (4.1a)–(4.1e) can be proved in the same way as
Stellenbosch University  http://scholar.sun.ac.za
Chapter 4. Malaria-Pneumonia Coinfection Model 40
TABLE. 4.1. Descriptions of variables and parameters of malaria model.
Variable/Parameter Description
S Individuals susceptible to malaria infection or with asymptomatic
malaria infection.
M non-severe malaria individuals.
M˜ severe malaria individuals.
B Birth term for humans.
r
M
Recovery rate from malaria.
λ
vh
, λ
hv
Infection terms for malaria.
µ, µ
M˜
Death rates for susceptible individuals, individuals with symp-
tomatic malaria and those with severe disease.
α
M
Rate into severe class.
θ
M
Rate out of severe disease class.
ϑ Reactivation rate for malaria.
b
v
, µ
v
Birth and death rate for mosquitoes respectively.
will be done for the malaria-pneumonia coinfection model in subsection 4.5.1.
We find the equilibrium points of the malaria sub-model and establish their stability.
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4.2.1 Equilibrium points
To get equilibrium points of the malaria model, we set equations (4.1a)–(4.1e) to zero and
solve them in terms of the infection terms, λ
vh
and λ
hv
of malaria to give
S∗ =
B(θ
M
(r
M
+ µ) + µ
M˜
(r
M
+ α
M
+ µ))
µr
M
(θ
M
+ µ
M˜
) + (µ+mϑ+m′λ∗
vh
)(αµ
M˜
+ µ(θ
M
+ µ
M˜
))
, (4.2a)
M∗ =
B(mϑ+m′λ∗
vh
)(θ
M
+ µ
M˜
)
µr
M
(θ
M
+ µ
M˜
) + (µ+mϑ+m′λ∗
vh
)(αµ
M˜
+ µ(θ
M
+ µ
M˜
))
, (4.2b)
M˜∗ =
Bα
M
(mϑ+m′λ∗
vh
)
µr
M
(θ
M
+ µ
M˜
) + (µ+mϑ+m′λ∗
vh
)(αµ
M˜
+ µ(θ
M
+ µ
M˜
))
, (4.2c)
S∗
v
=
b
v
λ∗
hv
+ µv
, (4.2d)
I∗
v
=
bvλ
∗
hv
µ
v
(λ∗
hv
+ µ
v
)
. (4.2e)
Solving λ
hv
in terms of λ
vh
and substituting equations (4.2a)–(4.2e) into the force of infec-
tion term, λ
vh
yields
Aλ∗3
vh
+ A1λ
∗2
vh
+ A2λ
∗
vh
+ A3 = 0, (4.3)
where:
A = Bm′2K2µ
v
(β
hv
+ µ
v
),
A1 = m
′K(−m′bvβhvβvhK1 +Bµv(βhv(K2 +K3 +K4) + 2µvK5)),
A2 = −m
′b
v
β
hv
β
vh
(K6 +K1K7) + BµvK5(mβhvK8 +K5µv),
A3 = −mbvβhvβvh(K8K9),
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with
K = θ
M
+ α
M
+ µ
M˜
, K1 = αMµM˜ + µ(θM + µM˜ ), (4.4a)
K2 = (1 +mζm)rM (θM + µM˜ ), K3 = (2mϑ+ (1 +mζm)µ)(θM + µM˜ ), (4.4b)
K4 = αM (2mϑ+ (1 +mζm)µM˜ ), (4.4c)
K5 = (θM + µM˜ )(rM +mϑ+ µ) + αM (mϑ+ µM˜ ), (4.4d)
K6 = rM (θM + µM˜ )(µ(1 +mζm)(θM + µM˜ ) + αM (µ+mζmµM˜ )), (4.4e)
K7 = (µ(1 +mζm) + 2mϑ)(θM + µM˜ ) + αM (µ+ 2mϑ+mζmµM˜ ), (4.4f)
K8 = (θM + µM˜ )(ζmrM + ϑ+ ζmµ) + αM (ϑ+ ζmµM˜ ), (4.4g)
K9 = µrM (θM + µM˜ ) + (µ+mϑ)K1. (4.4h)
We then consider two cases, where m 6= 0 and m = 0.
Case 1: m 6= 0
In this case, A3 is negative, which implies that there is no DFE and there exists at least
one positive endemic equilibrium.
Case 2: m = 0
A3 = 0 and we have
λ∗
vh
(A∗λ∗2
vh
+ A∗1λ
∗
vh
+ A∗2) = 0, (4.5)
where
A∗ = Bm21K
2µv(βhv + µv),
A∗1 = m1K(−m1bvβhvβvhK1 +Bµv(βhv(k
∗
2 + k
∗
3 + k
∗
4) + 2µvk
∗
5)),
A∗2 = Bµ
2
v
K∗25 (1− (R
M
0 )
2),
with
K∗2 = rM (θM + µM˜ ), K
∗
3 = µ(θM + µM˜ ), K
∗
4 = αMµM˜ . (4.6a)
K∗5 = αMµM˜ + (θM + µM˜ )(rM + µ). (4.6b)
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and
RM0 =
√
m1bvµβhvβvh(θM + αM + µM˜ )
Bµ2
v
(α
M
µ
M˜
+ (θ
M
+ µ
M˜
)(r
M
+ µ))
which is the malaria basic reproductive number and it will be discussed in the subsequent
subsubsection.
Solving equation (4.5) results into λ∗
vh
= 0 which gives the Disease Free Equilibrium
(DFEM) for malaria sub model. The DFEM is(
B
µ
, 0, 0,
b
v
µv
, 0
)
.
For λ∗
vh
6= 0, we have
λ∗
vh
=
−A∗1 ±
√
A∗21 − 4A
∗A∗2
2A∗
,
there exists a unique positive endemic equilibrium when RM0 > 1.
The equilibrium points calculation has revealed that the malaria model has a DFEM when
m = 0 and a unique endemic equilibrium when RM0 > 1. We will determine the local
stability of these equilibrium points in later subsubsections.
Malaria basic reproductive number, RM0
Generally, the basic reproductive number,
Definition 4.2.1 R0 is the mean number of new infections caused by an infected individual
introduced into a wholly susceptible population during the individual’s infectious period.
This number gives us an insight on how fast the disease is spreading. R0 < 1 means that
on average, an infected individual causes less than one new infected individual over the
course of the infectious period and R0 > 1 implies that an infected individual produces
more than one new infection. Therefore, the disease will die out when R0 < 1 and it will
invade the population with R0 > 1.
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For simple cases, R0 is given by the product of the infection rate and the mean duration of
infection [45]. However, in more complex models, it is calculated using the next generation
matrix method in [45] given by FV −1 where:
i F is the Jacobian matrix, evaluated at the DFE, of the vector field formed by the new
infection terms.
ii V is also a Jacobian matrix evaluated at the DFE of the vector field formed by other
transfer terms.
In this particular case, we find the basic reproductive number for malaria, RM0 and this is
calculated as follows:
F =

λ
vh
m1S
0
λ
hv
Sv
 and V =

−θ
M
M˜ + (r
M
+ α
M
+ µ)M
−α
M
M + (θ
M
+ µ
M˜
)M˜
µvIv
 .
Note that m = 0 at DFE.
We find the derivatives of F and V at DFE.
F =

0 0 m1βvh
0 0 0
bvµβhv
Bµv
bvµβhv
Bµv
0
 , V =

r
M
+ α
M
+ µ −θ
M
0
−α
M
θ
M
+ µ
M˜
0
0 0 µv
 .
RM0 is given by the spectral radius of FV
−1. Using mathematica software, we obtain
RM0 =
√
m1bvµβhvβvh(θM + αM + µM˜ )
Bµ2
v
(α
M
µ
M˜
+ (θ
M
+ µ
M˜
)(r
M
+ µ))
.
RM0 is useful in establishing the stability of the DFE
M which is summarised by Theorem
4.2.2
Theorem 4.2.2 The DFEM is locally asymptotically stable if RM0 < 1 and unstable if
RM0 > 1
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Stability of EEPM
For the local stability of the EEPM s, we will make use of the centre manifold Theorem
from [32] stated in Theorem A.0.1.
We denote the right hand side of system (4.1a)–(4.1e) by f = (f1, f2, f3)
T . The DFEM is
shifted to (0, 0, 0, 0, 0).
We consider the case when RM0 = 1 and take βvh to be our bifurcation parameter. It is
given as
β∗
vh
=
Bµ2
v
(α
M
µ
M˜
+ (θ
M
+ µ
M˜
)(r
M
+ µ
M
))
m1bvµβvh(θM + αM + µM˜ )
.
The linearised system with β
vh
= β∗
vh
has a zero eigenvalue which is simple.
We follow through the steps stated in Theorem A.0.1 to analyse the dynamics of (4.1a)–
(4.1e) near β
vh
= β∗
vh
after the DFEM has been shifted to (0, 0, 0, 0, 0) and in particular to
determine the local stability of the endemic equilibria of the system.
We look for the non-zero partial derivatives of f at DFEM and these are given in A.1. We
calculate the value of a and b.
We have,
a =
2µv(−BβhvµvK +m1bvβvh(−µβhvK + (αM (µ− µM˜ ) + (µ− µM˜ )(θM + µM˜ ))µv))
B
,
Since µ
M˜
> µ, then a < 0.
b =
m1µbvK(βhv − µv)
BµvK9
.
Then b < 0 if β
hv
< µv and b > 0 if βhv > µv . We establish the following result in Theorem
4.2.3.
Theorem 4.2.3 i) If β
hv
< µ
v
, the model system (4.1a-4.1e) has a positive unstable equi-
librium whenever RM0 < 1 but close to 1.
ii) If β
hv
> µv , the model system (4.1a-4.1e) has a unique endemic equilibrium which is
locally asymptotically stable whenever RM0 > 1 but close to 1.
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This result raises an important point that the persistence and eradication of malaria disease
is dependent on two parameters, that is, the death rate of the mosquito and the infection
rate from humans to mosquitoes. In particular, eradication would occur if the infection
rate of humans to mosquitoes, β
hv
< µv .
Note that in our study population, malaria is endemic. Our values for βhv and µv are 4
per month and 3.04 per month respectively averaging across the three age groups of [0, 5),
[5, 14) and [14, 50).
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FIG. 4.2. Numerical simulations for RM0
FIG. 4.2(a), FIG. 4.2(b) and FIG. 4.2(c) show that for all m > 0, there exists an endemic
equilibrium irrespective of the value of RM0 and for m = 0, an endemic equilibrium only
exists if RM0 > 1.
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4.3 Pneumonia model
We describe a model of pneumonia with no age structure. The model is made up of
three classes: susceptibles (S), non-severe pneumonia (P ) - uncomplicated pneumonia with
symptoms that are easily manageable and severe pneumonia (P˜ ) - complicated pneumonia
with advanced symptoms (emergency). We make the following assumptions:
1. We assume that a constant proportion, p of individuals always has asymptomatic
pneumonia infection.
2. Deaths due to pneumonia occur only in severe pneumonia (emergency) class.
Individuals are recruited into the system at a constant rate, B. Susceptibles either get
infected, reinfected (at a rate λ
vh
), reactivate infection (at a rate ω) to move to non-severe
symptomatic pneumonia class or die at a rate µ.
Individuals with non-severe symptomatic pneumonia either recover at a rate r
P
or develop
severe pneumonia at a rate α
P
and they die at a rate µ. Those with severe pneumonia
recover at a rate θ
P
and die at a rate µ
P˜
. The equations are in (4.7a)–(4.7c), FIG. 4.3 is
the model diagram and TABLE. 4.2 gives the definitions of the parameters and variables
of pneumonia.
pS
(1− p)S
P
P˜
B
µ
λ
P
+ ω
r
P
α
P
θ
P
µ
P˜
µ
FIG. 4.3. Pneumonia model
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dS
dt
= B + r
P
P − (λ
P
p′ + pω + µ)S, (4.7a)
dP
dt
= (λ
P
p′ + pω)S + θ
P
P˜ − (r
P
+ α
P
+ µ)P, (4.7b)
dP˜
dt
= α
P
P − (θ
P
+ µ
P˜
)P˜ , (4.7c)
where
(i) λ
P
= βpIP /N . βp is the infection rate for pneumonia. IP = ζppS + P + P˜ , N =
S + P + P˜ . I
P
is the infected population, ζp is the reduction in infectiousness of
individuals with asymptomatic pneumonia and N is the total population.
(ii) p′ = p1(1− p) + p2p. p1 and p2 are the proportions of new infections and reinfections
that progress to symptomatic disease respectively.
TABLE. 4.2. Parameters and variables of pneumonia and their descriptions
Variable Description
S Individuals susceptible to pneumonia infection or with asymptomatic in-
fection
P symptomatic individuals
P˜ severe pneumonia individuals
r
P
Recovery rate from pneumonia.
λ
P
Infection terms for pneumonia.
µ, µ
P˜
Death rates for susceptible individuals, individuals with symptomatic
pneumonia and those with severe pneumonia.
α
P
Rate into severe class.
θ
P
Rate out of severe disease class.
ω Reactivation rate for pneumonia.
The biological feasibility of model system (4.7a)–(4.7c) can be proved in the same way as
will be done for the malaria-pneumonia coinfection model in subsection 4.5.1.
We find the equilibrium points of the pneumonia sub-model and establish their stability.
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Equilibrium points
To get equilibrium points of pneumonia model, we set equations (4.7a)–(4.7c) to zero and
solve them in terms of the infection term of pneumonia, λ
P
, to obtain:
S∗ =
B(θ
P
(r
P
+ µ) + µ
P˜
(r
P
+ α
P
+ µ))
µr
P
(θ
P
+ µ
P˜
) + (µ+ pω + p′λ∗
P
)(α
P
µ
P˜
+ µ(θ
P
+ µ
P˜
))
, (4.8a)
P ∗ =
B(pω + p′λ∗
P
)(θ
P
+ µ
P˜
)
µr
P
(θ
P
+ µ
P˜
) + (µ+ pω + p′λ∗
P
)(α
P
µ
P˜
+ µ(θ
P
+ µ
P˜
))
, (4.8b)
P˜ ∗ =
B(α
P
(pω + p′λ∗
P
)
µr
P
(θ
P
+ µ
P˜
) + (µ+ pω + p′λ∗
P
)(α
P
µ
P˜
+ µ(θ
P
+ µ
P˜
))
, (4.8c)
Substituting equations (4.8a)–(4.8c) into the infection term, λ
P
leads to
Dλ∗2
P
+D1λ
∗
P
+D2 = 0, (4.9)
where:
D = p′(θ
P
+ α
P
+ µ
P˜
),
D1 = ((rP + µ)(θP + µP˜ ) + αPµP˜ )(1− (1− p)R
P
0
)− p(p2βP + ω)(θP + µP˜ + αP ),
D2 = −pβP ((θP + µP˜ )(ζprP + ω + ζpµ) + αP (ω + ζpµP˜ ))
with
RP0 =
p1βP (θP + αP + µP˜ )
α
P
µ
P˜
+ (θ
P
+ µ
P˜
)(r
P
+ µ)
which is the basic reproductive number of pneumonia and can be calculated using the next
generation matrix as was done for malaria.
Theorem 4.3.1 i) If p = 0, then the model system (4.7a)–(4.7c) exhibits a transcritical
bifurcation that is when RP0 < 1, only the DFE
P exists and is locally asymptotically stable
while for RP0 > 1, the DFE
P becomes unstable and an EEP exists and is stable.
ii) If p 6= 0, system (4.7a)–(4.7c) has no DFE and has exactly one EEP which is locally
asymptotically stable if and only if RP0 > 1.
Proof 4.3.1 We consider two cases
Case 1: p = 0
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We have:
Dλ∗2
P
+D∗1λ
∗
P
= 0,
where
D∗1 = (αPµP˜ + (θP + µP˜ )(rP + µ))(1−R
P
0 ). (4.10)
Solving equation (4.10) gives λ∗
P
= 0 and λ∗
P
=
(α
P
µ
P˜
+(θ
P
+µ
P˜
)(r
P
+µ))(RP0 −1)
p1(θP+αP +µP˜
)
.
λ∗
P
= 0 yields the DFEP for the pneumonia sub-model and it is given as
(
B
µ
, 0, 0
)
.
λ∗
P
=
(α
P
µ
P˜
+(θ
P
+µ
P˜
)(r
P
+µ))(RP
0
−1)
p1(θP +αP+µP˜
)
gives the EEP which only exists for RP0 > 1.
Case 2: p 6= 0
We have equation (4.9) where D2 is negative which implies that the system has no DFE
and has exactly one positive endemic equilibrium point.
EEPP and its local stability
For the local stability of the EEPP , we make use of the centre manifold theorem in [32]
stated in Theorem A.0.1.
We denote by f = (f1, f2, f3)
T , the right hand side of vector field of the system (4.7a)–(4.7c)
and shift the DFEP to (0, 0, 0) by making a change of variables.
We consider the case when RP0 = 1 and we choose βP as our bifurcation parameter. It is
given as
β∗
P
=
α
P
µ
P˜
+ (θ
P
+ µ
P˜
)(r
P
+ µ)
p1(θP + αP + µP˜ )
.
The linearised system with β
P
= β∗
P
has a zero eigenvalue which is simple.
We use Theorem A.0.1 to analyse the dynamics of the modified system near β
P
= β∗
P
and
in particular we can determine the local stability of the endemic equilibrium of system
(4.7a)–(4.7c).
For computation of a and b, we find the non-vanishing partial derivatives of f at DFEP .
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a = −
(
2p1µβP
B
)(
µ
(
θ
P
µ+ µ
P˜
(α
P
+ µ)
µα
P
)2
+
2µ(θ
P
+ µ
P˜
)
α
P
)
.
Clearly, a < 0.
b = p1µ(
θ
P
+ µ
P˜
α
P
+ 1).
Clearly, b > 0.
With a < 0 and b > 0, there exists a unique endemic equilibrium whenever RP0 > 1 but
close to 1 guaranteed by Theorem A.0.1 and it is locally asymptotically stable.
FIG. 4.4(a), FIG. 4.4(b) and FIG. 4.4(c) show that for all p > 0, there exists an endemic
equilibrium irrespective of the value of RP0 and for p = 0, an endemic equilibrium only
exists if RP0 > 1.
4.4 More on mathematical results
Note that our mathematical analysis considers models of one disease and with all the
parameters constant. This raises a number of concerns: are the insights we obtain and the
inferences we make relevant to our coinfection model with a time dependent parameter?
Suppose we study the malaria model with a time dependent mosquito birth rate, would
the mathematical results obtained for the constant case be related to that of the time
dependent case? Is the basic reproductive number still relevant and if not, is there its
equivalent for a model with a time dependent parameter? What about the long term
behaviour of such a system? We give a brief discussion on some of these concerns.
The mathematical analysis of models with time dependent parameters has not been ex-
plored greatly. There is need to develop threshold values such as the basic reproductive
number for the case of non-autonomous systems. In [32], only the upper and lower limits
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FIG. 4.4. Numerical simulations for RP0
for the persistence and eradiction of TB could be calculated. The results for the non-
autonomous system in [32] showed that when the parameters were taken to be constant,
the reproductive number obtained for elimination and that obtained for persistance were
equal to the basic reproduction number for the model with constant parameters. Thus
thresholds obtained for persistence and elimination of disease can help shed light on the
long time behaviour of models with time dependent parameters.
For our system, the long term behaviour of the system with a time dependent parameter
would depend on the asymptotic property of the mosquito birth rate, bv . A theorem is
given in [32] that helps characterize that kind of behaviour. It provides conditions for
differentiation of the two important biological states: disease elimination or persistence for
a non-autonomous system. Further, it is recommended in [32] that the method of averages
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by Ma et al [210] could be used to find sharp threshold conditions.
Considering time periodic models, [9, 84, 210] explain the meaning of the basic reproductive
number. In [84], a new definition of R
0
based on the generation evolution operator (GEO),
with intuitive clear biological meaning is introduced. The analysis in [84] shows that the
spectral radius of GEO equals the spectral radius of the next generation operator, thus it
gives the basic reproduction number. Further, a weak sign relation is proved which shows
that if the average Malthusian parameter exists, it is nonnegative when R
0
> 1 and it is
nonpositive when R
0
< 1.
In [9], the basic reproductive number, R
0
, is the asymptotic ratio of total births in two
successive generations of the family tree in demography. In epidemiology, it is defined as
the asymptotic ratio of total infections in two successive generations of the infection tree.
In conclusion, our time dependent and periodic models can be studied and their long term
behaviour analysed using insights from the articles we have discussed. Note that though we
did not carry out this analysis, using time dependent models was a useful way of connecting
the parameters in our model to data.
4.5 Malaria-pneumonia coinfection model
We present a mathematical model of malaria and pneumonia coinfection without age struc-
ture in this section. It is a combination of the malaria sub-model in section 4.2 and the
pneumonia sub-model in section 4.3. It is presented for purposes of clarification and as
a tool to understand the coinfection model of malaria and pneumonia with age structure.
We neither perform any mathematical analyses on it nor do we run numerical simulations
for it.
The malaria-pneumonia coinfection model without age structure comprises five classes:
Susceptibles (S), non-severe symptomatic malaria (M), non-severe symptomatic pneu-
monia (P ), non-severe symptomatic malaria-pneumonia coinfection (PM) and the severe
disease class (P˜M).
The severe disease class represents individuals with severe malaria, severe pneumonia and
severe malaria-pneumonia coinfection. We have combined the severe classes, for simplicity
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and also because the symptoms of severe malaria and severe pneumonia overlap [16, 20, 99]
and individuals with either disease in severe cases are treated for both diseases.
The assumptions we used in the malaria and pneumonia sub models still hold in that
susceptible class comprises proportions, m and p of individuals with asymptomatic malaria
and pneumonia infection respectively and malaria and pneumonia induced deaths occur in
the severe (emergency) class only.
In the model, individuals are recruited into the system at a constant rate, B. Susceptible
individuals develop symptomatic disease by infection and reinfection (terms λ
P
and λ
vh
)
and also by reactivation at rates ω and ϑ for pneumonia and malaria respectively and they
die at a rate µ.
Symptomatic pneumonia, malaria and coinfected individuals recover at rates r
P
and r
M
and r
PM
. Individuals in PM class are divided into three proportions, z, z1 and z2 to
represent those who recover from the symptomatic malaria-pneumonia coinfection, pneu-
monia and malaria respectively. z + z1 + z2 = 1. Symptomatic pneumonia, malaria and
coinfected individuals become severe cases at rates α
P
, α
M
and α
PM
accordingly, move out
of the severe class at a rate θ and die at a rate µ.
The severe class, P˜M is divided into three proportions: q represents severe malaria-
pneumonia coinfection, q1 is for severe pneumonia and q2 is for severe malaria. q+q1+q2 =
1. Individuals with severe disease die at a rate µ
P˜M
and it is a combination of the death
rate of severe malaria, severe pneumonia and severe malaria-pneumonia. Note that these
death rates are summation of the disease specific rates and the natural death rate, µ.
We also have mosquito dynamics with the population of mosquitoes being made up of
susceptible and infected mosquitoes. They are recruited into the population at a rate, bv,
are infected with malaria at a rate λ
hv
and die at a rate, µv.
The model equations are given by (4.11a)–(4.11g). Equations (4.11a)–(4.11e) are for the
human population and equations (4.11f) and (4.11g) represent the mosquito population.
FIG. 4.5 is the model diagram and TABLE 4.3 gives a summary of the descriptions of the
variables and some parameters for the coinfection. Note that some of the descriptions of
variables and parameters are already given in TABLE 4.1 and TABLE 4.2.
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FIG. 4.5. Non age structured malaria-pneumonia coinfection model
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dS
dt
= B + r
P
P + r
M
M + zr
PM
PM − (λ
P
p′ + pω + λ
vh
m′ +mϑ)S (4.11a)
−µS,
dP
dt
= (λ
P
p′ + pω)S + z2rMPM + θq1P˜M − (λvhm
′ +mϑ+ r
P
)P (4.11b)
−(α
P
+ µ)P,
dM
dt
= (λ
vh
m′ +mϑ)S + z1rPPM + θq2P˜M − (λP p
′ + pω + r
M
)M (4.11c)
−(α
M
+ µ
M
)M,
dPM
dt
= (λ
P
p′ + pω)M + (λ
vh
m′ +mϑ)P + θqP˜M − (zr
PM
+ z1rP )PM (4.11d)
−(z2rM + αPM + µPM )PM,
dP˜M
dt
= α
P
P + α
M
M + α
PM
PM − (θ + µ
P˜M
)P˜M, (4.11e)
dSv
dt
= bv − (λhv + µv)Sv , (4.11f)
dIv
dt
= λ
hv
S
v
− µ
v
I
v
, (4.11g)
where:
(i) λ
vh
= β
vh
Iv/N . βvh is the rate at which a vector (mosquito) infects a human, Iv is
the infected vector (mosquito) population and N is the human population.
(ii) m′ = m1(1 − m) + m2m. m1 and m2 are the proportions of new infections and
reinfections that progress to symptomatic disease respectively.
(iii) λ
hv
= β
hv
(I
M
/N). β
hv
is the rate at which a vector (mosquito) becomes infected by
biting an infected human and I
M
= ζmmS+M+PM+(q+ q2)P˜M is the population
of humans with malaria infection.
(iv) λ
P
= βpIP /N . βp is the infection rate for pneumonia. IP = ζppS + P + PM + (q +
q1)P˜M is the population of individuals infected with pneumonia.
(v) p′ = p1(1− p) + p2p. p1 and p2 are the proportions of new infections and reinfections
that progress to symptomatic pneumonia disease respectively.
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TABLE. 4.3. Variables, parameters for malaria-pneumonia coinfection model and their
descriptions
Variable/Parameter Description
S Individuals susceptible to malaria or pneumonia infec-
tion and those with asymptomatic malaria or pneumonia
infection
PM symptomatic malaria-pneumonia individuals
P˜M Individuals with severe malaria, severe pneumonia or
severe malaria-pneumonia disease.
r
PM
Recovery rate for malaria-pneumonia coinfection disease
α
PM
Rate at which malaria-pneumonia coinfected individuals
move to severe class
θ Rate out of severe disease class
µ
P˜M
Death rate for severe disease
q, q1, q2 Proportions of individuals with severe malaria-
pneumonia coinfection, severe pneumonia and severe
malaria respectively.
z, z1, z2 Proportions of individuals with malaria-pneumonia
coinfection who move to susceptible, malaria and pneu-
monia classes respectively after recovery from the coin-
fection, pneumonia and malaria accordingly.
4.5.1 Positivity and boundedness of solutions
For biological feasibility of system (4.11a)–(4.11g), it is important that all variables stay
positive at all times and as such we analyse this system in the region
Ω =
{
(S, P,M, PM, P˜M, Sv , Iv) ∈ ℜ
7
+ : S + P +M + PM + P˜M ≤
B
µ
, Sv + Iv ≤
bv
µv
}
.
Solutions of the system, remain positive for all time t ≥ 0 and are bounded in Ω.
Proposition 4.5.1 System (4.11a)–(4.11g) has for each positive initial condition, a unique
solution that is positive. Moreover, the region Ω is positively invariant.
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Proof. Let S(0), P (0),M(0), PM(0), P˜M(0), Sv(0), Iv(0) be positive initial conditions and
t1 = sup
{
t > 0 : S(τ) > 0, P (τ) > 0, M(τ) > 0, PM(τ) > 0, P˜M(τ) > 0, Sv(τ) > 0,
Iv(τ) > 0, for all τ ∈ [0, t]
}
.
Since S(0) ≥ 0, P (0) ≥ 0,M(0) ≥ 0, PM(0) ≥ 0, P˜M(0) ≥ 0, Sv(0) ≥ 0, Iv(0) ≥ 0, thus
t1 > 0. If t1 < ∞, then necessarily S or P or M or PM or P˜M is equal to zero at t1.
Using the variation of constants formula, we have:
S(t1) = S(0) exp[−
∫ t1
0
(λ1 + µ)(s)ds]
+
∫ t1
0
(B + r
P
P + r
M
M + zr
PM
PM) exp[−
∫ t1
s
(λ1 + µ)(τ)dτ ]ds.
where λ1 = λP p
′ + pω + λ
vh
m′ +mϑ.
Moreover, since all the variables are positive in [0, t1], then S(t1) > 0. It can be shown in
a similar way that P (t1) > 0, M(t1) > 0, PM(t1) > 0, P˜M(t1) > 0 and Iv(t1) > 0 which
is a contradiction. Hence t1 =∞.
For the invariance of Ω, we add the equations of system (4.11a)–(4.11e) for the human
population to obtain:
dN(t)
dt
= B − µ(PM + P +M + S)− µ
P˜M
P˜M.
Since the solution is positive and µ
P˜M
> µ, then
dN(t)
dt
≤ B − µN(t).
Therefore, N(t) ≤ N(0)e−µt + B
µ
(1 − e−µt) and if N(0) ≤ B
µ
then so is N(t). Moreover,
whenever N(t) > B
µ
, N(t)′ < 0.
For the mosquito population
dNv(t)
dt
= b
v
− µ
v
N
v
.
Therefore, Nv(t) ≤ Nv(0)e
−µv t+ bv
µv
(1−e−µv t) and if Nv(0) ≤
bv
µv
then so is Nv(t). Moreover,
whenever Nv(t) >
bv
µv
, Nv(t)
′ < 0. Thus every solution of the model equations (4.11a)–
(4.11g) with initial conditions in R7+ approaches and stays in Ω as t→∞.
Having shown that the coinfection model with no age-structure is biologically feasible, the
biological feasibility of the sub models of malaria and pneumonia can be shown in the same
way.
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4.6 Age structured malaria-pneumonia model
The coinfection model with age structure is an extension of the model without age structure
in section 4.5. It is made up of three age groups, [0, 5), [5, 14) and [14, 50) and these are
represented by subscript j = c, b, a on the variables and parameters. Individuals age from
one age group to the next at a rate ηi, i = 1, 2, 3.
All the other definitions of variables and parameters stay the same as explained in section
4.5 with a subscript c, b or a to represent which age group the variable or parameter is in.
The mosquito dynamics are as before except that we have different infection rates for the
different age groups.
Model equations are given by (4.12a)–(4.12e) for the [0, 5) age group, (4.13a)–(4.13e) for
the [5, 14) age group, (4.14a)–(4.14e) for the [14, 50) age group and (4.15a)–(4.15b) for
mosquito dynamics. The model diagram is given by FIG. 4.6.
Sc
S
b Sa
Pc
Mc
PMc
P˜Mc
P
b
M
b
PM
b
P˜M
b
Pa
Ma
PMa
P˜Ma
B
µc
η1
µ
b
η2
µa
µ
Pc
, µ
Mc
, µ
PMc
, µ
P˜Mc
µ
P
b
, µ
M
b
, µ
PM
b
, µ
P˜M
b
µ
Pa
, µ
Ma
, µ
PMa
, µ
P˜Ma
bv Sv
µvµv
λ
hv
Iv
η3
FIG. 4.6. Malaria and pneumonia co-infection model
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Equations for [0, 5) age group
dS
c
dt
= B + r
Pc
Pc + rMcMc + zcrPMcPMc − (λPc p
′
c + pcωc + λvhcm
′
c)Sc (4.12a)
−(mcϑc + µc + η1)Sc ,
dPc
dt
= (λ
Pc
p′c + pcωc)Sc + z2crMcPMc + θcq1cP˜Mc − (λvhcm
′
c +mcϑc)Pc(4.12b)
−(r
Pc
+ α
Pc
+ µ
Pc
+ η1)Pc ,
dM
c
dt
= (λ
vhc
m′c +mcϑc)Sc + z1crPcPMc + θcq2cP˜Mc − (λPc p
′
c + pcωc)Mc(4.12c)
−(r
Mc
+ α
Mc
+ µ
Mc
+ η1)Mc ,
dPM
c
dt
= (λ
Pc
p′c + pcωc)Mc + (λvhcm
′
c +mcϑc)Pc + θcqcP˜Mc − z1crPcPMc (4.12d)
−(z2crMc + zcrPMc + αPMc + µPc + η1)PMc,
dP˜M
c
dt
= α
Pc
Pc + αMcMc + αPMcPMc − (θc + µP˜Mc
+ η1)P˜Mc , (4.12e)
Equations for [5, 14)
dS
b
dt
= η1Sc + rP
b
P
b
+ r
M
b
M
b
+ r
PM
b
PM
b
− (λ
P
b
p′b + pbωb + λvh
b
m′b)Sb (4.13a)
−(mbϑb + µb + η2)Sb ,
dP
b
dt
= η1Pc + (λP
b
p′b + pbωb)Sb + z2brM
b
PM
b
+ θ
1b
q1bP˜Mb − (λvh
b
m′b)Pb(4.13b)
−(mbϑb + αP
b
+ µ
P
b
+ η2)Pb ,
dM
b
dt
= η1Mc + (λvh
b
m′b +mbϑb)Sb + z1brP
b
PM
b
+ θ
2b
q2bP˜Mb − λP
b
p′bMb(4.13c)
−(pbωb + rM
b
+ α
M
b
+ µ
P
b
+ η2)Mb ,
dPM
b
dt
= η1PMc + (λP
b
p′b + pbωb)Mb + (λvh
b
m′b +mbϑb)Pb + θbqbP˜Mb (4.13d)
−(z1brP
b
+ z2brM
b
+ zbrPM
b
+ α
PM
b
+ µ
P
b
+ η2)PMb ,
dP˜M
b
dt
= η1P˜Mc + αP
b
P
b
+ α
M
b
M
b
+ α
PM
b
PM
b
− (θ
b
+ µ
P˜M
b
+ η2)P˜Mb, (4.13e)
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Equations for [14, 50)
dS
a
dt
= η2Sb + rPaPa + rMaMa + rPMaPMa − (λPa p
′
a + paωa)Sa (4.14a)
−(λ
vha
m′a +maϑa + µa + η3)Sa ,
dPa
dt
= η2Pb + (λPa p
′
a + paωa)Sa + z2arMaPMa + θ1aq1aP˜Ma (4.14b)
−(λ
vha
m′a +maϑa + αPa + µPa + η3)Pa,
dM
a
dt
= η2Mb + (λvham
′
a +maϑa)Sa + z1arPaPMa + θ2aq2aP˜Ma (4.14c)
−(λ
P
p′a + paωa + rMa + αMa + µPa + η3)Ma ,
dPM
a
dt
= η2PMb + (λPa p
′
a + paωa)Ma + (λvham
′
a +maϑa)Pa + θaqaP˜Ma (4.14d)
−(z1arPa + z2arMa + zarPMa + αPMa + µPa + η3)PMa,
dP˜Ma
dt
= η2P˜Mb + αPaPa + αMaMa + αPMaPMa − (θa + µP˜Ma
+ η3)P˜Ma.(4.14e)
The mosquito dynamics are given by
dSv
dt
= bv − (λhvc + λhvb
+ λ
hva
)Sv − µvSv , (4.15a)
dIv
dt
= (λ
hvc
+ λ
hv
b
+ λ
hva
)Sv − µvIv , (4.15b)
where:
(i) λ
vhc
= β
vhc
Iv/N , λvh
b
= β
vh
b
Iv/N , λvha = βvha Iv/N . βvhc , βvhb
, β
vha
are the rates
at which a vector (mosquito) infects an individual in the [0, 5), [5, 14), [14, 50) age
groups respectively. Iv is the infected vector (mosquito) population and N is the
human population.
(ii) For the [0, 5) age group, m′c = m1c(1−mc)+m2cmc. m1c and m2c are the proportions
of new infections and reinfections that progress to symptomatic disease respectively.
The same definitions hold for the [5, 14) and [14, 50) age groups which are represented
by subscripts b and a accordingly.
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(iii) λ
hvc
= β
hvc
(I
M
/N). β
hvc
is the rate at which a vector (mosquito) becomes infected by
biting an infected human in the [0, 5) age group. I
M
=
∑
j=c,b,a ζmmjSj+Mj+PMj+
(qj + q2j)P˜Mj is the population of humans with malaria infection. The same defini-
tions hold for the [5, 14) and [14, 50) age groups which are represented by subscripts
b and a in turn.
We use this age structured malaria-pneumonia coinfection model to generate the numerical
simulations we present in this chapter.
4.7 Parameters from literature
In addition to parameters obtained using IDCAP data, we also get parameters from liter-
ature. In this section, we describe and give information about parameter values and their
source. The parameters are displayed in TABLE. 4.4 and TABLE. 4.5. Most of the rates
will be given in units of years, a few in months and some in days. However, all the model
simulations are run using the time unit of months.
4.7.1 Birth rate
We use demographical data for Uganda: according to the 2000/2001 census, the crude
birth rate of Uganda was 47.3 per 1000 [148] and in the 2005/2006, it was 41 per 1000
[149].
Uganda has a young population with approximately 50% of its population being under 15
years of age [85]. Therefore, a model with a density dependent birth term and realistic
aging rates would represent its demography well. It would show a population growing
exponentially which is representative of Uganda’s population for the last two decades up-
to-date. However, when disease dynamics are incorporated, using such a model would also
show an exponential growth in the number of disease cases. To avoid this, we use a model
with a constant birth term and choose appropriate aging, birth and death rates to obtain
a realistic age structure.
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4.7.2 Natural death rates
We calculated natural death rates using population numbers from Spectrum (DemProj)
[87] with default Uganda country data. Probabilities of dying in different age groups in the
years 2009 to 2011 were obtained (Number of deaths within an age group in a particular
year/Population of age group in that year). Using these probabilities, the rates of death
for the years under consideration were calculated using formulas in [61, 124]. We took the
average death rates, considering the years 2009 to 2011, and these were given as µc = 0.026,
µ
b
= 0.004 and µa = 0.008 for the [0, 5), [5, 14) and [14, 50) age groups respectively.
4.7.3 Aging rates
The age distribution of Uganda is about 19% for [0, 5), 27% for [5, 14) and 54% for [14, 50)
[85]. To reflect this age structure, we adopted the following aging rates: 0.19 for [0, 5), 0.13
for [5, 14) and 0.057 for [14, 50).
4.7.4 Parameters of malaria
Mosquito birth rate
This is time dependent to account for the change in the number of mosquitoes born in the
different seasons which in turn accounts for the number of malaria cases seen at health
facilities.
We estimate four values for the mosquito birth rate using 23 months of data available
(refer to subsection 3.2.1) and then use a periodic function which considers the averages
of the first two low ones and the first two peak ones afterwards. The absolute numbers of
mosquitoes born are given by b0, b1, b2 and b3 in TABLE. 4.6 and the ones after, b4 is the
average of b0 and b2 and b5 is the average of b1 and b3 and then have a repetition, with
b6 = b4.
When changing the values of the mosquito birth rate, we make use of a function that joins
two values smoothly. Suppose the number of mosquitoes born changes from value bj to
Stellenbosch University  http://scholar.sun.ac.za
Chapter 4. Malaria-Pneumonia Coinfection Model 64
value bj+1, then the function is given by
f(t) = b0 +
5∑
j=0
(bj+1 − bj)e
−ks (t−τj)
eks(t−τj ) + e−ks(t−τj )
,
where t is the time, ks is parameter that determines the slope and τj is the time point at
which the value changes from bj to bj+1.
The times (in months) at which one value changes to another are given by τ0, τ1, τ2, τ3, τ4, τ5.
τ0, τ1, τ2 and τ3 are given in TABLE. 4.6. The values τ4 and τ5 are got by examining the
differences τ1 − τ0 = 3.5, τ3 − τ2 = 3 and τ2 − τ1 = 9. We then take the difference between
τ4 and τ3 as equal to 9 and that between τ5 and τ4 as 3.5 and thus we have τ4 = 28.5 and
τ5 = 32.
FIG. 4.7.4 shows the simulated time dependent mosquito births.
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FIG. 4.7. Mosquito births
Infection term
This is calculated from two terms, the probability of transmission of malaria from mosquito
to human, p
vh
or the probability of transmission of malaria from human to mosquito, p
hv
and the mosquito biting rate.
p
vh
ranges from 0.01 to 0.2 [17] and p
hv
ranges from 0.2 to 0.5 [58, 101, 105, 175]. The
mosquito biting rate is given as 0.3 per day [58, 101, 105, 175].
We estimated these probabilities of transmission of malaria for the different age groups and
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their values are given in TABLE. 4.6. Furthermore, asymptomatic and symptomatic indi-
viduals have differences in infection rates. It is not clear which of the two kinds of individu-
als is more infectious than the other [103], because some studies report that asymptomatic
individuals are more infectious than symptomatic individuals [4, 156] and others report the
opposite [67]. However, for our model simulations, we considered that the infection rate
of asymptomatic individuals is reduced by a factor ζm = 0.5 as compared to symptomatic
individuals.
Rate into emergency and reactivation rate
The rate of progressing to severe disease depends on the time taken before one becomes
an emergency case. It may differ in different individuals depending on their immunity to
the disease. Individuals who have not been exposed to malaria before may develop severe
disease in 3 to 30 days after infection if not treated, yet it might take 14 days even months
for those who have been exposed to malaria [189]. The rates out of emergency for the age
groups [0, 5), [5, 14) and [14, 50) were estimated and their values are in TABLE. 4.6.
Individuals with malaria infection may develop symptomatic malaria after infection or
they may stay with the infection and reactivate it later. In [189], it may take months and
even years before malaria infection is reactivated and it might be due to the individuals
immunity being compromised by other infections. We estimated the reactivation rates for
the age groups [0, 5), [5, 14) and [14, 50) and their values are given in TABLE. 4.6.
Malaria death rates
One of our model’s assumption is that deaths due to malaria occur only in the severe
class and that individuals with symptomatic malaria just experience natural death as the
susceptible individuals (fully susceptible and asymptomatic individuals).
For individuals who are untreated, the average duration that they spend in the severe
disease class is unknown as there is very little literature on severe disease in untreated
individuals and an experiment carried out to that effect would be unethical. In [189], it
is said that death from severe disease may occur within hours or days. Lubell et al [111]
state that the probability of dying from severe malaria in untreated cases is 73% for low
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transmission settings and it is 60% for high to medium transmission settings. However,
there is no time frame mentioned. Thus, we use the population mortality rates of all
malaria that are given in [2, 117, 127, 178, 206] and choose the severe malaria induced
death rates such that they show these population mortality rates. Please note that the
death rate experienced by individuals with severe malaria will be a summation of the
natural death rate and the severe malaria induced death rate. These death rates are given
in TABLE. 4.4.
Prevalence of malaria parasitaemia
This ranges from 15% to 81% [138, 149, 152] in children less than 10 years of age depending
on the area. In individuals greater than 5 years of age, it was given as 24.7% in very
high transmission districts and 16.8% in moderate to high transmission districts [138]. It
is measured by either microscopy, RDTs or PCR. Microscopy and RDTs are the most
commonly used though the most sensitive method is PCR [27, 150].
4.7.5 Parameters of pneumonia
Infection rate
This is the rate at which individuals acquire pneumonia infection. In [176], the probabil-
ity of acquisition of different serotypes of S. pneumoniae in young children ranged from
0.00007 to 0.0059 per day which gives a range of rates from 0.025 to 2.16 per year.
Only a proportion of individuals with pneumonia infection develop symptomatic pneumo-
nia and it is dependent on the age and immune status of the individual. Moreover, asymp-
tomatic individuals are less infectious than symptomatic individuals, their infectiousness
is reduced by a factor ζp = 0.5.
Rate into emergency and reactivation rate
Severe disease occurs mostly in children under five years of age. Children may develop
severe pneumonia in the range of 3 to 7 days [98]. Severe disease does occur in adults but
rarely and there might be other underlying causes such as infection with malaria.
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TABLE. 4.4. Demography parameters and parameters of malaria
Parameter Description Value (unit time) Reference
ρ Human birth rate 0.0435 (yr−1) Chosen [85,
148, 149]
µ
c
, µ
b
, µ
a
Natural death rates 0.026, 0.004, 0.008 (yr−1) Spectrum
[87]
η1, η2, η3 Aging rates 0.19, 0.13, 0.057 (yr
−1) Chosen
a
b
Number of bites per
mosquito per unit of
time
0.3 (day−1) [58, 101,
105, 175]
ζm Reduction in infectious-
ness of asymptomatic
individuals
0.5 Chosen
[4, 156]
µ
v
Death rate of mosquito 0.1 (day−1) [58, 101,
105, 175]
µ
M˜c
, µ
M˜
b
, µ
M˜a
. Death rate in emer-
gency
0.028, 0.109, 0.0107
(mth−1)
Chosen
mc, mb, ma Proportion with asymp-
tomatic malaria
0.5, 0.3, 0.2 [118, 149]
m1c = m2c, m1b =
m2c, m1a = m2a
Proportion of new
infections and rein-
fections that develop
symptomatic disease
0.1, 0.05, 0.05 Assumed
Some individuals with asymptomatic pneumonia may reactivate their infection.
The rates into emergency and the reactivation rates for individuals in the three age groups
were estimated and their values are given in TABLE 4.6.
Death rates
As with the malaria, we consider that only individuals with severe pneumonia die due to
pneumonia. Lubella et al [111] state that the probability of dying from a severe illness
requiring antibiotics ranges from 28% to 68%. On the other hand, the case fatality ratio of
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non-severe pneumonia ranges from 3% to 10% and that of severe pneumonia ranges from
10% to 50%[13, 18, 55, 57, 60, 98, 102, 128, 166, 177, 179, 182]. However, we are unable
to use this information because the time frame for untreated individuals with pneumonia
is unknown.
In [161], pneumonia induced mortality rate for children less than 5 years of age was given
as 67.5 per 10, 000. For the other age groups, it is less than 5 per 1000 [2].
Thus, we choose the death rate for severe pneumonia so as to reflect these population
mortality rates. The death rates for individuals with severe pneumonia for the three age
groups is given in TABLE 4.5.
TABLE. 4.5. Parameters of pneumonia model
Parameter Description Value (unit time) Reference
β
Pc
, β
P
b
, β
Pa
infection rates 0.025 to 4.38 (yr−1) [3, 176, 187]
ζp Reduction in infectious-
ness of asymptomatic
individuals
0.5 Chosen
µ
P˜c
, µ
P˜
b
, µ
P˜a
Pneumonia death rate
in emergency
0.302, 0.759, 0.117 (mth−1)
pc, pb, pa proportion with asymp-
tomatic pneumonia
0.6, 0.3, 0.2 [22, 91]
p1c = p2c, p1b =
p2b, p1a = p2a
Proportion of new
infections and rein-
fections that develop
symptomatic disease
0.15, 0.05, 0.01 [69]
4.7.6 Parameters of malaria-pneumonia coinfection
Proportion of coinfection
The proportion of individuals with malaria who have pneumonia ranges from 4% to 37%
[16, 19, 20, 54, 99, 173]. However, it is important to note that some studies such as the
one by Karin et al. [99] were presumptive and most of the studies were carried out among
children of less than 5 years of age.
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The proportion of children with ARIs (pneumonia) who had malaria was 45% in [60].
Death rates
The death rate is higher for individuals with malaria-pneumonia coinfection than for indi-
viduals with malaria only.
In [16], the case fatality ratio of severe malaria cases who also had bacteraemia was 22.0%
yet that of severe malaria cases only was 4% and in [173], the case fatality for children with
severe pneumonia and clinical malaria was 14% and that for clinical malaria only was 9%.
There is a 2 to 5 fold increase in mortality if there is bacteraemia (pneumonia) present
in children with severe malaria [16, 20, 173]. In our model simulations, we use a 3 fold
increase in mortality individuals with severe malaria-pneumonia coinfection.
4.8 Model fitting and parameter estimation
4.8.1 Human and mosquito population
We use a human population of 36000 for the average study site in Arm A and this number
is divided into the respective classes of susceptibles, malaria, pneumonia and coinfection.
The population for the mosquitoes is determined by using the Entomological Inoculation
Rate (EIR) which is expressed in terms of average numbers of infective bites per person per
unit time. It is simply the product of the human biting rate and prevalence of sporozoites
in the mosquito population [17, 76, 93, 97] which gives the number of infective bites per
person per unit time.
In equation terms and in relation to our model, the EIR is given as a
b
Iv
Nv
Nv
N
, where a
b
is
the mosquito biting rate given per year. Iv
Nv
is the sporozoite rate and Nv
N
is the mosquito
to human ratio.
In Uganda, about 70% of the regions have an EIR > 100 and about 20% have an EIR > 10
and the other 10% have an EIR > 1% [152, 206]. The sporozoite rate ranges from 1% to
20% [17, 50, 53, 97, 106].
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We use an EIR of approximately 130 per year and a sporozoite rate of 19% to give a ratio
of mosquito to humans. Multiplying this ratio with the human population gives us the
population of mosquitoes at the site of 224946.
Note that the sporozoite rate of 19% is the fitted value that we get and it is the average
considering all the available months of data. However, we use a sporozoite rate of 5% for
initial conditions so as to capture the low malaria values at baseline.
Our initial conditions for the model are:
Sc(0) = 6605, Pc(0) = 20, Mc(0) = 109, PMc(0) = 6, P˜Mc(0) = 100
S
b
(0) = 9604, P
b
(0) = 6, M
b
(0) = 78, PM
b
(0) = 0, P˜M
b
(0) = 32
Sa(0) = 19251, Pa(0) = 28, Ma(0) = 111, PMa(0) = 1, P˜Ma(0) = 49
Sv(0) = 213699, Iv(0) = 11247.
4.8.2 Fitting baseline data
We fit baseline data from Arm A sites using an optimization tool built in Matlab that uses
the least squares method and goodness of fit techniques. The data fitted are the average
predicted number of malaria cases and the average predicted number of pneumonia cases
for an average study site of Arm A.
The number of pneumonia cases at baseline for the three age groups, [0, 5), [5, 14) and
[14, 50) are given in TABLE. 3.2.
FIG. 3.1(a), FIG. 3.1(b) and FIG. 3.1(c) show the predicted number of malaria cases for the
age groups [0, 5), [5, 14) and [14, 50) at baseline and after the two interventions of Integrated
Management of Infectious Disease (IMID) training and On-Site Support Services (OSS).
Malaria data is seasonal with a peak in the June of the first year and July of the second
year and these months correspond to the rainy season in Uganda.
To capture this dynamics, we use a time dependent mosquito birth rate (refer to subsection
4.7.4) since it is known that the number of mosquitoes increases during the rainy season
due to the availability of stagnant pools of water for breeding of mosquitoes.
Individuals in the population have asymptomatic malaria infection and thus high numbers
of mosquitoes lead to an increase in malaria transmission which in turn translates into
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disease and explains the peak in the number of malaria cases that is seen at health facilities
[29, 47, 65] during the rainy season.
TABLE. 4.6 gives the fitted parameter values for the baseline data. The rates’ units are
in months.
The model fits to the malaria data using the optimization tool built in Matlab are given
in FIG. 4.8(a), FIG. 4.8(b) and FIG. 4.8(c).
FIG. 4.9(a) is the fit to pneumonia data and FIG. 4.9(b) of malaria-pneumonia cases is a
consequence of the first two fits.
TABLE. 4.6. Estimated parameters with baseline data
Parameter Estimated value
b0, b1, b2, b3 2567, 649900, 125232, 649900
τ0, τ1, τ2, τ3 4.0, 7.5, 16.5, 19.5
k 0.9
α
Pc
= α
PMc
, α
P
b
= α
PM
b
, α
Pa
= α
PMa
2.0278, 0.1521, 0.1217
α
Mc
, α
M
b
, α
Ma
0.468, 0.1014, 0.1014
β
Pc
, β
P
b
, β
Pa
0.0353, 0.0128, 0.0238
ω
Pc
, ω
P
b
, ω
Pa
0.0459, 0.0075, 0.0295
ϑ
Pc
, ϑ
P
b
, ϑ
Pa
0.04, 0.0317, 0.0408
p
vhc
, p
vhb
, p
vha
0.025, 0.045, 0.02
p
hvc
, p
hvb
, p
hva
0.015, 0.305, 0.89
Duration of symptomatic malaria and coin-
fection disease
7 days
Duration of symptomatic pneumonia 3 days
At baseline, the prevalence of severe cases for malaria-pneumonia coinfection is 7%, pneu-
monia is 2% and that of malaria is 25%. The incidence rate of malaria disease is 0.03 per
month for [0, 5) age group, 0.02 per month for [5, 14 and 0.015 per month for the [14, 50)
age group as shown in FIG. 4.14(c).
The incidence rate of pneumonia disease is 0.03 per month for [0, 5) age group, 0.02 per
month for [5, 14 and 0.015 per month for the [14, 50) age group as shown in FIG. 4.19(c).
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FIG. 4.8. Fitting malaria cases at baseline for age groups [0, 5), [5, 14) and [14, 50)
4.8.3 Fitting intervention data
In fitting IMID combined with OSS data, we change the parameters of recovery rate and
the rate out of emergency according to the changes in the indicators after the intervention.
We make use of the following formula:
Indicator after intervention = indicator before intervention × (1 + (coverage of intervention
× impact of intervention on indicator))
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FIG. 4.9. Pneumonia and coinfection cases for baseline for age groups [0, 5), [5, 14) and
[14, 50). The number of [0, 5) coinfection cases per month is about 30 and it is about 2
cases each for [5, 14) and [14, 50)
Coverage of intervention
This was expressed as the percentage of patients that were attended to by MLPs who had
taken part in IMID training (IMID intervention) and those that had attended OSS (OSS
intervention).
The coverage of intervention with IMID was calculated using IDCAP data on the percent-
age of patients who were attended to by clinicians who had taken part in IMID training.
It was given as 26% across all age groups.
For the combination intervention of IMID and OSS, we used the coverage of intervention
as 21% for the [0, 5) and 60% for the [5, 14) age groups and 40% for the [14, 50) age group
for the model to fit the data. Please note that in this case, we did not make use of an
optimization tool because the only value that was needed for the fit was the coverage of
the intervention and we could easily vary it until we obtained a reasonable fit.
To estimate the effect of IMID only as well as the incremental effect of OSS, we used the
impact of IMID and IMID+OSS on the indicators as calculated in section 3.3 and given
in TABLE. 3.4.
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4.9 Numerical results
4.9.1 Malaria
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FIG. 4.10. Model fit to malaria cases after combination intervention of IMID and OSS
for age groups [0, 5), [5, 14) and [14, 50) in FIG. 4.10(a), FIG. 4.10(b), FIG. 4.10(c). The
effect of IMID, IMID+OSS and incremental impact of OSS on all malaria cases is shown
in FIG. 4.10(d).
FIG. 4.10(a), FIG. 4.10(b) and FIG. 4.10(c) show a decrease in the number of malaria
cases after the intervention of IMID and the IMID+OSS intervention for the [0, 5), [5, 14)
and [14, 50) age groups respectively.
The effect of IMID increases initially for a period of five months of the IMID intervention
and then stays relatively constant for the rest of the intervention as displayed by FIG.
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4.10(d). After the initial increase during the first five months of the IMID intervention,
the effect of IMID for the [0, 5) age group remains constant with an average value of 4.4%
for the rest of the intervention period. For the [5, 14) age group, the average effect of IMID
after the initial rise in the first five months is 2.6%. For the [14, 50), the effect of IMID
increases for a period of five months and then stays constant with an average effect of 2.7%
for the rest of the intervention period.
0 5 10 15 20 25
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Time (months)
IM
ID
+O
SS
 e
ffe
ct
 o
n 
m
al
 c
as
es
 
 
[0,5)
[5,14)
[14,50)
(a)
0 5 10 15 20 25
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Time (months)
In
cr
em
en
ta
l i
m
pa
ct
 (O
SS
)
 
 
[0,5)
[5,14)
[14,50)
(b)
FIG. 4.11. Effect of OSS on malaria cases for the age groups [0, 5), [5, 14) and [14, 50) in
FIG. 4.11(a), FIG. 4.11(b), gives the incremental impact of OSS on malaria cases for the
three age groups.
There is a noted initial rise in the effect of IMID+OSS intervention and the incremental
impact of OSS on malaria cases for the first five months after the start of the intervention
across all age groups and then it stabilizes as displayed in FIG. 4.11(a). The average effect
of OSS on malaria cases for the [0, 5) age group is 17%, 26.9% for the [5, 14) age group and
20.7% for the [14, 50) for the remaining intervention period.
FIG. 4.11(b) shows the incremental impact of OSS across all the three age groups. There
is a rise in the incremental impact of OSS for the first five months of the intervention and
then it stabilizes for the remaining period of the intervention. The average incremental
impact of on malaria cases for the stable period is 13.2%, 24.9%, 18.6% for the [0, 5),
[5, 14), [14, 50) age groups respectively.
There is a decline in the number of malaria deaths across all age groups as displayed in
FIG. 4.12(a), FIG. 4.12(b) and FIG. 4.12(c). The average effect of IMID on malaria deaths
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FIG. 4.12. Malaria deaths for age groups [0, 5), [5, 14) and [14, 50) in FIG. 4.12(a), FIG.
4.12(b), FIG. 4.12(c) respectively. FIG. 4.12(d) illustrates the effect of IMID, IMID+OSS
and incremental impact of OSS on all malaria deaths
is a decrease of approximately 7.8% for all the age groups as shown in FIG. 4.12(d).
The average effect of IMID+OSS on malaria deaths for the remaining intervention period
after the initial rise in the first five months is a fall of 30.8% for the [0, 5) age group, 64.5%
for the [5, 14) age group and 52.9% for the [14, 50).
The incremental impact of OSS also rises in the initial five months and then relatively
stabilizes for the rest of the intervention period. For the [0, 5) age group, the incremental
impact of OSS is a decline of 25% and it is 61.5% and 48.8% for the [5, 14) and [14, 50)
respectively.
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FIG. 4.13. Effect of OSS on malaria deaths in FIG. 4.13(a) and the incremental impact of
OSS on malaria cases for the three age groups in FIG. 4.13(b).
In FIG. 4.14(a),malaria disease prevalence decreases with the interventions of IMID and
combination intervention of IMID and OSS from a baseline value of 1.41% to 1.2% with
the combination intervention of IMID and OSS.
The effect of IMID on all malaria disease prevalence is a decrease of 3.2%. The effect of
OSS is a decline of 19.7% and the incremental impact of OSS is 17.1%. This is displayed
in FIG. 4.14(b).
In FIG. 4.14(c), there is no change in malaria incidence with the intervention across all
age groups.
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FIG. 4.14. Malaria disease prevalence for all individuals in FIG. 4.14(a) and the effect on
malaria prevalence in FIG. 4.14(b). FIG. 4.14(c) shows the malaria incidence for the [0, 5),
[5, 14) and [14, 50) age groups
4.9.2 Pneumonia
FIG. 4.15(a), FIG. 4.15(b) and FIG. 4.15(c) show a decrease in the number of pneumonia
cases after the interventions for the [0, 5), [5, 14) and [14, 50) age groups respectively. How-
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FIG. 4.15. Pneumonia cases for age groups [0, 5), [5, 14) and [14, 50) in FIG. 4.15(a), FIG.
4.15(b), FIG. 4.15(c). The effect of IMID and OSS, IMID and the incremental impact of
OSS is shown in FIG. 4.15(d).
ever, for the [14, 50) age group, the IMID intervention reduces the number of pneumonia
cases than the combination intervention of IMID and OSS.
The effect of IMID increases initially for a period of five months of the IMID intervention
and then stays relatively constant for the rest of the intervention as displayed by FIG.
4.15(d). The effect of IMID for the [0, 5) age group for the rest of the intervention after
the initial rise in the first five months is on average a decrease of 4.8%. For the [5, 14) and
[14, 50) age groups, it is 3.6% and 3.2% respectively.
There is a noted initial rise in the effect of IMID+OSS and the incremental impact of
OSS on pneumonia cases for the first five months after the start of the intervention across
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FIG. 4.16. The effect of combination intervention of IMID and OSS and the incremental
impact of OSS in FIG. 4.16(a) and 4.16(b)
all age groups and then it stabilizes as displayed in FIG. 4.16(a). The average effect of
IMID+OSS on pneumonia cases for the [0, 5) age group is 14.6%, 8.3% for the [5, 14) age
group and 2.1% for the [14, 50) for the remaining intervention period.
FIG. 4.16(b) shows the incremental impact of OSS across all the three age groups. For
the [0, 5) and [5, 14) age groups, the incremental impact of OSS is positive which implies
that there is an additional benefit in having the OSS intervention. However, this is not the
case for the [14, 50) age group where the incremental impact of OSS is negative meaning
that the OSS intervention is not needed for this age group infact it does not do well. The
average incremental impact of on pneumonia cases for the stable period after the first five
months is 10.2%, 4.9%, −1.1% for the [0, 5), [5, 14), [14, 50) age groups respectively.
There is a decline in the number of pneumonia deaths across all age groups as displayed
in FIG. 4.17(a), FIG. 4.17(b) and FIG. 4.17(c). The average effect of IMID on pneumonia
deaths is a decrease of approximately 7.8% for all the age groups as shown in FIG. 4.17(d).
The average effect of IMID+OSS on pneumonia deaths for the remaining intervention
period after the initial rise in the first five months is a fall of 30.8% for the [0, 5) age group,
64.5% for the [5, 14) age group and 52.9% for the [14, 50).
The incremental impact of OSS also rises in the initial five months and then relatively
stabilizes for the rest of the intervention period. For the [0, 5) age group, the incremental
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FIG. 4.17. Deaths due to pneumonia for age groups [0, 5), [5, 14) and [14, 50). The effect
of IMID, and IMID+OSS on pneumonia deaths is displayed in FIG. 4.17(d)
impact of OSS is a decline of 25% and it is 61.5% and 48.8% for the [5, 14) and [14, 50)
respectively.
In FIG. 4.19(a),pneumonia disease prevalence decreases with the interventions of IMID
and combination intervention of IMID and OSS from a baseline value of 31.3% to 29.1%
with the combination intervention of IMID and OSS.
The effect of IMID on all pneumonia disease prevalence is a decrease of 4.1%. The effect
of IMID+OSS is a decline of 9.2% and the incremental impact of OSS is 5.3%. This is
displayed in FIG. 4.19(b).
In FIG. 4.19(c), there is no change in pneumonia incidence with the intervention across all
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FIG. 4.18. The effect of IMID+OSS, and incremental impact of OSS on pneumonia deaths
is displayed in FIG. 4.18(a) and FIG. 4.18(b)
age groups.
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FIG. 4.19. Pneumonia disease prevalence for all age groups in FIG. 4.19(a) and the effect
on prevalence in FIG. 4.19(b), FIG. 4.19(c) illustrates the pneumonia incidence for age
groups [0, 5), [5, 14) and [14, 50).
4.9.3 Malaria-pneumonia coinfection
In FIG. 4.20(a), the prevalence of coinfection disease declines by both interventions. The
effect on coinfection prevalence is a reduction of 6.5% by IMID and 24% by IMID and OSS
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FIG. 4.20. Malaria-pneumonia disease prevalence for all age groups in FIG. 4.20(a) and
the effect on prevalence in FIG. 4.20(b), FIG. 4.20(c) shows the malaria-pneumonia deaths
for all age groups and the effect on deaths is shown in FIG. 4.20(d).
together and the incremental impact of OSS is a fall of 18.7% as given in FIG. 4.20(b).
In FIG. 4.20(c), the number of malaria-pneumonia deaths decrease with the interventions.
The effect on malaria-pneumonia deaths is a reduction of 7.7% by IMID and 32.9% by
IMID and OSS together and the incremental impact of OSS is a reduction by 27.2%.
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4.10 Impact by proportion triaged
In this section, we investigate the effect of IMID and IMID+OSS contributed by triaging
of patients.
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FIG. 4.21. Effect of IMID and IMID+OSS on malaria cases and deaths in FIG. 4.21(a),
FIG. 4.21(b), FIG. 4.21(c), FIG. 4.21(d), contributed by proportion triaged
In FIG. 4.21(a), the effect of IMID on malaria cases is 2.5%, 0.82% and 0.93% for the [0, 5),
[5, 14) and [14, 50) age groups respectively. The contribution by proportion triaged on the
effect of IMID is 56.8%, 31.5% and 34.4% for the respective age groups of [0, 5), [5, 14) and
[14, 50).
The effect of IMID+OSS on malaria cases is 6.5%, 4.2%, 3.9% for the [0, 5), [5, 14) and
Stellenbosch University  http://scholar.sun.ac.za
Chapter 4. Malaria-Pneumonia Coinfection Model 86
[14, 50) age groups accordingly as illustrated in FIG. 4.21(b). The proportion triaged
contributes 38.2%, 15.6% and 18.8% to that effect for the age groups [0, 5), [5, 14) and
[14, 50) in turn.
In FIG. 4.21(c), the effect of IMID on malaria deaths is 6.5%, 6.9%, 7% for the [0, 5),
[5, 14) and [14, 50) age groups respectively. The contribution by proportion triaged on the
effect of IMID is 83.3%, 88.5% and 88.6% for the respective age groups of [0, 5), [5, 14) and
[14, 50).
The effect of IMID+OSS on malaria deaths is 16.9%, 36.7%, 29.5% for the [0, 5), [5, 14)
and [14, 50) age groups accordingly as illustrated in FIG. 4.21(d). The proportion triaged
contributes 54.9%, 56.9% and 55.8% to that effect for the age groups [0, 5), [5, 14) and
[14, 50) in turn.
In FIG. 4.22(a), the effect of IMID on pneumonia cases is 3%, 1% and 0.45% for the [0, 5),
[5, 14) and [14, 50) age groups respectively. The contribution by proportion triaged on the
effect of IMID is 62.5%, 27.8% and 14.1% for the respective age groups of [0, 5), [5, 14) and
[14, 50).
The effect of IMID+OSS on pneumonia cases is 7.7%, 5.2%, 1.9% for the [0, 5), [5, 14)
and [14, 50) age groups accordingly as illustrated in FIG. 4.22(b). The proportion triaged
contributes 52.7%, 62.7% and 90.5% to that effect for the age groups [0, 5), [5, 14) and
[14, 50) in turn.
In FIG. 4.22(c) and FIG. 4.22(d), the effect of IMID and effect of IMID+OSS on pneumonia
deaths is the same as that for malaria deaths and also with the same contribution by the
proportion triaged on those effects.
4.11 Discussion
We have used a mathematical model to study the coinfection of malaria and pneumonia.
The model categorizes individuals according to clinical symptoms with the inclusion of a
severe disease class. It is divided into three age groups. We calibrated the model using
data on malaria and pneumonia cases collected by IDCAP.
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FIG. 4.22. Effect of IMID and IMID+OSS on pneumonia cases and deaths in FIG. 4.22(a),
FIG. 4.22(b), FIG. 4.22(c), FIG. 4.22(d), contributed by proportion triaged.
The model was used to investigate the effect of IMID, IMID+OSS and the incremental
impact of OSS on number of cases, deaths, prevalence and incidence for malaria and
pneumonia, for the period of the intervention. It has been shown that the two training
interventions lead to a reduction in the number of cases, deaths and prevalence of disease
but not incidence of episodes of disease.
The reduction in the number of disease cases is due to increase in the proportion of patients
that receive appropriate medication and the fall in the number of deaths is due to the rise
in the proportion of patients triaged. The percentage reduction in the number of deaths
for either malaria or pneumonia is the same (7.8%) across all age-groups and for children
under 5 years of age, this means that a life is being saved per month.
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Considering the incidence of episodes of disease, there is no change in either malaria or
pneumonia incidence. This is understandable as IMID and OSS were purely training
interventions on case management and not on prevention of infection. Though there is a
reduction in number of cases which decreases the infectious reservoir, it is not big enough
to result in a decrease in incidence of episodes of disease.
The coverage of the intervention for the combined intervention of IMID and OSS is higher
in the [5, 14) age group as compared to the other two age groups and it is lowest in the
[0, 5) age group though comparable to that of the [14, 50) age group. The reason for this is
that there are more children that come to the clinic as compared to the other age groups
and thus the probability that they will be attended to by clinicians trained in IMID+OSS
is lower as compared to the other age groups.
The contribution by the proportion triaged to the effect of IMID is more than the contri-
bution to the effect of IMID+OSS for malaria cases while it is the reverse for pneumonia
cases. On the other hand, the contribution of proportion triaged to the effect of IMID
is more as compared to its contribution to effect of IMID+OSS while considering deaths.
Important to note is that the contribution of proportion triaged to the effect of the in-
terventions with regard to deaths is more than 50% which highlights the importance of
triaging of patients to prevent deaths.
IMID+OSS and OSS alone perform better than IMID though IMID also has considerable
impact. The implication for this is that supervision and practical training are important
in case management and that classroom based training is enhanced when a practical com-
ponent is applied with it.
It is not the first time that the impact of IMID has been investigated. Infact, in [180], the
impact of training was shown by the improvement in indicators such as the proportion of
patients who were tested and treated. However, this study did not go ahead to investigate
what effect improvement of these indicators could have on population outcomes such as
prevalence, incidence and mortality.
There are a number of limitations in this study. One of them being that the pneumonia
data was lacking and for the most part we relied on the malaria data in estimating coverage
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of the IMID+OSS.
It is also important to note that although the IDCAP project considered testing of individ-
uals for malaria and assessment for pneumonia, we were unable to use these results because
it was noted that prescription of medication for patients did not depend on testing or as-
sessment results and as such most individuals with fever did receive malaria medication
and those that did not get malaria medication were given antibiotics. Besides, most of the
individuals who presented with cough and cold were given antibiotics and thus assessment
of pneumonia did not matter. In fact some patients were diagnosed with pneumonia even
without assessment.
Even with these limitations, the study shows the importance of classroom training as well
as the enhanced improvement in population outcomes when practical training is added on.
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4.12 Summary
In this chapter, we have explored the transmission dynamics of malaria and pneumonia
using models that are relatively simplified. We have carried out a mathematical analysis
that looked at the stability analysis of the equilibrium points given by the sub models of
malaria and pneumonia. The coinfection model of malaria and pneumonia was extended
to include age structure and the different parameters for the model were obtained, some
from literature and others from fitting the model to available data.
We then investigated the effect of two training interventions, IMID and IMID with OSS on
malaria and pneumonia cases, deaths, prevalence and incidence. The results demonstrated
a reduction in number of cases, deaths, prevalence but no change in incidence with the two
interventions. Nevertheless, training of MLPs is effective in reducing patient deaths and
cases and supervision and practical training does a lot in improving quality of health care.
.
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HIV-TB Coinfection
5.1 Introduction
In this chapter, we formulate and use an HIV-TB coinfection model to investigate the
effect of IMID and OSS on HIV care and TB management. The reason for this being
that individuals infected with HIV progress quickly to active TB disease if they have the
TB infection, and also because HIV and TB were part of the infectious diseases that were
considered in the IDCAP study.
The points of interest in the management of TB cases were testing, initiation and com-
pletion of treatment. For HIV, the areas of concern were: PMTCT, ART enrolment for
eligible HIV infected individuals and CTX coverage.
IDCAP evaluated the effect of IMID and OSS on indicators such as the proportion of TB
suspects tested for TB, proportion of TB patients who initiated and completed treatment,
proportion of HIV positive mothers who were on ART and those that received ART med-
ication at delivery as well as the proportion of HIV exposed babies who are given ART on
delivery.
With regard to evaluating these effects in an integrated way, we use a mathematical HIV-
TB model with age structure.
91
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5.2 HIV-TB coinfection model
The non age structured HIV-TB model consists of 6 classes. There is a class of individuals
susceptible (S) to HIV infection. A proportion, (1− e) of these susceptible individuals (S)
is fully susceptible to TB while the other proportion, e has latent TB.
Infection by HIV represented by λH occurs taking individuals to S1, they get onto ART
(at a rate r
H
) to move to S2 and they fail ART at a rate fH .
Infection and reinfection by TB (λT ) occurs for the individuals in the susceptible class
sending them to the active TB class, I. Individuals with latent TB, a proportion e of the
susceptible class also reactivate TB infection at a rate ν and move to I. Active TB people
recover at a rate r
T
.
Individuals with active TB may also be infected with HIV to go to I1, they get onto ART
at a rate r
H
and move to I2.
Recruitment occurs by birth and is represented by terms, B and B1. B is the recruitment
for HIV negative people and B1 accounts for HIV transmission at birth. HIV transmission
through breast feeding is represented by b
f
.
The death rate of individuals is represented by µ with a subscript or without a subscript,
the subscript stands for the class where the death is occurring.
FIG. 5.1 shows the model diagram and the model equations are given by (5.1a)–(5.1f).
dS
dt
= B + r
T
I − bf − (λH + λT e
′ + νe + µ)S, (5.1a)
dI
dt
= (λ
T
e′ + νe)S − (λ
H
+ r
T
+ µ
I
)I, (5.1b)
dS1
dt
= B1 + bf + λHS + fHS2 + rT
1
I1 − (λT e
′ + ν1e+ rH + µS1 )S1, (5.1c)
dI1
dt
= λ
H
I + (λ
T
e′ + ν1e)S1 + fHI1 − (rT
1
+ r
H
1
+ µ
I1
)I1, (5.1d)
dS2
dt
= r
H
S1 + rT
2
I2 − (fH + λT e
′ + ν2e + µS2 )S2, (5.1e)
dI2
dt
= r
H
1
I1 + (λT e
′ + ν2e)S2 − (rT
2
+ f
H
+ µ
I2
)I2, (5.1f)
where:
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FIG. 5.1. HIV-TB model diagram
(i) λ
H
= β
H
IH/N . βH is the infection rate for HIV. IH = S1 + I1 + S2 + I2 is the HIV
infected human population and N = S + I + S1 + I1 + S2 + I2 is the total human
population.
(ii) λ
T
= (β
T
I + β
TH
(I1 + I2))/N . βT is the rate at which individuals with active TB
but no HIV pass on TB infection and βTH is the rate at which coinfected HIV-TB
individuals spread TB infection.
(iii) e′ = e1(1− e) + e2e. e1 and e2 are the proportions of new infections and reinfections
that progress to active TB.
It can be shown in a similar way as what was done with the malaria-pneumonia model in
Chapter 4 that system (5.1a)–(5.1f) is biologically feasible in
0 =
{
(S, I, S1, I1, S2, I2) ∈ ℜ
6
+ : S + I + S1 + I1 + S2 + I2 ≤
B
µ
}
.
5.3 Mathematical analysis
This is carried out with the consideration that the parameters are constant.
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5.3.1 Equilibrium points
These are time-independent states of a system. We determine them by setting the system
of equations (5.1a)–(5.1f) to zero.
Disease Free Equilibrium (DFEHT)
This is the trivial equilibrium of the system where there is no infection in the population,
that is I = 0, S1 = 0, I1 = 0, S2 = 0, I2 = 0 which exists if B1 = bf = e = 0.
It is given as
DFEHT = (B/µ, 0, 0, 0, 0, 0).
The stability of the DFEHT depends on the basic reproductive number, RHT0 .
Basic reproduction number
It is computed following the same steps as discussed in Chapter 4. Let F be the vector
formed by the rates of appearance of new infections and V be that formed by the rates of
the transfers in and out of the compartments. The Jacobian matrices of F and V at DFE
are given by:
F =

λ
T
e′S
B1 + bf + λHS
λ
H
I + λ
T
e′S1
0
λ
T
e′S2

, V =

−νeS + (λ
H
+ r
T
+ µ
I
)I
−f
H
S2 − rT
1
I1 + (λT e
′ + ν1e+ rH + µS1 )S1
−ν1eS1 − fHI1 + (rT
1
+ r
H
1
+ µ
I1
)I1
−r
H
S1 − rT
2
I2 + (fH + λT e
′ + ν2e + µS2 )S2
−r
H
1
I1 − ν2eS2 + (rT
2
+ f
H
+ µ
I2
)I2

.
We find the derivatives of F and V at DFE: e = 0.
F =

e1βT 0 e1βTH 0 e1βTH
0 β
H
β
H
β
H
β
H
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0

,
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V =

r
T
+ µ
I
0 0 0 0
0 r
H
+ µ
S1
−r
T
1
−f
H
0
0 0 −f
H
+ r
H1
+ r
T
1
+ µ
I
1
0 0
0 −r
H
0 f
H
+ µ
S2
−r
T
2
0 0 −r
H1
0 f
H
+ r
T
2
+ µ
I
2

.
RHT0 is the spectral radius of FV
−1. Using mathematica, we obtain
RHT0 = max{R
H
0 , R
T
0 }
where:
RH0 =
βH(fH + rH + µS2 )
f
H
µ
S1
+ (r
H
+ µ
S1
)µ
S2
,
RT0 =
e1βT
r
T
+ µ
I
,
are the reproduction numbers for HIV and TB respectively .
Local stability of the DFE
This is summarized in Theorem 5.3.1
Theorem 5.3.1 If B1 = bf = e = 0, then the DFE
HT exists. Moreover if RHT0 < 1, then
DFEHT is locally asymptotically stable.
5.3.2 HIV sub model
The system of the HIV sub model is given by
dS
dt
= B − bf − (λH + µ)S, (5.2a)
dS1
dt
= B1 + bf + λHS + fHS2 − (µS1 + rH )S1, (5.2b)
dS2
dt
= r
H
S1 − (fH + µS2)S2, (5.2c)
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Setting equations (5.2a)–(5.2c) to zero gives:
S∗ =
B − b
f
µ+ λ∗
H
,
S∗1 =
(µ(b
f
+B1) + (B +B1)λ∗H)(fH + µS2 )
(µ+ λ∗
H
)(f
H
µ
S1
+ µ
S2
(r
H
+ µ
S1
))
,
S∗2 =
r
H
(µ(b
f
+B1) + (B +B1)λ∗H )
(µ+ λ∗
H
)(f
H
µ
S1
+ µ
S2
(r
H
+ µ
S1
))
.
Substituting, S∗, S∗1 and S
∗
2 into λ
∗
H
results into
Cλ∗2
H
+ C1λ
∗
H
+ C2 = 0, (5.3)
where:
C = (B +B1)(fH + rH + µS2 ),
C1 = (fH + rH + µS2 )(µ(bf +B1)− (B +B1)) + (B − bf )(µS2 (rH + µS1 ) + fHµS1 ),
C2 = −µ(bf +B1)βH (fH + rH + µS2 ).
From equation (5.3), it is clear that when B1 6= 0 and bf 6= 0, then the system has one
endemic equilibrium point (EEPH) since C2 is negative.
5.3.3 Stability of the EEPH
For the local stability of the EEPH , we use the centre manifold theorem from [32], stated
in Theorem A.0.1.
We consider the case RH0 = 1 and use βH = β
∗
H
as our bifurcation parameter. It is given as
β∗
H
=
f
H
µ
S1
+ (r
H
+ µ
S1
)µ
S2
f
H
+ r
H
+ µ
S2
.
The linearised system with β
H
= β∗
H
has a zero eigenvalue which is simple and we can use
the centre manifold theory to analyse the dynamics of the system near β
H
= β∗
H
.
Denote by f = (f1, f2, f3)
T the right hand side vector of (5.2a)–(5.2c). Following from
Theorem A.0.1, we are required to compute values, a and b which we do by finding the
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non-vanishing partial derivatives of f at DFE. All the necessary calculations are in appendix
section A.3.
The values are given as:
a = v2w1w2
β
H
(B − µ)
B
+ v2w1w3
β
H
(B − µ)
B
+ v2w2w1
β
H
(B − µ)
B
− v2w
2
2
2β
H
µ
B
−v2w2w3
2β
H
µ
B
+ v2w3w1
β
H
(B − µ)
B
− v2w3w2
2β
H
µ
B
− v2w
2
3
2β
H
µ
B
,
w1, w2, w3 and v2 are defined in appendix section A.3.
Note that B > µ, v2 > 0, w1 < 0, w2 > 0, w3 > 0. Therefore a < 0.
b = v2(w2 + w3),
=
f
H
+ r
H
+ µ
S2
f
H
+ r
H
+ µ
S1
(
f
H
+ µ
S2
r
H
+ 1
)
.
Clearly, b > 0.
From Theorem A.0.1, since a < 0 and b > 0, we have a positive endemic which is locally
asymptotically stable. We also establish the following result.
Theorem 5.3.2 If RH0 > 1, an endemic equilibrium guaranteed by Theorem A.0.1 exists
and is locally asymptotically stable.
FIG. 5.2(a) and FIG. 5.2(b) show the numerical simulations for RH0 < 1 and R
H
0 > 1
5.3.4 TB sub model
The endemic equilibrium for the TB sub model is obtained as follows:
B + r
T
I − (λ
T
e′ + νe+ µ)S = 0, (5.4a)
(λ
T
e′ + νe)S − (r
T
+ µ
I
)I = 0, (5.4b)
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FIG. 5.2. Numerical simulations for RH0
where λ
T
= β
T
I/N , e′ = e1(1− e) + e2e. N = S + I is the total population.
The definitions of the parameters are in section 5.2.
Setting equations (5.4a)–(5.4b) and solving in terms of λ
T
gives
S∗ =
B(r
T
+ µ
I
)
µr
T
+ (µ+ eν + e′λ∗
T
)µ
I
,
I∗ =
B(eν + e′λ∗
T
)
µr
T
+ (µ+ eν + e′λ∗
T
)µ
I
,
Substituting S∗ and I∗ into λ
T
yields equation 5.5.
λ∗2
T
+
(eν + r
T
+ µ
I
− β
T
e′)
e′
λ∗
T
−
β
T
eν
e′
= 0, (5.5)
We then consider two cases
Case 1: e = 0
When e = 0, equation 5.5 becomes
λ∗
T
(λ∗
T
+
r
T
+ µ
I
e′
(1− RTB0 )) = 0,
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which gives λ∗
T
= 0, the DFE equilibrium and λ∗
T
=
r
T
+µ
I
e′
(RTB0 − 1) which only exists iff
RTB0 > 1.
This implies that if there are no individuals with latent TB, then the endemic equilibrium
exists only if the reproductive number is greater than 1.
Case 2: e 6= 0
When e 6= 0, we have equation 5.5
λ∗2
T
+
(eν + r
T
+ µ
I
− β
T
e′)
e′
λ∗
T
−
β
T
eν
e′
= 0,
which has one positive endemic equilibrium.
Local stability of EEPT
To establish the local stability of the endemic equilibrium, we make use of the centre
manifold theorem stated in Theorem A.0.1.
We denote the right hand side of system (5.4a)–(5.4b) by f = (f1, f2)
T . We consider the
case when RTB0 = 1 and take βT = β
∗
T
as our bifurcation parameter. It is given as
β∗
T
=
r
T
+ µ
I
e1
.
The linearised system with β
T
= β∗
T
has a zero eigenvalue which is simple.
We can use the centre manifold theory to analyse the dynamics of the modified system near
β
T
= β∗
T
and in particular we can determine the local stability of the endemic equilibrium
of system (5.4a)–(5.4b).
We then compute a and b by finding the non-zero partial derivatives of f at DFE. All the
calculations are in appendix section A.4. Thus
a = e1βTµT
(
1
µ
−
1
B
)
+
2e1βTµ
B
.
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Since B > µ, then a > 0.
b =
e1µ
B
.
We have b > 0.
From Theorem A.0.1, we have a subcritical (backward) bifurcation at RTB0 = 1 and we
establish the following result.
Theorem 5.3.3 An endemic equilibrium guaranteed by Theorem A.0.1 exists and is locally
asymptotically stable when RTB0 < 1 but close to 1.
This result raises an important point, that for effective eradication of TB, it is not only
sufficient that RTB0 to be less than one but that it must be smaller than a certain critical
value less than one.
FIG. 5.3(a), FIG. 5.3(b) and FIG. 5.3(c) show the numerical simulations for RT0 < 1 and
RT0 > 1 with e = 0 and e 6= 0.
The implications of the mathematical analysis carried out for the non-age structured HIV-
TB model with constant parameters on the model with time dependent parameters are
discussed in section 4.4.
5.4 HIV-TB model with age structure
The model of HIV-TB with age structure is an extension of the one in section 5.2. It
is divided into three age groups [0, 5), [5, 14) and [14, 50). Individuals age from [0, 5) to
[5, 14) at a rate η1, from [5, 14) to [14, 50) at a rate η2 and out of [14, 50) at a rate η3.
The parameters in this model are defined similarly as the ones in the model without age
structure except that they now have subscript j = c, b, a representing [0, 5), [5, 14) and
[14, 50) age groups respectively.
Important to note is that:
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FIG. 5.3. Numerical simulations for RT0
(i) We have two kinds of transmission of HIV, mother to child transmission both at birth
(B1) or through breastfeeding, bf (t) and HIV transmission (λH) between individuals
in the [14, 50) age group.
(ii) There is no HIV transmission in the [5, 14) age group but we have some HIV infected
individuals from the [0, 5) who age into the [5, 14) age group.
(iii) We also assume that HIV negative babies born to HIV positive mothers only get
infected through breastfeeding and none of these babies develops active TB before
infection with HIV.
Considering model diagram FIG. 5.1, the model diagram for the [0, 5) age group does not
have the HIV transmission term λ
H
and there is no movement from Ic to I1c . The rest of
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the in and out flows stay the same.
Model diagram for [5, 14) has no birth terms and no HIV transmission terms but the other
flows in and out are the same.
The diagram for [14, 50) has no birth terms, no HIV transmission through breastfeeding
but HIV transmission given by λ
H
and the rest of the flows in and out are the same.
The model equations are given by set of equations (5.6a)–(5.6f) for the [0, 5) age group,
(5.7a)–(5.7f) for the [5, 14) and (5.8a)–(5.8f) for the [14, 50) age group.
dS
c
dt
= B + r
T
I − bf (t)− (λTc e
′
c + νec + µc + η1)Sc , (5.6a)
dIc
dt
= (λ
Tc
e′c + νec)Sc − (rT + µIc + η1)Ic , (5.6b)
dS1c
dt
= B1 + bf + fHS2c + rT1 I1c − (λTc e
′
c + ν1ec + rH + µS1c
+ η1)S1c , (5.6c)
dI1c
dt
= (λ
Tc
e′c + ν1ec)S1c + fHI1c − (rT1
+ r
H
+ µ
I1c
+ η1)I1c , (5.6d)
dS2c
dt
= r
H
S1c + rT2
I2c − (fH + λTc e
′
c + ν2ec + µS2c
+ η1)S2c , (5.6e)
dI2c
dt
= r
H
1
I1c + (λTc e
′
c + ν2ec)S2c − (rT2 + fH + µI2c
+ η1)I2, (5.6f)
dS
b
dt
= η1Sc + rT Ib − (λT
b
e′b + νeb + µb + η2)Sb, (5.7a)
dI
b
dt
= η1Ic + (λT
b
e′b + νeb)S − (rT + µI
b
+ η2)Ib , (5.7b)
dS1
b
dt
= η1S1c + fHS2b + rT1
I1 − (λT
b
e′b + ν1eb + rH + µS1
b
+ η2)S1
b
, (5.7c)
dI1
b
dt
= η1I1c + (λTb
e′b + ν1eb)S1b + fHI2b − (rT1 + rH + µI1b
+ η2)I1
b
, (5.7d)
dS2
b
dt
= η1S2c + rHS1b + rT2 I2b − (fH + λTb
e′b + ν2eb + µS2
b
)S2
b
, (5.7e)
dI2
b
dt
= η1I2c + rH1
I1
b
+ (λ
T
b
e′b + ν2eb)S2b − (rT2
+ f
H
+ µ
I2
b
+ η2)I2
b
, (5.7f)
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dSa
dt
= η2Sb + rT Ia − (λH + λTa e
′
a + νea + µa + η3)Sa , (5.8a)
dIa
dt
= η2Ib + (λTa e
′
a + νea)Sa − (λH + rT + µIa + η3)Ia, (5.8b)
dS1a
dt
= η2S1
b
+ λ
H
S
a
+ f
H
S2a + rT1
I1a − (λTa e
′
a + ν1ea + rH + µS1a
)S1a (5.8c)
−η3S1a ,
dI1a
dt
= η2I1
b
+ λ
H
Ia + (λTa e
′
a + ν1ea)S1a + fHI2a − (rT1 + rH + µI1a
)I1a (5.8d)
−η3I1a ,
dS2a
dt
= η2S2
b
+ r
H
S1a + rT2 I2a − (fH + λTa e
′
a + ν2ea + µS2a
+ η3)S2a , (5.8e)
dI2a
dt
= η2I2
b
+ r
H
1
I1a + (λTa e
′
a + ν2ea)S2a − (rT2 + fH + µI2a
+ η3)I2a , (5.8f)
where:
(i) λ
H
= β
H
IH/N . βH is the infection rate for HIV. IH is the HIV infected human
population and N is the total human population.
(ii) λ
Tc
= (β
Tc
I
T
+β
THc
I
TH
)/N . β
Tc
is the rate at which HIV negative active TB individ-
uals pass on infection to individuals in the [0, 5) age group. β
THc
is the rate at which
HIV-TB coinfected individuals pass on infection to individuals in the [0, 5) age group.
Similar definitions hold for the [5, 14) and [14, 50) age groups with the infection term
being represented by subscripts b and a respectively.
(iii) e′c = e1c(1 − ec) + e2cec. e1c and e2c are the proportions of new infections and rein-
fections that progress to active TB in the [0, 5) age group. Similar definitions hold
for the [5, 14) and [14, 50) age groups with the proportions of new infections and
reinfections being represented by subscripts b and a accordingly.
5.5 Formulations, parameter values from literature
In this section, we discuss various parameters for HIV, TB and HIV-TB coinfection and
give values obtained from literature.
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5.5.1 HIV parameters
HIV positive births, B1
Suppose that ρ1, ρ2, ρ3 and ρ4 are the crude per capita birth rates for HIV negative
individuals, HIV positive individuals unaware of their status, HIV positive individuals
aware of their status but are not on ART or not on PMTCT and those on ART or PMTCT
respectively (Please note that the effect of ART and PMTCT is not differentiated).
The birth rates of these groups are different. Fertility is reduced in HIV positive individuals
[66, 207] and being on ART increases the chances of wanting a child though it is still not
equal to those individuals who are HIV negative [35, 114]. Using ρ2 = 0.8ρ1 [66] and
ρ4 = 1.877ρ3 [114] and taking ρ as the total crude birth rate of the whole population, we
calculate ρ1 and ρ3. Thus we have ρ1 =
ρ
(1−p
H
)+(0.8∗p
H
)
and ρ3 =
ρ2
(1+0.877kγ1)
, where p
H
is
the proportion of individuals with HIV, k is the proportion of HIV positive individuals on
ART/PMTCT and γ1 is the proportion of individuals tested.
Among the population giving birth, a constant proportion, γ1 is tested. Of those found HIV
positive, a proportion, k receive ART. The risk of transmission for HIV positive individuals
not on ART/PMTCT is (φ1) and for those on ART/PMTCT, it is (φ2).
Thus we have:
 The number of births per unit time from HIV negative people is given as
ρ1NH−.
where N
H−
is the HIV negative population.
 The number of births per unit time from HIV positive people unaware of their status
is given by:
(1− γ1)ρ2NH+.
where N
H+
is the HIV positive population
 Births for HIV positive people tested not on ART/PMTCT are:
(1− k)γ1ρ3NH+.
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 Then, births for HIV positive people tested and on ART/PMTCT are given by:
kγ1ρ4NH+.
Using the risks of transmission, we have the number of HIV positive babies at birth being,
B1 = (φ1(1− γ1)ρ2 + (φ1(1− k)ρ3 + φ2kρ4)γ1)NH+
and the number of HIV negative babies from HIV positive mothers is
B2 = ((1− φ1)(1− γ1)ρ2 + ((1− φ1)(1− k)ρ3 + (1− φ2)kρ4)γ1)NH+.
Accounting for the number of HIV negative babies, we obtain
B = ρ1NH− +B2.
The risk of transmission of HIV at birth for mothers not on ART varies from 15% to
50% [49, 183, 185, 197] and the for mothers on ART, this risk is reduced by 30% to 75%
[41, 183, 185, 197] giving a risk of transmission between 4% and 35%.
In the model we consider the risk of transmission of HIV at birth for mothers not on
ART/PMTCT to be 30% for those on ART/PMTCT to be 5%. These parameter values
and their references are summarized in TABLE. 5.1.
HIV transmission through breastfeeding
At each point in time, the number of HIV negative children born to HIV positive mothers
increases by B2 = ((1−φ1)(1−γ1)ρ2+((1−φ1)(1−k)ρ3+(1−φ2)kρ4)γ1)NH+ . Of these, a
proportion, p
bf
is breastfed which increases their risk of acquiring HIV. Moreover, the risk
of MTCT through breastfeeding differs when there is no ART/PMTCT, ϕ1, to when there
is ART/PMTCT, ϕ2. Hence, we consider that a proportion, pA of these children receive
ART/PMTCT and the other proportion does not.
The number of children who would get infected with HIV through breastfeeding at a point
in time is given as CN
H+
where C = (ϕ1(1− pA) + ϕ2pA)B2pbf .
We used breastfeeding data of Uganda from Spectrum which gives the proportion of chil-
dren breastfeeding from birth up to three years and we considered this to be the probability
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of still being breastfed. FIG. 5.4 shows this data fitted to a Weibull function ψ(t) = e−λt
δ
,
where t is the age of the baby with λ = 0.06 as the shape parameter and δ = 4.18, the
scale parameter. These parameter values and their references have been summarized in
TABLE. 5.1.
FIG. 5.4. Probability of still being breastfed
Given that the death rate µc of children is constant, the probability of surviving until age
t is given by e−µc t.
Putting all this into consideration, we have the number of children born to HIV positive
mothers who are breastfeeding children at time, t as:∫ t
−∞
ψ(t− s)e−µc (t−s)CN
H+
(s) ds.
The expression above involves an infinite delay, and knowing that the probability of being
breastfed is small for ages higher than 3 years, we approximate the infinite delay integral
as ∫ t
t−τ
ψ(t− s)e−µc (t−s)CN
H+
(s) ds.
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with τ large enough.
We define G(t, s) = ψ(t− s)e−µc(t−s)CN
H+
(s). This equation implies that the model is an
integro-differential equation with delay.
When t < τ , the above expression involves the history of the N
H+
. Thus, we split the
integral as follows:
∫ t
t−τ
G(t, s) ds =
∫ 0
t−τ
G(t, s) ds+
∫ t
0
G(t, s) ds
For our particular case, we assume that N
H+
(s) = N
H+
(0) for −τ ≤ s ≤ 0 where N
H+
(0)
is the initial value of N
H+
(s).
Thus the number of children born to HIV positive mothers who are still being breastfed
at time t is given by ∫ t
t−τ
G(t, s) ds = N¯
H+
G¯(t, s) +
∫ t
0
G(t, s) ds.
where G¯(t, s) =
∫ 0
t−τ
Cψ(t− s)e−µc (t−s)ds and N¯
H+
= N
H+
(0).
Cotrimoxazole prophylaxis (CTX) uptake
CTX is given to HIV positive individuals and it reduces their mortality and morbidity
rates [193]. It is modelled implicitly by reducing, in individuals on CTX, the mortality
rate (µ
S1
) and the proportion of HIV positive individuals who progress to active TB.
It is important to note that these individuals are aware of their HIV status. We define γ
as the proportion that are tested and ps is the proportion of HIV positive individuals on
CTX.
Considering S1, the number of HIV positive individuals on CTX is given as γpsS1 and that
not on CTX is given as (1− γps)S1.
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TABLE. 5.1. Parameters of MTCT and births
Parameter Description Value Reference
ρ Crude birth rate 0.0423 Chosen [85, 148, 149]
φ1 Risk of mother-to-child trans-
mission (MTCT) at birth - no
ART
30% (14%− 42%) [49, 137, 183, 197]
φ2 Risk of MTCT at birth - with
ART
5% (4.5%− 15%) [137, 197]
ϕ1 Risk of MTCT through
breastfeeding - no ART
15% (5%− 20%) [43, 142, 197]
ϕ2 Risk of MTCT through
breastfeeding - with ART
5% (2.5%− 10%) [73, 188]
ψ(α, λ) λ = 0.06-shape parameter
and δ = 4.18-scale parameter.
Function gives the probability
that a child is being breastfed
ψ(4.18, 0.06) Spectrum data [87]
p
bf
proportion of children from
HIV positive mothers who
breastfeed
0.91 [137]
ART enrollment and failure rates
The ART enrollment rate, r
H
can be obtained by using the fraction of HIV positive indi-
viduals that go onto ART:
A
f
=
r
H
γS1
r
H
γS1 + (µS1
0
(1− γps) + µS1
1
γps)S1
.
where 0 and 1 subscripts for µ
S1
represent not on and on cotrimoxazole respectively.
Thus,
r
H
=
A
f
(µ
S1
0
(1− γps) + µS1
1
γps)
γ(1−A
f
)
.
This expression corresponds to that in [11, 23].
By end of 2009, the percentage of individuals, both adults and children in need of ART
was 54% as per national guidelines of a cut off of CD4-T cell count less than 250 cells
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per microlitre and the proportion of these receiving ART was 53.5% [40, 199]. Using both
these values gives 0.29 as the proportion of all HIV positive individuals on ART.
For our study population, the proportion of eligible HIV positive individuals receiving ART
is lower than the national average. Considering information in TABLE 3.6, the average
proportion of adults initiating ART treatment is calculated as 0.27 (using the proportion
enrolled into HIV care, the proportion that receives ART and the respective proportions
for pregnant women and HIV-TB coinfected individuals in the HIV population). Thus
considering all HIV positive individuals in our study population and using the proportion
in need of ART as 0.54 [40], we calculate the proportion of HIV positive adults on ART as
0.15.
In [40], of the patients on ART, 8.5% were children (< 15 years) and the other percentage,
91.5% were adults (> 15 years). This means that in our study population only about 1.3%
of HIV positive children are on ART.
We thus choose the fraction of HIV positive adults starting ART so as to end up with the
proportion of HIV positive adults on ART as being 0.15. For the [0, 5) and [5, 14), the
fractions we choose are such that we end up with the proportion of HIV positive children
on ART as being about 1.3% in either age group. We chose different fractions for HIV
positive individuals without TB and for HIV-TB coinfected individuals for the three age
groups, [0, 5), [5, 14) and [14, 50). For HIV positive individuals without TB, the fractions
are: 4/10000 for the [0, 5), 9/100000 for the [5, 14) and 245/10000 for the [14, 50) age
group.
For HIV-TB coinfected individuals, these fractions are: 4/100 for the [0, 5), 9/1000 for the
[5, 14) and 25/100 for the [14, 50) age group.
Some individuals on ART will fail ART due to some side effects. Failure of ART can
occur when immunological or virological failure occurs. Immunological outcomes consist
of CD4 cell count measurements while virological outcomes are obtained by measuring
the viral load. Immunological failure is what is commonly and currently considered when
investigating ART failure though it is also important to consider virological failure. In
[89, 159, 162], the rates of virological failure ranged from 0.05 to 0.09 per year. The rates
of immunological failure ranged from 0.0034 to 0.08 per year [159, 162]. In [11], the rate
of ART failure (rate at which individuals drop out of ART programme) was taken to be
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0.015. For our model, we use 0.03 per year.
HIV infection and death rates
The HIV infection rate, β
H
, is obtained by calibrating the incidence, β
H
I
H
/N to that from
Spectrum [87]. We input the incidence from Spectrum reduced by a factor to result into
an HIV prevalence of 5.4% that is observed in the population under study.
Death rates due to HIV infected individuals not on ART were calculated in a similar way as
the natural death rates in Chapter 3 using population numbers from Spectrum (DemProj
and AIM) [87] with default Uganda country data.
As a comparison, in [88], the mortality rate for HIV positive adults was given as 0.049 which
is not different from the one calculated from Spectum, of 0.047 for the [14, 50) age group.
The death rates for HIV infected individuals not on ART are summarized in TABLE. 5.2.
Mortality rates for HIV positive individuals on ART and on CTX are obtained from a
number of studies. The death rate of individuals on ART differs depending on how long
the individual has been on ART and what CD4 cell count they had when initiating ART.
In [126], the death rate of individuals initiating ART ranged from 0.0538 in those with a
CD4 cell count of less than 50 to 0.0157 for those with at least 300 CD4 cell count.
In [125], the mortality rate of HIV positive adults on ART was given as 0.0318. For our
model, we are interested in the average death rate of HIV positive individuals on ART and
thus we use the one in [125] for the [14, 50) age group. For the age groups [5, 14) and [0, 5),
we use the death rates given in [12] and these are: 0.0365 for adolescents and 0.0228 for
children.
The total death rates are a summation of these HIV specific death rates with the natural
death rates (in TABLE. 4.4) and they are reported in TABLE 5.2.
For HIV positive individuals on CTX, there is 30% to 50% reduction in the death rate
[79, 121, 157].
In addition, ART and CTX not only reduce the mortality rates of HIV positive individuals,
but also reduce their morbidity. ART is known to reduce the morbidity of HIV positive
individuals eligible for ART by 53% and CTX reduces their morbidity by 35% [123].
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5.5.2 TB parameters for HIV negative people
Infection and reinfection
It is estimated that an active TB person infects about 10 to 14 people per year [10]. Given
that we have age groups, there is limited literature on the infection rates for individuals in
different age groups.
For our model, we chose the infection rate for the [0, 5) age group as 0.25 per year, 0.05
per year for the [5, 14) age group, and for [14, 50), we used 7.0 per year. These were chosen
in accordance to maintaining a reasonable TB prevalence of 280 per 100000 for adults and
12 per 100000 for the [0, 5) and [5, 14).
The reinfection rates are the same as the infection rates except that progression to disease
is reduced by 33% if it is a reinfection. In [10], a 30% reduction was considered with
reinfection.
Progression to disease and reactivation
The rate of progression of disease is a decreasing function of time since infection. In [192],
the cumulative risk of progression to disease after 5 years of infection was estimated to be
14%, and 4% for individuals of ages [0, 10], and 9% for individuals aged 15.
Individuals in the age group [5, 14) have a lower risk of progressing to disease and they are
sometimes called the ‘golden age group’ [109, 211].
We do not include time since infection in our model, but we consider that a constant
proportion of individuals, e1 develop active TB after infection and a proportion, e2 develop
disease after reinfection. We have different values of these proportions for the different age
groups and they are differentiated by subscripts, c, b and a which represent the age groups
[0, 5), [5, 14 and [14, 50). The values of the proportions are stated in TABLE 5.2.
The rate of reactivation ranges from 0.0001 to 0.00074 [10, 30, 192] in individuals who are
HIV negative. The values of rates of reactivation for the different age groups are given in
TABLE. 5.2.
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Treatment and recovery
Individuals with active TB may recover naturally at a rate 0.2 per year [10] and when they
receive treatment and complete it successfully, they recover at a rate ranging from 12/6 to
12/8 per year depending on the duration of treatment [52, 134]. However, there are other
conditions that determine the recovery such as the patient reporting to the clinic, getting
a TB diagnosis, receiving medication and completing the medication. The recovery rate
for TB is fully defined in subsection 3.2.3.
Death rate
The death rate of TB for the Ugandan population was 29/100000 population per year in
2009 [200, 212]. Taking into consideration that the prevalence of TB in Uganda in 2009
was given as 277/100000 population [200]. We calculate the death rate of TB individuals
as 29/277 which is 0.105 per TB case per year. [10] also gives some values for the death
rate of TB cases.
5.5.3 Parameters of HIV-TB coinfection
The parameters for HIV-TB coinfection are influenced mainly by HIV.
Infection and reinfection
HIV positive people are more susceptible to TB infection and reinfection [190]. Moreover,
most HIV infected patients have fewer bacilli in their sputum and have more extrapul-
monary tuberculosis than HIV-negative patients [10, 33, 38, 48]. For this reason, HIV
infected patients are less infectious than HIV-negative patients with active tuberculosis.
We take that the rate at which HIV-TB coinfected individuals infect others is reduced by
33% as in [10].
Stellenbosch University  http://scholar.sun.ac.za
Chapter 5. HIV-TB Coinfection Model 113
Progression to disease and reactivation
As compared to HIV negative individuals, HIV positive ones have a higher risk of progres-
sion to active TB [33, 211].
While the risk of progression of HIV negative individuals infected with TB is 10% for their
lifetime, that of individuals coinfected with both HIV and TB is 10% per year [33]. About
70% of all HIV-infected individuals develop active TB [33, 191].
The reactivation rate of individuals with HIV-TB coinfection ranges from 40 to 500 times
that of individuals infected with TB only [95, 198]. For our model, we take the reactiva-
tion rate of HIV-TB coinfected individuals to be 80 times more than that of individuals
infected with TB but without HIV infection. We also consider that the reactivation rate
for individuals who are on ART reduces by 5 times that of HIV-TB coinfected individuals
not on ART.
Death rate
It has been noted that individuals with coinfection of TB and HIV have a death rate that
is 6 times higher than that of individuals with HIV only [10] and this is what we use for
our model simulations.
5.6 Model simulations
We run the model with baseline values before we incorporate in the effect of the inter-
ventions. All the numerical simulations are generated using the HIV-TB model with age
structure (refer to section 5.4).
Uganda HIV prevalence was about 6.4% in 2006 in adults and 0.7% in children less than 15
years of age [39]. The sites that IDCAP considered have a lower HIV prevalence because
most of them are in rural areas. We calculated the HIV prevalence in adults as being 5.4%
using prevalence data from Uganda’s sentinel sites in [40].
We inputed HIV incidence from Spectrum [87] with default Uganda data and reduced it
by a factor (we multiplied it by 0.85) until it gave a prevalence of 5.4% (refer to subsection
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TABLE. 5.2. Parameters for HIV, TB, HIV-TB
Parameter Description Value Reference
µS1c , µS1b
, µS1a HIV death rates for
individuals who are
not on ART for corre-
sponding age groups.
0.166, 0.064,0.065 Spectrum [87],
[88]
µS2c , µS2b
, µS2a HIV death rates for in-
dividuals who are on
ART for correspond-
ing age groups.
0.0488, 0.0405, 0.048 [12, 125, 126,
129]
ec, eb, ea Proportion with latent
TB
0.05, 0.2, 0.52 Chosen to end
up with overall
proportion with
latent TB as be-
ing 33%
e1c, e1b, e1a Proportion of new in-
fections that develop
active TB
0.1, 0.025, 0.05 [10, 192]
ν, ν1, ν2 Reactivation rates
for TB positive-HIV
negative, HIV-TB
coinfected not on
ART and HIV-TB
coinfected on ART
0.0003, 0.0228, 0.0114 [10, 30, 33, 198]
µ
Ic
, µ
I
b
, µ
Ia
Death rates due to TB 0.105 Calculated [10]
5.5.1 under HIV infection and death rates).
We use 52% as the proportion of HIV in TB cases. In [203], it was given as 54% and it
takes values of 50% or more in other studies [10].
The TB prevalence in adults was 0.3% in 2005 and fell to 0.2% in 2009 [200]. We use a
TB prevalence of 280/100000 for adults at baseline.
For age groups [0, 5) and [5, 14), we take note of [6], where it is stated that about 5% to 6%
of annual TB cases are among children less than 15 years of age with 60% of these being
in children under 5 years of age. With this insight, we use a TB prevalence of 12/100000
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for the two age groups, [0, 5) and [5, 14).
For the initial conditions, we use the following numbers.
Sc(0) = 6968, S1c (0) = 47, S2c (0) = 1, Ic(0) = 1, I1c = 0.15, I2c = 0.001
S
b
(0) = 9881, S1
b
(0) = 51, S2
b
(0) = 1, I
b
(0) = 1, I1
b
= 0.3, I2
b
= 0.002
S
a
(0) = 17987, S1a (0) = 856, S2a (0) = 154, Ia(0) = 25, I1a = 24, I2a = 4.0
These values correspond to the steady states of the model without interventions. The I1c ,
I2c , I1b and I2b are set as such so that the proportion of HIV in TB cases does not appear
as being zero initially.
For the model simulations, we use parameters in TABLE.5.1, TABLE. 5.2, TABLE. 3.5
and TABLE. 3.6.
The graphs for model simulations at baseline are in FIG. 5.5(a), FIG. 5.5(b), FIG. 5.5(c),
FIG. 5.5(d), FIG. 5.6(a) and FIG. 5.6(b).
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FIG. 5.5. Plots of HIV indicators at baseline
5.6.1 Short term effect of IMID and OSS
In this subsection, we run the model to determine the effect of IMID and combination of
IMID and OSS for the period of the intervention.
The cumulative number of HIV positive children at birth decreases with the interventions
as displayed by FIG. 5.7(a). On average, the percentage reduction in number of HIV
positive children at birth is 0.42 with IMID, 3.3 with IMID+OSS and the incremental
percentage reduction by OSS is 2.9 as illustrated in FIG. 5.7(b).
FIG. 5.7(c) shows an increase in the cumulative number of children who acquire HIV
through breastfeeding with the interventions as compared to baseline. A percentage in-
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FIG. 5.6. Prevalence of TB in 5.6(a) and TB deaths in Figure. 5.6(b)
crease of 1.5 occurs in that number with IMID and 8.25 with IMID+OSS on average. The
incremental increase of OSS is 6.7% and these results are shown in FIG. 5.7(d).
There is a fall in the cumulative number of individuals that get onto ART as illustrated in
FIG. 5.8(a) during the period of IMID and the combination of IMID and OSS interventions.
The number decreases by 0.037% with IMID and 4.2% with IMID+OSS on average. The
reduction due to OSS is 4.2%.
FIG. 5.8(c) demonstrates a very small decrease in the cumulative number of deaths for
individuals not on ART. It decreases by 0.0049% with IMID and 0.039% with IMID+OSS.
The incremental impact of OSS is a decline of 0.034% as displayed by FIG. 5.8(d).
FIG. 5.9(a) displays a decrease in the cumulative number of TB recovered individuals
during the intervention period. In FIG. 5.9(b), this number decreases by 6.9% with IMID
and it falls by 5.3% with the combination intervention. The incremental impact of OSS is
an increase by 1.63%.
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FIG. 5.7. The cumulative numbers of HIV positive children born and the effect of the
interventions are shown in FIG. 5.7(a) and FIG. 5.7(b) in turn. FIG. 5.7(c) and FIG. 5.7(d)
illustrate the cumulative numbers of children who get HIV infection through breastfeeding
and the effect of the interventions for the period of intervention.
5.6.2 Long term effect of IMID and OSS
HIV and TB are diseases that progress on a long time scale. It is thus important that the
model is run for a longer period to determine the effect of IMID and the combination of
IMID and OSS in the long term.
We simulated the model for an additional five years and the incidence used was extrapolated
using the nearest method in Matlab.
We plot averted numbers of HIV infections, deaths and gained numbers of TB recovered
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FIG. 5.8. The cumulative numbers of HIV positive individuals recruited onto ART and the
cumulative number of deaths in the group with no ART for the period of the interventions
are displayed in FIG. 5.8(a) and FIG. 5.8(c). The effect of the interventions on these are
given by FIG. 5.8(b) and FIG. 5.8(d).
with the interventions and the effect of the interventions for the additional five years.
Considering number of HIV infections at birth in FIG. 5.10(a), IMID averts about 7,
combination of IMID and OSS averts 57 and the incremental infections averted by OSS
are 50. The reduction in the number of HIV infections at birth is 0.58% with IMID and
4.58% with IMID and OSS on average and the incremental percentage reduction by OSS
is 4.03 in FIG. 5.10(b).
On the other hand, the interventions do not avert any HIV infections that occur through
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FIG. 5.9. FIG. 5.9(a) shows the cumulative number of TB individuals that recover for the
period of the intervention. FIG. 5.9(b) gives the effect of the intervention on TB recovered
individuals.
breastfeeding, infact the number of HIV infections through breastfeeding increase for the
period of the interventions as demonstrated by FIG. 5.10(c). 2 more HIV infections occur
during the period of the combination intervention of IMID and OSS.
In FIG. 5.10(d), the cumulative number of children who acquire HIV through breastfeeding
increases by 1.98% during period of IMID intervention. During the period of combination
intervention, this number rises by 11.1%. The incremental increase during OSS period is
8.95%.
A decline occurs in the cumulative number of individuals that get onto ART. This number
reduces by 9 with IMID+OSS and the incremental reduction by OSS is 8 in FIG. 5.11(a).
There is a decrease of 0.041% with IMID and 5.8% with IMID and OSS on average. The
average reduction for the OSS period is 5.7% as displayed by FIG. 5.11(b).
FIG. 5.11(c) shows a fall in the number of deaths averted for individuals not on ART. On
average, the number of deaths averted for individuals not on ART decreases by 0.003%
during IMID intervention and 0.032% during the combined intervention. The incremental
impact of OSS is a decline of 0.03% as illustrated by FIG. 5.11(d).
In FIG. 5.12(a), the number of TB recovered individuals decreases during the period of
the interventions as compared to baseline. This number decreases by 20.2% during IMID
and by 11.9% during IMID+OSS. The incremental impact of OSS is an increase by 8.34%.
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FIG. 5.10. FIG. 5.10(a) and FIG. 5.10(c) display the number of HIV infections that is
averted at birth and through breastfeeding. FIG. 5.10(b) and FIG. 5.10(d) show the long
term effect of the interventions on the cumulative number of HIV positive children at birth
and through breastfeeding respectively.
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FIG. 5.11. Gained number of individuals that get enrolled onto ART is shown in FIG.
5.11(a) and the number of deaths averted by CTX in group with no ART is given in FIG.
5.11(c). The effect of the intervention of ART enrolment and CTX are shown in FIG.
5.11(b) and FIG. 5.11(d) in turn.
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FIG. 5.12. FIG. 5.12(a) gives the gain in the number of TB recovered individuals with
the interventions and FIG. 5.12(b) shows the long term effect of the intervention on TB
recovered individuals.
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5.7 Discussion
We have explored the impact of IMID and IMID+OSS on HIV and TB in this Chapter
for the period of the intervention and an additional period of five years. The results have
demonstrated some gains with regards to the interventions in areas such as PMTCT for
HIV positive children at birth. However, in some other areas such as ART enrollment,
prevention of deaths in individuals not on ART by CTX and TB recoveries, there are little
or no gains. Infact, in some cases, the performance was poorer during the interventions as
compared to baseline.
HIV positive children The reduction in the cumulative number of HIV positive chil-
dren at birth can be attributed to the interventions’ increase in the testing of HIV positive
mothers during IMID+OSS and the increase in the proportion of mothers and infants en-
rolled into HIV care (refer to TABLE. 3.6). Though the proportion that receive ART for
either mothers or HIV exposed children reduces slightly with the interventions, the increase
in the testing and enrollment into HIV care proportions cause a positive impact of reducing
the number of HIV positive children born as evidenced both in the short term and long
term model simulations in FIG. 5.7(a) and FIG. 5.10(a). The results suggest that testing
HIV positive mothers and getting them and their infants into HIV care while maintaining
(or increasing) the proportion that gets onto ART leads to a reduction in the number of
HIV positive births.
On the other hand, the cumulative number of children infected with HIV through breast-
feeding increased during the period of the interventions (FIG. 5.7(c) and FIG. 5.10(c)).
The reason for this is that the proportion of HIV-exposed children and HIV positive moth-
ers who receive ART on delivery decreased during the IMID and IMID+OSS interventions
(refer to TABLE. 3.6).
ART and CTX The cumulative number of HIV infected individuals enrolled onto ART
reduced during the intervention period (FIG. 5.8(a) and FIG. 5.11(a)). This is because
the proportions of individuals getting onto ART decreased with the interventions (refer
to TABLE. 3.6). Though the proportion testing for HIV and enrolling into HIV care
Stellenbosch University  http://scholar.sun.ac.za
Chapter 5. HIV-TB Coinfection Model 125
increased, the interventions had no control over drug supplies and stock-outs and as such
could do nothing much on getting eligible HIV positive individuals onto ART. This result
demonstrates that training for HIV testing, treatment and care needs to be supplemented
with availability of drug supplies and equipment as was noted in [155]. Moreover, the
proportion of HIV positive individuals on ART in this setting is lower as compared to the
national average and this is an already noted concern in some studies [153, 193].
Given that there is almost no change in the proportion of HIV infected individuals that
receive CTX during the intervention period, as compared to baseline (refer to TABLE.
3.6), we have the cumulative number of deaths for HIV individuals not on ART decreasing
at the start of the interventions (FIG. 5.8(c) and FIG. 5.11(c)) and then increasing soon
after that start.
Note that the proportion of HIV positive individuals on CTX is high (≥ 0.9). However,
CTX is only accessible to HIV positive individuals who have tested for HIV and have been
enrolled into HIV care. The proportion of individuals who take an HIV test (≤ 0.2) and
those enrolled into HIV care (≤ 0.6) is small. This implies that the overall proportion of
HIV positive individuals on CTX will be small and thus the avertion of HIV deaths by use
of CTX will be negligible as suggested by our results.
TB recoveries For the period of the intervention, there is a very small decline in the
cumulative number of TB recovered individuals with the interventions as compared to
baseline (FIG. 5.9(a) and FIG. 5.12(a)). This is because the proportion of individuals who
initiated TB treatment is lower with IMID as compared to baseline where as it is higher
for IMID and OSS as compared to baseline (TABLE 3.5).
Note that though the proportion that complete treatment decreases with both interventions
and the proportion who initiate treatment falls with IMID, the proportion of individuals
who are tested as compared to baseline increases with both interventions (TABLE 3.5)
and this accounts for the increase in the cumulative number of TB recovered individuals
during the IMID+OSS intervention. This result highlights the importance of testing in
management of TB cases.
It is also important to note that the initial proportion of individuals tested for TB is
very small which sheds light on the state of the TB management in Uganda, where by
individuals are only tested for TB if they have symptoms [170], and there also a number
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of delays before patients are initiated on TB treatment [167, 168].
Study limitations There were a number of limitations of the study:
(i) We used the value of the proportion of HIV positive individuals tested as given by the
IDCAP data which was the testing proportion considering all outpatients whether
positive or negative. We think the testing proportion of HIV positive individuals
might be higher than for the general population, but we have no evidence to that
thus we used what IDCAP gave. Besides some of the sites were rural and testing
proportions are lower there. We assumed a testing proportion of 20% (as given in
[40]) that was a higher than the 7.2% for the outpatients but still used the same effect
on the proportion of testing as that given in the IDCAP data.
(ii) The effect of ART and PMTCT were not differentiated for pregnant women and we
used one average effect putting both of them into consideration.
(iii) For the proportion of HIV positive individuals on ART and on CTX, we considered
the proportion that is given for HIV-TB coinfected individuals. This is not so different
for other HIV infected individuals such as pregnant women. Moreover, HIV-TB coin-
fected individual are more likely to get CTX and ART as compared to other groups
and HIV pregnant women are fewer in number as compared to HIV-TB coinfected
individuals.
(iv) We lacked time series data for HIV and TB cases.
5.8 Summary.
In this section, we have investigated the transmission dynamics of HIV and TB coinfection.
We did a mathematical analysis for the sub models and proved the existence and stability
of endemic equilibria for both TB and HIV. It was noted that the TB model exhibited a
backward bifurcation phenomenon meaning that RT0 < 1 is not sufficient to eradicate the
disease.
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We then explored the effects of the interventions of IMID and IMID plus OSS for the
case management of HIV and TB. HIV testing and TB testing are important in improving
quality of health care. We also noted that training alone is not enough and government
effort in stocking health centres with drug supplies and equipment is crucial.
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HIV-TB-Malaria-Pneumonia
(HTMP) Model
6.1 Introduction
As a continuation of our investigation of the effect of IMID and the combined intervention
of IMID and OSS in an integrated way, we formulate a mathematical model that considers
all the four diseases: HIV, TB, malaria and pneumonia.
The construction of the HIV-TB-Malaria-Pneumonia (HTMP) model follows from Chap-
ters 4 and 5 that examined the coinfections of malaria and pneumonia and HIV and TB
respectively. In addition to those coinfections, we also consider coinfection of HIV and
malaria, HIV and pneumonia, TB and malaria, TB and pneumonia and three and more
coinfections such as HIV, TB and malaria. However, it is important to note that coinfec-
tions with more than two diseases are very rare and mostly occur in severely immunocom-
promised individuals [104, 108, 110, 190].
6.2 HTMP model
We merge our two models in Chapter 4 and Chapter 5, the model of malaria-pneumonia
coinfection with the one of HIV-TB coinfection to form the model with HIV, TB, malaria
and pneumonia (HTMP). The coinfections for TB-pneumonia and TB-malaria are rare
128
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and are only considered for model completion.
6.2.1 Model description
The non age structured HTMP model consists of 30 classes. There is a class of susceptible
individuals, S. S is made up of individuals that are susceptible to HIV, TB, malaria and
pneumonia infections. It also has individuals who are asymptomatic to malaria, pneumonia
and latent with TB and these are represented by proportions, m, p and e accordingly.
Infection with HIV represented by λH occurs taking individuals to S1. These get onto ART
(at a rate r
H
) to move to S2 and they fail ART at a rate fH .
Infection and reinfection with TB (λT ) occurs for the individuals in the susceptible class
sending them to active TB class, I. Individuals with latent TB, a proportion e of susceptible
class also reactivate TB infection at a rate ν and move to I. Individual in class I recover
at a rate r
T
. People with active TB may also be infected with HIV to go to I1 and some
of these get onto ART and move to I2.
In the respective classes of S, S1, S2, I, I1 and I2, individuals can get infected and reinfected
with either malaria (λ
vh
) or pneumonia (λ
P
) to progress to symptomatic disease of malaria,
M or pneumonia, P . While in the M or P class, people can get infected with pneumonia
or malaria in turn to move to malaria-pneumonia coinfection, PM . Symptomatic malaria
or pneumonia individuals can develop severe disease at rates α
M
, α
P
and α
PM
to move
to emergency class, P˜M and they get out of emergency class at a rate θ. Please note
that we have assumed that individuals with malaria and pneumonia do not get infected
or reinfected with TB or HIV because malaria and pneumonia are short term duration
diseases.
Recruitment occurs by birth and is represented by terms, B and B1. B is the recruitment
for HIV negative people and B1 accounts for HIV transmission at birth. HIV transmission
through breast feeding is represented by b
f
.
The death rate of individuals is given by µ with a subscript or without. The subscript
represents where the death is occurring.
The model diagram is given in FIG. 6.1 and the system of equations are (6.1a)–(6.1e),
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(6.2a)–(6.2e), (6.3a)–(6.3e), (6.4a)–(6.4e), (6.5a)–(6.5e),(6.6a)–(6.6e) and (6.7a)–(6.7b).
Please note that the description of the non age structured model is given for purposes of
comprehension and we do not use it to obtain any results in this chapter.
The HTMP model with age structure is an extension of the non age structured one. It
is divided into three age groups [0, 5), [5, 14) and [14, 50). Individuals age from [0, 5) to
[5, 14) at a rate η1, from [5, 14) to [14, 50) at a rate η2 and out of [14, 50) at a rate η3.
The parameters in this model are defined similarly as the ones in the model without age
structure except that they now have subscript j = c, b, a representing [0, 5), [5, 14) and
[14, 50) age groups respectively. When writing the equations for the age structured model,
we code c as equal to 1, b = 2 and a = 3 such that j = 1, 2, 3 stands for j = c, b, a in
that order. We do not use j = 1, 2, 3 directly because of the some of the parameters and
variables we have such as e1, e2, p1, p2, m1, m2, S1 and S2 already use the 1 and 2 and need
further differentiation with c, b, a to represent which group they are in. The equations of
the age structured HTMP model are given in appendix B.
We do not present model diagrams for the age groups, but considering model diagram FIG.
6.1, the one for the [0, 5) age group does not have the HIV transmission term λ
H
and there
is no movement from Ic to I1c . The rest of the in and out flows stay the same.
Model diagram for [5, 14) has no birth terms and no HIV transmission terms but the other
flows in and out are the same.
The diagram for [14, 50) has no birth terms, no HIV transmission through breastfeeding
but HIV transmission given by λ
H
and the rest of the flows in and out are the same.
All the model simulations in this chapter are obtained using the age structured model.
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FIG. 6.1. HTMP model diagram
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6.2.2 Model equations
Equations for HIV negative individuals
dS
dt
= B − b
f
+ r
P
P + r
M
M + zr
PM
PM + r
T
I − (λ
H
+ λ
T
e′ + νe)S (6.1a)
−(λ
P
p′ + ωp+ λ
vh
m′ + ϑm+ µ)S,
dP
dt
= (λ
P
p′ + ωp)S + z2rMPM + θq1P˜M − (λvhm
′ + ϑm)P (6.1b)
−(r
P
+ α
P
+ µ
P
)P,
dM
dt
= (λ
vh
m′ + ϑm)S + z1rPPM + θq2P˜M − (λP p
′ + ωp)M (6.1c)
−(r
M
+ α
M
+ µ
M
)M,
dPM
dt
= (λ
vh
m′ + ϑm)P + (λ
P
p′ + ωp)M + θqP˜M − zr
PM
PM (6.1d)
−(z1rP + z2rM + αPM + µPM )PM,
dP˜M
dt
= α
P
P + α
M
M + α
PM
PM − (θ + µ
P˜M
)P˜M. (6.1e)
dI
dt
= (λ
T
e′ + νe)S + r
P
IP + r
M
IM + zr
PM
IPM − r
T
I (6.2a)
−(λ
H
+ λ
P
p′ + ωp+ λ
vh
m′ + ϑm+ µ
I
)I,
dIP
dt
= (λ
P
p′ + ωp)I + z2rM IPM + θq1I˜PM − (rP + λvhm
′)IP (6.2b)
−(ϑm+ α
IP
+ µ
IP
)IP,
dIM
dt
= (λ
vh
m′ + ϑm)I + z1rP IPM + θq2I˜PM − (rM + λP p
′)IM (6.2c)
−(ωp+ α
IM
+ µ
IM
)IM,
dIPM
dt
= (λ
vh
m′ + ϑm)IP + (λ
P
p′ + ωp)IM + θqI˜PM − zr
PM
IPM (6.2d)
−(z2rM + z1rP + αIPM + µIPM )IPM,
dI˜PM
dt
= α
IP
IP + α
IM
IM + α
IPM
IPM − (θ + µ
I˜PM
)I˜PM. (6.2e)
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Equations for HIV positive not on ART
dS1
dt
= B1 + bf + λHS + fHS2 + rP1S1P + rM1S1M + zrPMS1PM + rT I1 (6.3a)
−(λ
P
p′1 + ω1p+ λvhm
′
1 + ϑ1m+ λT e
′
1 + ν1e+ rH )S1
−(µ
0
(1− γps) + µ1γps)S1,
dS1P
dt
= (λ
P
p′1 + ω1p)S1 + z2rM1S1PM + θq1S˜1PM − rP1S1P (6.3b)
−(λ
vh
m′1 + ϑ1m+ αS1P + µS1P )S1P,
dS1M
dt
= (λ
vh
m′1 + ϑ1m)S1 + z1rP1S1PM + θq2S˜1PM − rM1S1M (6.3c)
−(λ
P
p′1 + ω1p+ αS1M + µS1M )S1M,
dS1PM
dt
= (λ
vh
m′1 + ϑ1m)S1P + (λP p
′
1 + ω1p)S1M + θqS˜1PM + zrPMS1PM (6.3d)
−(z1rP1 + z2rM1 + αS1PM + µS1PM )S1PM,
dS˜1PM
dt
= α
S1P
S1P + αS1MS1M + αS1PMS1PM − (θ + µS˜1PM
)S˜1PM. (6.3e)
dI1
dt
= λ
H
I + (λ
T
e′1 + ν1e)S1 + fHI2 + rP1 I1P + rM1 I1M + zrPM I1PM (6.4a)
−(λ
P
p′1 + ω1p+ λvhm
′
1 + ϑ1m)I1 − (rH
1
+ µ
I1c0
(1− γps))I1
−(µ
I1c1
γps + rT
1
)I1,
dI1P
dt
= (λ
P
p′1 + ω1p)I1 + z2rM1 I1PM + θq1I˜1PM − rP1 I1P (6.4b)
−(λ
vh
m′1 + ϑ1m+ αI1P + µI1P )I1P,
dI1M
dt
= (λ
vh
m′1 + ϑ1m)I1 + z1rP1 I1PM + θq2I˜1PM − rM1 I1M (6.4c)
−(λ
P
p′1 + ω1p+ αI1M + µI1M )I1M,
dI1PM
dt
= (λ
vh
m′1 + ϑ1m)I1P + (λP p
′
1 + ω1p)I1M + θqI˜1PM (6.4d)
−(zr
PM
+ z1rP1 + z2rM1 + αI1PM + µI1PM )I1PM,
dI˜1PM
dt
= α
I1P
I1P + αI1M I1M + αI1PM I1PM − (θ + µI˜1PM
)I˜1PM. (6.4e)
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Equations for HIV positive on ART
dS2
dt
= r
H
S1 + rP2S2P + rM2S2M + zrPMS2PM + rT2
I2 − fHS2 (6.5a)
−(λ
P
p′2 + ω2p+ λvhm
′
2 + ϑ2m+ λT e
′
2 + ν2e+ µS2 )S2,
dS2P
dt
= (λ
P
p′2 + ω2p)S2 + z2rM2S2PM + θq1S˜2PM − rP2S2P (6.5b)
−(λ
vh
m′2 + ϑ2m+ αS2P + µS2P )S2P,
dS2M
dt
= (λ
vh
m′2 + ϑ2m)S2 + z1rP2S2PM + θq2S˜2PM − rM2S2M (6.5c)
−(λ
P
p′2 + ω2 + αS2M + µS2M )S2M,
dS2PM
dt
= (λ
vh
m′2 + ϑ2m)S2P + (λP p
′
2 + ω2)S2M + θqS˜2PM (6.5d)
−(zr
PM
+ z1r
M2
+ z2r
P2
+ α
S2PM
+ µ
S2PM
)S2PM,
dS˜2PM
dt
= α
S2P
S2P + αS2MS2M + αS2PMS2PM − (θ + µS˜2PM
)S˜2PM. (6.5e)
dI2
dt
= (λ
T
e′2 + ν2e)S2 + rH
1
I1 + rP2 I2P + rM2 I2M + zrPM I2PM (6.6a)
−(r
T
2
+ f
H
+ λ
P
p′2 + ω2p+ λvhm
′
2 + ϑ2m+ µI2 )I2,
dI2P
dt
= (λ
P
p′2 + ω2p)I2 + z2rM2 I2PM + θq1I˜2PM − rP2 I2P (6.6b)
−(λ
vh
m′2 + ϑ2m+ αI2P + µI2P )I2P,
dI2M
dt
= (λ
vh
m′2 + ϑ2m)I2 + z1rP2 I2PM + θq2I˜2PM − rM2 I2M (6.6c)
−(λ
P
p′2 + ω2p+ αI2M + µI2M )I2M,
dI2PM
dt
= (λ
vh
m′2 + ϑ2m)I2P + (λP p
′
2 + ω2p)I2M + θqI˜2PM (6.6d)
−(zr
PM
+ z1rP2 + z2rM2 + αI2PM + µI2PM )I2PM,
dI˜2PM
dt
= α
I2P
I2P + αI2M I2M + αI2PM I2PM − (θ + µI˜2PM
)I˜2PM. (6.6e)
The mosquito dynamics are given by:
dSv
dt
= bv − (λhvc + λhvb
+ λ
hva
)Sv − µvSv , (6.7a)
dIv
dt
= (λ
hvc
+ λ
hv
b
+ λ
hva
)Sv − µvIv . (6.7b)
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Considering the system of equations (6.1a)–(6.1e), (6.2a)–(6.2e), (6.3a)–(6.3e), (6.4a)–
(6.4e), (6.5a)–(6.5e),(6.6a)–(6.6e), (6.7a)–(6.7b), we have the following definitions:
p′1 = (γpsp1 + (1− γps)p0), p1 = (1− p)p
1
1 + pp
1
2, p0 = (1− p)p
0
1 + pp
0
2.
m′1 = (γpsm1 + (1− γps)m0), m1 = (1−m)m
1
1 +mm
1
2, m0 = (1−m)m
0
1 +mm
0
2.
e′1 = (γpse1 + (1− γps)e0), e1 = (1− e)e
1
1 + ee
1
2, e0 = (1− e)e
0
1 + ee
0
2.
where:
(i) 0 represents not on CTX and 1 represents being on CTX for the respective asymp-
tomatic and symptomatic classes.
p01, m
0
1, e
0
1 are the proportions of new infections that become symptomatic for HIV
infected individuals not on CTX for pneumonia, malaria and TB respectively.
p11, m
1
1, e
1
1 are the proportions of new infections that become symptomatic for HIV
infected individuals on CTX for pneumonia, malaria and TB accordingly.
(ii) p02, m
0
2, e
0
2 are the proportions of reinfections that become symptomatic for HIV
infected individuals not on CTX for pneumonia, malaria and TB respectively.
p12, m
1
2, e
1
2 are the proportions of reinfections that become symptomatic for HIV
infected individuals on CTX for pneumonia, malaria and TB in turn.
(iii) λ
H
= β
H
IH/N . βH is the infection rate for HIV. IH is the HIV infected human
population and N is the total human population.
(iv) λ
T
= (β
T
I
T
+β
TH
I
TH
)/N . β
T
is the rate at which HIV negative active TB individuals
pass on infection and β
TH
at which coinfected HIV-TB individuals transmit the TB
infection.
(v) λ
vh
= β
vh
Iv/N . βvh is the rate at which a vector (mosquito) infects a human, Iv is
the infected vector (mosquito) population and N is the human population.
(vi) λ
hv
= β
hv
(I
M
/N), β
hv
is the rate at which a vector (mosquito) becomes infected
by biting an infected human and IM is the human population infected with malaria
and it is made up of all the malaria individuals including those with asymptomatic
malaria infection.
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(vii) λ
P
= β
p
I
P
/N . β
p
is the infection rate for pneumonia. I
P
is the infected pneumonia
population and it is made up of all the pneumonia individuals including those with
asymptomatic pneumonia infection.
6.3 Coinfections
This section deals with the other coinfections that have not been studied in detail. It
is important to note that the prescence of HIV infection plays an important role in the
occurrence of coinfections. We consider the effect of coinfections on infection, recovery,
mortality and morbidity of patients and the effect of treatment such as ART and CTX
when administered to coinfected patients.
6.3.1 HIV-malaria coinfection
HIV increases the risk of malaria infection and the development of clinical malaria, both
uncomplicated and severe [1, 72, 83, 104, 174]. HIV and malaria coinfection was associated
with clinical episodes of malaria in a Ugandan study [63] and increase in malarial fever
was noted with advanced HIV infection [72].
The increase in infection rates and malarial fevers in HIV individuals coinfected with
malaria is approximately 2-fold when compared to HIV infected individuals without malaria.
There is also evidence of increased viral load if an HIV infected individual has malaria [15].
ART and CTX use reduce the incidence of malaria in HIV positive individuals [36, 121, 163].
The reduction of malaria incidence by CTX ranges between 30% to 82% [121, 194] and
that of ART ranges from 40% to 93% [121].
6.3.2 HIV-pneumonia coinfection
HIV infection is considered a risk factor for pneumonia both in adults and children [70, 113].
The most causative agent is S. pneumoniae whose colonisation is increased by HIV infection
[70, 113, 209]. Other causative agents include Staphylococcus aureus and Gram-negative
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bacteria and Pneumocystis jirovecii (PCP) [68, 70]. In a Ugandan study, the prevalence of
oropharyngeal colonization with pneumococci was 18% in HIV infected patients [22].
Incidence of pneumonia is higher in HIV infected individuals than in HIV uninfected indi-
viduals [56, 173, 181, 182] and it increases with falling CD4 cell count [56, 78, 136]. The
risk of invasive disease due to S. pneumoniae was estimated to be 40 times more in HIV
infected children than HIV negative children [68] and about 25 times higher in HIV infected
adults than HIV negative ones [56].
The rate of pneumonia episodes was 0.055 per year for HIV positive and 0.009 for HIV
negative [78]. The rates of pneumonia per year ranged from 0.023 to 0.108 for CD4 cell
count of > 500/mm3 to < 200/mm3 and the rate was 0.02 per year for HIV negative
individuals [78, 136].
Mortality due to pneumonia is higher in HIV positive individuals than in uninfected people
[173, 182]. There is a three to six fold increase in mortality for HIV infected individuals
with pneumonia than those that do not have it [182, 209]. The case fatality rate for acute
pneumonia in HIV infected children is 3 to 6 times more than that for HIV negative children
[68].
Increased access to ART has lead to a decrease in pneumonia morbidity and mortality [70,
113, 182]. A decrease in the range 0.0082 to 0.016 rate of pneumonia in AIDS patients per
year in the pre-HAART era to the range 0.0019 to 0.0042 after the introduction of HAART
occurred. This is about 4 times reduction in rate of pneumonia with ART. Incidence of
pneumonia requiring hospitalization reduced from 1.4 to a range 0.035 to 0.08 because of
HAART. Bacteremia incident episodes decreased from 0.0118 in the pre HAART era to a
range 0.005 to 0.0063 in the post HAART era [136].
CTX also reduces the morbidity with pneumonia by 65% in HIV positive individuals eligible
for ART [123, 131, 208].
6.3.3 TB-malaria or TB-pneumonia
TB coinfection with malaria is very rare and has very little documention. TB coinfection
with pneumonia is also rare but there are a few case studies that have looked at individuals
with both TB and pneumonia [130, 169]. It is important to note that these individuals
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had other infections such as Influenza and HIV. This highlights the role that HIV plays in
coinfections.
6.3.4 Three or more coinfections
These are rare but can occur in very immunocompromised patients. With HIV infection,
it is relatively common for infected individuals to have mixed pulmonary infections. Some
studies looked at HIV infected individuals with HIV, TB and pneumonia [110, 165]. In
[133], a study to characterize the coinfections of HIV with TB and malaria was done. HIV-
malaria and HIV-TB-malaria were the least prevalent. HIV-TB coinfection was the most
deadliest, followed by HIV-TB-malaria. In [164], some of the HIV infected children with
culture positive TB also had pneumonia.
There is very limited literature on the effects of three or more coinfections and for this
reason, we will refer to HIV and its effect when part of a coinfection and the rest of the
effects will be assumed.
6.4 Parameters of the HTMP model
Most of the parameters used in the numerical simulations for this model remain the same
as those in Chapters 3 and 4 except for the progression to disease proportions, reactivation
rates and mortality rates.
Even though there is evidence suggesting that HIV positive individuals are more suscepti-
ble to malaria infection [77, 92, 195] and more colonisation by S. pneumoniae [70, 113, 209],
we do not differentiate the infection rate between HIV positive and HIV negative individ-
uals. However, we consider that the proportions that develop disease after infection and
reinfection and those that reactivate to disease are higher for HIV positive individuals than
for HIV negative individuals.
We assume that the reactivation rate for HIV positive individuals is increased by 6 times
for both HIV coinfected individuals with malaria and pneumonia and the proportions that
progress to disease are increased by 4 times.
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ART reduces the reactivation rates and proportions that progress to disease by 50% and
CTX reduces these rates and proportions by 40% [36, 121, 163, 194]. Note that higher
reductions by ART and CTX consider individuals who are eligible for ART but for our
case we consider the average for all the HIV positive individuals and thus we use an a lower
percentage reduction.
Mortality is increased by 6 times for HIV individuals coinfected with pneumonia as com-
pared to HIV positive individuals without pneumonia [182, 209].
For mortality in HIV-malaria coinfected individuals, we assume that it is 5 times that of
HIV positive individuals without malaria. Please note that though there are documenta-
tions about the higher risks in mortality, morbidity for HIV-malaria coinfected individuals,
concrete values about how much being HIV positive increases one’s mortality or morbidity
rates are not given [77, 92, 195].
There is conflicting evidence about recovery from malaria in HIV-malaria coinfected in-
dividuals [77]. However, in a study carried out in Uganda [92], results suggested that
HIV-malaria coinfected individuals had a lower recovery rate than those that had HIV
only. Nevertheless, for our model simulations, we did not differentiate the recovery rates
between HIV positive and HIV negative individuals.
This model has very many parameters and in some instances, we considered some of the
parameters to be constant for both HIV positive and HIV negative individuals if it was
within reason, for example, the recovery rates. Also note that though some literature
exists on HIV coinfections, it is mostly comparison between HIV negative and HIV positive
individuals and not necessarily a comparison between HIV positive and HIV-coinfected.
6.5 Model simulations
In this section, we simulate the age-structured HTMPmodel given by equations in appendix
B. We run simulations for baseline and those for the effect of IMID and combination of
IMID and OSS. However we need to take note of some of the mathematical challenges that
this model faces
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6.5.1 Numerical challenges
Please note that the HTMP model has two different time scales and this presents numerical
challenges. Malaria and pneumonia occur in the order of days while HIV and TB dynamics
are in order of years. In such cases, the steady-state approximation is used (as was done
in [107]) and this leads to the formation of differential algebraic equations. These are stiff
ODEs and are solved by using non-standard numerical methods. However, Matlab software
can solve differential algebraic equations of index 1 [171].
The steady-state approximation is generalised by the slow manifold theory and the singular
perturbation theory [25]. The slow manifold theory is such that the curves and surfaces
that arise from the steady-state approximation can be understood as approximations to
slow invariant manifolds of the differential equations.
On the other hand, the singular perturbation theory is such that a small parameter that
multiplies a derivative is considered.
For our case, we did not consider a steady-state approximation for malaria and pneumonia
because we had to use the change in mosquito dynamics to fit the malaria data that
we have. Thus, we used an intermediate time scale of months for malaria, pneumonia,
HIV and TB. This solved the stiffness problem and gave reasonable results. Besides, the
interventions were evaluated in period of months and not days or years.
6.5.2 Baseline graphs
The HTMP model is calibrated to have a similar baseline to that of malaria-pneumonia
coinfection and HIV-TB coinfection models. FIG. 6.2(a), FIG. 6.2(b), FIG. 6.2(c) and FIG.
6.2(d) show baseline HIV and TB prevalence, malaria and pneumonia cases respectively.
FIG. 6.3(a), FIG. 6.3(b), FIG. 6.3(c) and FIG. 6.3(d) also show the proportion of TB
diseased individuals with HIV, proportion of HIV individuals with malaria, proportion of
HIV individuals with pneumonia and proportion of pneumonia individuals with TB.
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6. HIV-TB-Malaria-Pneumonia Model 141
0 5 10 15 20 25
0
1
2
3
4
5
6
Time (months)
H
IV
 p
re
va
le
nc
e 
(%
)
 
 
[0,5)
[5,14)
[14,50)
(a)
0 5 10 15 20 25
0
50
100
150
200
250
300
Time (months)
TB
 p
re
va
le
nc
e 
/1
00
00
0
 
 
[0,5)
[5,14)
[14,50)
(b)
0 5 10 15 20 25
50
100
150
200
250
300
Time (months)
M
al
ar
ia
 c
as
es
 
 
 
[0,5)
[5,14)
[14,50)
(c)
0 5 10 15 20 25
0
10
20
30
40
50
60
70
Time (months)
Pn
eu
m
on
ia
 c
as
es
 
 
 
[0,5)
[5,14)
[14,50)
(d)
FIG. 6.2. Baseline indicators for HIV, TB, malaria and pneumonia.
6.5.3 Effect of IMID and OSS
In this subsection we run simulations of the cumulative number of deaths in HIV, TB,
malaria and pneumonia and estimate the effect of IMID and combined intervention of
IMID and OSS on these.
The cumulative number of malaria deaths decreases with the two interventions as shown
in FIG. 6.4(a). During the period of IMID, this number decreases by about 5 deaths and it
decreases by 32 deaths during the combined intervention of IMID and OSS. The percentage
reduction by IMID is 4.0, that of the combined intervention is 24.6 and the incremental
percentage reduction is 21.5 on average. This is displayed by FIG. 6.4(b).
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FIG. 6.3. Proportions of coinfection disease
FIG. 6.4(c) shows that IMID and IMID+OSS lead to a fall in the cumulative number of
pneumonia deaths. On average, this number is reduced by 14 deaths for IMID, 64 deaths
by IMID+OSS. The mean reduction by IMID on the number of deaths is 4.1%, that of
IMID+OSS is 18.7% and the added reduction by OSS alone is 15.3%.
FIG. 6.5(a) shows a decrease in the cumulative number of HIV deaths with the interven-
tions. In FIG. 6.5(b), the number of HIV deaths is reduced by 0.085% during IMID period
and it declines by 0.47% for IMID+OSS. The incremental decrease by OSS is 0.39%.
FIG. 6.5(c) displays a decline in the cumulative TB deaths for the duration of the inter-
ventions. The results in FIG. 6.5(d) give the estimated reduction by IMID as 0.11% on
average, that by IMID+OSS as 0.35% and that by OSS alone as 0.23%.
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FIG. 6.4. Cumulative numbers of deaths in malaria and pneumonia and the effect of IMID
and OSS on malaria deaths and pneumonia deaths
The cumulative number of TB recovered individuals decreases during the period of the
interventions as demonstrated by in FIG. 6.9(c). The percentage increase by IMID is 0.43,
that of IMID and OSS is 0.21% and the added percentage increase by OSS is 0.22
In FIG. 6.6(a), the cumulative number of individuals going onto ART decreases with the
two interventions with the fall being more with the combined intervention of IMID and
OSS. There is about 1 individual less going onto ART for IMID+OSS. In FIG. 6.6(b), the
percentage decrease by IMID is 0.013%, that of the combined intervention is 3.9% and the
incremental reduction by OSS is 3.9%.
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FIG. 6.5. Cumulative numbers of deaths in HIV and TB and the effect of IMID and OSS
on HIV deaths and TB deaths
6.5.4 Investigating Scenarios
We then consider an hypothetical situation of having 25% effect by IMID on the indicators
followed by 25% effect by IMID+OSS on the indicators, with 100% coverage for the period
of the intervention.
Since the performance indicators (TABLE. 3.4 and TABLE. 3.5) are given in terms of
proportions, we make sure that they do not go beyond 1. Thus the only proportions that
get a 25% effect by IMID, followed by 25% effect by OSS are those ≤ 0.64.
For those greater than 0.64 but ≤ 0.79, we apply the 25% effect by IMID, followed by an
effect of OSS that results into a proportion of 1.
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FIG. 6.6. Cumulative numbers of individuals enrolled onto ART, TB recovered individuals
in FIG. 6.6(a) and FIG. 6.6(c). The effects of IMID, IMID and OSS and the incremental
impacts of OSS are shown in in FIG. 6.6(b) and in FIG. 6.6(c) respectively.
For those greater than 0.79, we only apply the effect by IMID that takes them to a pro-
portion of 1 and no effect by OSS.
With the baseline as the reference, the proportions that are ≤ 0.64 will have a 25% effect
by IMID and 56.3% effect by IMID+OSS.
For our numerical simulations, we consider the number of deaths averted for malaria,
pneumonia, HIV and TB. We also run simulations for gains in number of individuals that
go onto ART and gain in number of TB recovered individuals with the interventions.
The number of malaria deaths decreases with the two interventions as shown in FIG.
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FIG. 6.7. Averted deaths for malaria and pneumonia with the interventions in FIG. 6.7(a)
and FIG. 6.7(c). FIG. 6.7(b) and FIG. 6.7(d) given the effects of the two interventions on
malaria and pneumonia deaths respectively.
6.7(a). It decreases by 34 deaths with IMID, 53 deaths with IMID+OSS and 19 deaths
with OSS only. On average, the percentage reduction by IMID is 25.6, that of the combined
intervention is 40.8 and the incremental percentage reduction is 21.6 as displayed by FIG.
6.7(b).
FIG. 6.7(c) shows that IMID and IMID+OSS lead to a fall in the number of pneumonia
deaths. IMID averts 88 deaths, combined intervention averts 138 deaths and OSS only
averts 50 deaths. IMID decreases the number of pneumonia deaths by 25.8%, IMID+OSS
reduces it by 41% and the reduction by OSS only is 21.8%.
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6. HIV-TB-Malaria-Pneumonia Model 147
0
1
2
3
4
5
H
IV
 d
ea
th
s 
av
er
te
d
 
 
IMID−base
IMID+OSS−base
OSS−IMID
(a)
0 5 10 15 20 25
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
Time (months)
Ef
fe
ct
 o
n 
HI
V 
de
at
hs
 
 
IMID+OSS
IMID
Incremental (OSS)
(b)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
TB
 d
ea
th
s 
av
er
te
d
 
 
IMID−base
IMID+OSS−base
OSS−IMID
(c)
0 5 10 15 20 25
0
0.01
0.02
0.03
0.04
0.05
Time (months)
Ef
fe
ct
 o
n 
TB
 d
ea
th
s
 
 
IMID+OSS
IMID
Incremental (OSS)
(d)
FIG. 6.8. HIV and TB deaths averted with the interventions of IMID and IMID plus OSS
in FIG. 6.8(a) and FIG. 6.8(c). The effects of IMID and OSS on HIV deaths and TB
deaths are shown in FIG. 6.8(b) and FIG. 6.8(d)
On average, 3 HIV deaths are averted during IMID, 5 deaths are averted during IMID+OSS
and 2 deaths are averted by OSS only as shown in FIG. 6.8(a). The average effect of IMID
on HIV deaths is a reduction of 1.2%, that by IMID+OSS is 2.0% and the incremental
decrease by OSS only is 0.87%.
FIG. 6.8(c) shows that IMID and OSS averts one TB death but with most of this being as
a result of IMID and not OSS. The estimated mean reduction by IMID is 2.2%, that by
IMID and OSS is 2.7% and the incremental decrease by OSS is 0.57%.
In FIG. 6.9(a), 1 more individual is enrolled onto ART by IMID+OSS intervention as
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FIG. 6.9. Cumulative numbers of individuals enrolled onto ART, TB recovered individuals
in FIG. 6.9(a) and FIG. 6.9(c). The effects of IMID, IMID and OSS and the incremental
impacts of OSS are shown in in FIG. 6.9(b) and in FIG. 6.9(c) respectively.
compared to baseline. OSS contributes more for ART enrollment. The effect of IMID is
an increase of 1.7%, that for IMID and OSS is 2.7% and the incremental impact by OSS
is an increase by 1.98% as shown in FIG. 6.9(b).
The number of TB recovered individuals increases by 1 with IMID as compared to baseline
and by 2 with the combined intervention as compared to baseline in FIG. 6.9(c). The
percentage increase by IMID is 2.7, that of IMID and OSS is 7.2% and the added percentage
increase by OSS is 4.6
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6.6 Discussion
We have explored the effect of IMID and OSS on HIV, TB, malaria and pneumonia using an
integrated infectious diseases model that we developed. We have simulated the model with
the actual effects of IMID and combination intervention of IMID and OSS to investigate
the effect of the interventions on the cumulative number of deaths resulting from the
four diseases, the cumulative number of individuals who are enrolled onto ART, and the
cumulative number of individuals who recover from TB. We also investigated a scenario
of having a 25% effect of IMID followed by a 25% effect of IMID+OSS on performance
indicators with 100% coverage, and simulated results.
Malaria and pneumonia Considering results for malaria and pneumonia, it is clear
that the two interventions are effective in reducing the number of deaths.
Increasing the coverage and effect of the two interventions leads to more reduction in
the number of deaths as demonstrated by the hypothetical situation. This reduction as
discussed in Chapter 3 is due to the improvement in the performance indicators (TABLE
3.4) by the two interventions.
OSS performs better than IMID with the actual effects on the indicators as well as with
the hypothetical situation. This is as expected because practical training should add value
to classroom training.
HIV and TB The interventions reduce the number of HIV deaths with more reduction
noted with the combined intervention of IMID and OSS. This decrease is more pronounced
when we consider the hypothetical situation.
The reduction in the number of HIV deaths would be as a result of rolling out of ART
as this increases the life expectancy of HIV positive individuals. Note that the proportion
that are on ART with the two interventions are lower than the baseline proportion but
only slightly and even though they are lower, the proportion of adult individuals ([14, 50))
tested for HIV increases with the interventions. This increase offsets some of the decrease
in the ART proportions which results in a higher number of individuals on ART with the
interventions than at baseline, and this leads to aversion of HIV deaths.
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On the other hand, the number of TB deaths are changed negligibly by the interventions.
In the hypothetical situation, the number of deaths just reduces by 1 which shows that
even with 100% coverage of interventions and increase in the effect of the interventions,
there is little effect on mortality of TB individuals.
The reason for this is that the proportion of TB patients that reports to the clinic, propor-
tion which is tested and treated is small (all < 0.45). This is the major problem facing the
TB management health system in Uganda [167, 168]. There are a number of delays such
as patient delay (patients do not report to the health centres early), health system delays
[170] and as such the baseline proportions of TB patients reporting, tested and treated are
low. This is worsened by the fact that most of the clinics in our study were in rural areas.
The implication for this is that even if coverage of training of MLPs in TB case manage-
ment is increased, the mentioned barriers and problems need to be addressed if the training
is to have considerable impact.
ART enrollment Results with the actual effects of IMID and OSS on the performance
indicators show a decrease in the number of HIV positive individuals enrolled onto ART.
This is because the interventions are purely training interventions with no other additives
such as ascertaining availability of drug supplies. Though the interventions increase the
number that are tested and those that get into HIV care, they can not do anything about
getting them onto ART when there are no drugs available. This has been noted as one of
the barriers of ART provision and ART coverage [94].
However, when we consider the hypothetical situation of a 25% effect on IMID and OSS,
there are some improvements seen which shows that if there are drugs are available then
more individuals will be able to get onto ART.
TB recoveries The actual results on the cumulative number of TB recovereds show that
there is a decrease in this number with the interventions as compared to baseline. It is
more with IMID than with IMID+OSS. This is because the the proportion that initiated
treatment declined with IMID but increased with IMID+OSS as compared to baseline and
the proportion of individuals that completed treatment decreased during the period of both
interventions.
When coverage of the interventions is increased to 100% and the effects on the performance
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indicators are increased by 25%, 2 more active TB individuals recover with reference to
baseline. Though the number of TB recovered individuals is small, the result proposes
that increasing the coverage of training interventions can have positive impacts on patient
recovery. However, the gains in TB recoveries are still small and this poses the same
concern about the barriers that are experienced by the TB case management system in
Uganda that have been noted in other studies [167, 168, 170].
Study limitations One of the limitations that we had for this study were that there were
no integrated data which calls for more advances in integrated health services. Although
there have been some efforts with HIV-TB services [139, 153] and some work with malaria-
pneumonia [54, 75, 98], a lot more needs to be done.
The other limitation was the limited literature on some coinfections such as TB-pneumonia,
TB-malaria and coinfections with three or more diseases. This presented a huge problem
when searching for parameter values.
6.7 Summary
In this Chapter, we have developed a model of four infectious diseases: HIV, TB, malaria
and pneumonia (HTMP model). We have given an overview of the existing coinfections
and have parametrised the model in accordance to being HIV positive or HIV negative.
We simulated the HTMP model for the effect of IMID, combination effect of IMID and
OSS on the integrated management of the four diseases in terms of deaths, ART enrollment
and TB recovery. The results have demonstrated that training of MLPs and maintaining
or increasing the coverage of training has the potential to improve quality of health care
and to yield gains in survival and reduce the morbidity of patients. However, they also
highlight that training alone is not enough and other factors such as availability of drug
supplies and equipment are necessary for a substantial effect.
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Conclusions and Recommendations
In this thesis, we have investigated the effect of two training interventions on infectious dis-
eases by formulating and studying three mathematical models: one that describes malaria-
pneumonia coinfection, a second that considers HIV-TB coinfection and lastly, one that
incorporates all the four diseases together. A qualitative analysis of the non age structured
sub models of malaria, pneumonia, HIV and TB was done and also the effects of the two
training interventions, IMID and IMID+OSS, together with the incremental impact of OSS
on malaria-pneumonia coinfection, HIV-TB coinfection were estimated. These results are
presented in Chapters 4, 5 and 6 of this thesis.
An overview of the results in Chapter 4 is as follows:
(i) Mathematical analysis of the non age structured model of malaria showed that it had
a DFE withm = 0. Depending on the value of the infection rate from human to vector
and the death rate of the mosquito, the results proposed that there is existence of a
unique endemic equilibrium that is locally asymptotically stable whenever RM0 > 1 or
possibility of the phenomenon of backward bifurcation in which the epidemiological
requirement of disease eradication of RM0 < 1 no longer holds.
(ii) The analysis of the non age structured model of pneumonia showed that it had a DFE
with p = 0 and a unique endemic equilibrium that is locally asymptotically stable
whenever RP0 > 1. This means that pneumonia disease will persist in the population
if the reproductive number is greater than unity and it will die out if it is less than
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unity.
(iii) The mathematical analysis was performed for the small models of malaria and pneu-
monia with constant parameters and not for the models with time dependent param-
eters. The results of these models are limited in their implications on the models with
time dependent parameters. Nevertheless, we did gain some useful insights from the
analysis.
(iv) IMID and IMID with OSS lead to a reduction in the number of cases, deaths and no
change in disease incidence for malaria and pneumonia.
(v) Triaging contributes a lot to the effect of training of MLPs. It contributes more than
50% to that effect in reduction of deaths and its contribution ranges from 14% to
63% in reduction of disease cases.
(vi) Overall, training of MLPs has a positive effect on patient outcomes such as morbidity
and mortality but not on the incidence of disease episodes. This shows the usefulness
of case management interventions and highlights the importance of prevention of
transmission interventions.
Conclusions from Chapter 5 are given below:
(i) The qualitative analysis of the model of HIV only showed that it has an endemic
equilibrium that is locally asymptotically stable. This implies that for parameters
that give RH0 > 1, we have disease persisting in the population.
(ii) The qualitative analysis of the model of TB showed that it had multiple endemic
equilibria and exhibited backward bifurcation. The implication of this occurrence is
that the classical epidemiological requirement for effective eradication of TB, RT0 to
be less than one, is no longer sufficient, even though necessary. In fact, for the disease
to be eradicated, the reproductive number must be smaller than a critical value less
than one.
(iii) The cumulative number of HIV positive babies at birth decreased, the cumulative
number of HIV exposed babies that got HIV positive through breastfeeding increased
during the period of the interventions of IMID and IMID+OSS. IMID and IMID+OSS
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also decreased the cumulative number of TB recovered, the cumulative number going
onto ART and decreased the cumulative number of deaths in individuals not onto
ART for the period of the intervention.
(iv) For the additional five years, most of the effects of IMID and those of the combination
intervention of IMID and OSS stayed the same except for the case of the cumulative
number of deaths of HIV positive individuals not on ART which increased with the
interventions as compared to baseline.
(v) Increase in proportion of individuals tested for HIV testing and TB testing plays a
major role in getting patients into HIV care or TB care and even if the proportions
that initiate TB treatment and ART decrease slightly, considerable reduction in HIV
infections and increase in recovered TB individuals is seen.
(vi) The results highlighted the problem of the health system delays in management of
TB patients and also the unavailability of drugs that delay ART initiation and CTX
provision.
Conclusions from Chapter 6 are given below:
(i) Merging of all the four diseases into the HTMP model and running simulations for
the cumulative number of deaths yielded similar results as those that were obtained
in the Chapters 4 and 5.
(ii) The hypothetical situation of using 100% coverage of the interventions and a 25%
effect on IMID and OSS indicators yielded more positive impact on patient outcomes
of mortality and morbidity.
Conclusions overall
(i) Training of MLPs has the potential to improve quality of health care and improve
patient outcomes such as mortality and morbidity. Moreover, for diseases such as
malaria and pneumonia, training of MLPs is very effective because there is already a
good baseline (performance indicator proportions are high) to start with.
However for TB and HIV where the baseline is not good (performance indicator
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proportions are low), training is not enough and other problems such as patient and
health system delays for TB patients, availability of drugs and equipment supplies
need to be addressed.
7.1 Contribution
(i) This is the first time a model using non-linear ordinary differential equations has
been formulated to explicitly study the effect of training interventions. The model
was used to estimate the effect of two training interventions on infectious diseases of
malaria, pneumonia, HIV and TB relating it to patient outcomes such as mortality
and morbidity.
It has the advantage that it incorporates the transmission dynamics of the diseases.
It also used most of the available information such as Spectrum software, Uganda
HIV reports and WHO reports.
(ii) Modelling of malaria-pneumonia coinfection and modelling of four diseases together is
novel. Numerical simulations using the malaria-pneumonia coinfection model showed
that triaging contributes more than 50% to the effect of training of MLPs in the
reduction of deaths. The malaria-pneumonia coinfection model showed that a life
per month is saved for children under five years of age with the implementation of
the training interventions. Furthermore, it was shown that there was no change in
incidence of diseases even though there was a reduction in the number of cases.
Numerical simulations for the HTMP model suggested that increasing the coverage
of the interventions and their effect, increased the number of patient recoveries even
in the current state of lack of adequate drugs, supplies and equipment.
(iii) Incorporation of the effect of CTX in a mathematical model is also an addition to
knowledge. The model displayed a reduction in the number of HIV positive deaths
by CTX initially but since the coverage of CTX remained almost unchanged for
the entire period of the intervention, the number of HIV positive deaths started to
increase after some time.
(iv) Fitting the malaria and pneumonia model to data using an optimization tool built in
Matlab and estimating certain parameters is also an added advantage of our work as
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most of the mathematical models are simulated without using data.
7.2 Limitations and future research
These were the limitations that we faced in this study:
(i) Lack of data for validation of models is a limitation. In our study, we relied mostly
on malaria data when modelling the malaria-pneumonia coinfection and there were
no time series data for HIV and TB.
(ii) For HIV and TB, we used parameter values for certain groups of individuals such as
the coinfected HIV-TB individuals to represent all the HIV positive individuals.
(iii) There was limited literature on coinfections of TB with pneumonia or malaria and
also little literature on three or more coinfections and this presented a problem in our
search for parameter values.
For future research, the following can be considered:
(i) Having separate classes for symptomatic and asymptomatic individuals.
(ii) Differentiating the effect of ART from that of PMTCT.
(iii) Modelling the effect of CTX explicitly.
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Centre Manifold Theorem
Theorem A.0.1 Consider the following general system of ordinary differential equations
with a parameter, φ
dx
dt
= f(x, φ), f : Rn × R→ R and f ∈ C2(Rn × R),
where 0 is an equilibrium point of the system (that is, f(0, φ) ≡ 0 for all φ) and assume
A1: A = Dxf(0, 0) = (
∂fi
∂xi
(0, 0)) is the linearisation matrix of the system (3.1) around the
equilibrium, 0 with φ evaluated at 0. Zero is a simple eigenvalue of A and other eigenvalues
of A have negative real parts;
A2: Matrix A has a right eigenvector w and a left eigenvector v (each corresponding to the
zero eigenvalue).
Let fr be the r
th component of f and
a =
n∑
r,i,j=1
vrwiwj
∂2fr
∂xi∂xj
(0, 0),
b =
n∑
r,i=1
vrwi
∂2fr
∂xi∂φ
(0, 0).
The local dynamics of the system around 0 is totally determined by the signs of a and b.
1. a > 0, b > 0. When φ < 0 with |φ| << 1, 0 is locally asymptotically stable and
there exists a positive unstable equilibrium; when 0 < φ << 1, 0 is unstable and there
exists a negative, locally asymptotically stable equilibrium;
2. a < 0, b < 0. When φ < 0 with |φ| << 1, 0 is unstable; when 0 < φ << 1, 0 is
locally asymptotically stable, and there exists a positive unstable equilibrium;
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3. a > 0, b < 0. When φ < 0 with |φ| << 1, 0 is unstable; and there exists a locally
asymptotically stable equilibrium; when 0 < φ << 1, 0 is stable, and a positive
unstable equilibrium appears;
4. a < 0, b > 0. When φ changes from negative to positive, 0 changes its stability from
stable to unstable. Correspondingly a negative unstable equilibrium becomes positive
and locally asymptotically stable.
Particularly, if a > 0, b > 0, then a backward bifurcation occurs at φ = 0.
We apply Theorem A.0.1 to the system of equations of malaria, pneumonia, HIV and TB.
A.1 Malaria
The Jacobian of the shifted system of equations (4.1a)–(4.1e) at β
vh
= β∗
vh
has the following
eigenvalues,{
0,−µ,−µ
v
,−1
2
(
−K10 ±
1
K
√
(K(−4KK∗5 − 4K11µv +KK
2
10)
) }
,
where
K10 = (θM + rM + αM + µM + µM˜ + µv),
K11 = α
2
M
+ (θ
M
+ µ
M˜
)2 + α
M
(2θ
M
+ r
M
+ µ
M
+ µ2
M
),
and K, K∗5 have been defined in equations (4.4a) and (4.6b) respectively.
We find the right and left eigenvectors associated with the zero eigenvalue. The right
eigenvector, w = [w1, w2, w3, w4, w5]
T is given as:
w1 = −
Bµ2
v
K1
µ2bvβhvK
, w2 =
Bµ2
v
(θ
M
+ µ
M˜
)
µbvβhvK
, w3 =
Bα
M
µ2
v
µbvβhvK
, w4 = −1, w5 = 1.
The left eigenvector, v = [v1, v2, v3, v4, v5]
T is given as:
v1 = 0, v2 =
bvµβhvK
Bµ
v
K∗5
, v3 =
bvµβhv(θM + rM + αM + µM )
Bµ
v
K∗5
, v4 = 0, v5 = 1.
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where K,K1 and K
∗
5 are defined in equations (4.4a) and (4.6b).
We then compute a and b. We look for the non-zero partial derivatives of f at DFE. Since
v1 = 0, v4 = 0 then the partial derivatives of f1 and f4 will cancel out after substitution.
For calculation of a, the partial derivatives of f3 also vanish. The remaining non-vanishing
partial derivatives of f2 and f5 are:
∂2f2
∂x1∂x2
=
∂2f2
∂x2∂x1
=
∂2f2
∂x1∂x3
=
∂2f2
∂x3∂x1
=
m1µ
2bvβvh
B2µv
.
∂2f2
(∂x2)2
=
∂2f2
∂x2∂x3
=
∂2f2
∂x3∂x2
=
∂2f2
(∂x3)2
=
2m1µ
2bvβvh
B2µv
.
∂2f2
∂x2∂x5
=
∂2f2
∂x5∂x2
=
∂2f2
∂x5∂x3
=
∂2f2
∂x3∂x5
= −
m1βvhµ
B
.
∂2f5
∂x2∂x4
=
∂2f5
∂x3∂x4
=
∂2f5
∂x4∂x2
=
∂2f5
∂x4∂x3
=
β
vh
µ
B
.
For the computation of b, the non-zero partial derivatives are given by:
∂2f2
∂x2∂β∗vh
=
∂2f2
∂x3∂β∗vh
= −
m1µbv
Bµv
,
∂2f2
∂x5∂β∗vh
= m1.
A.2 Pneumonia
The Jacobian of the shifted system of equations (4.7a)–(4.7c) at β
P
= β∗
P
has the following
eigenvalues, {
0,−µ,−
α2
P
+(θ
P
+µ
P˜
)2+α
P
(2θ
P
+r
P
+µ
P
+µ
P˜
)
θ
P
+α
P
+µ
P˜
}
.
We find the right and left eigenvectors associated with the zero eigenvalue. The right
eigenvector, w = [w1, w2, w3]
T is given as:
w1 = −
θ
P
µ
P
+ µ
P˜
(α
P
+ µ
P
)
µα
P
, w2 =
θ
P
+ µ
P˜
α
P
, w3 = 1.
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The left eigenvector, v = [v1, v2, v3]
T is given as:
v1 = −µ, v2 = v3 = 0.
To calculate a and b, we look for the non-vanishing partial derivatives of f at DFE. Since
v2 = 0, v3 = 0, then the partial derivatives of f2 and f3 will cancel out after substitution.
For computation of a, the non-zero partial derivatives of f1 are:
∂2f1
(∂x2)2
=
∂2f1
∂x2∂x3
=
∂2f1
∂x3∂x2
=
∂2f1
(∂x3)2
=
2p1µβP
B
.
For the computation of b, the non-vanishing partial derivatives are given by:
∂2f1
∂x2∂β∗P
=
∂2f1
∂x3∂β∗P
= −p1.
A.3 HIV
The Jacobian of shifted system of equations (5.2a)–(5.2c) at β
H
= β∗
H
has the following
eigenvalues, {
0,−µ,−
f2
H
+2f
H
r
H
+r2
H
+r
H
µ
S1
+2f
H
µ
S2
+r
H
µ
S2
+µ2
S2
f
H
+r
H
+µ
S2
}
.
We find the right and left eigenvectors associated with the zero eigenvalue.
The right eigenvector, w = [w1, w2, w3]
T is given as:
w1 = −
f
H
µ
S1
+ r
H
µ
S2
+ µ
S1
µ
S2
µr
H
,
w2 =
f
H
+ µ
S2
r
H
,
w3 = 1.
The left eigenvector, v = [v1, v2, v3]
T is given as:
v1 = 0,
v2 =
f
H
+ r
H
+ µ
S2
f
H
+ r
H
+ µ
S1
,
v3 = 1.
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To compute a and b, we find the non-zero partial derivatives of f at DFE. Since v1 = 0,
then the partial derivatives of f1 will cancel out after substitution.
For calculation of a, we use the non-zero partial derivatives of f1 and these are:
∂2f2
∂x1∂x2
=
β
H
(B − µ)
B
,
∂2f2
∂x1∂x3
=
β
H
(B − µ)
B
,
∂2f2
∂x2∂x1
=
β
H
(B − µ)
B
,
∂2f2
(∂x2)2
= −
2β
H
µ
B
,
∂2f2
∂x2∂x3
=
β
H
(B − µ)
B
,
∂2f2
∂x3∂x1
=
β
H
(B − µ)
B
,
∂2f2
∂x3∂x2
=
β
H
(B − µ)
B
,
∂2f2
(∂x3)2
= −
2β
H
µ
B
.
For the computation of b, the non-zero partial derivatives are given by:
∂2f2
∂x2∂β∗H
= 1,
∂2f2
∂x3∂β∗H
= 1.
A.4 TB
The Jacobian of the shifted system of equations (5.4a)–(5.4b) at β
T
= β∗
T
has the following
eigenvalues: {
0,−µ
}
.
We find the right and left eigenvectors associated with the zero eigenvalue. The right
eigenvector, w = [w1, w2]
T is given as:
w1 =
−µ
I
µ
,
w2 = 1.
The left eigenvector, v = [v1, v2]
T is given as:
v1 = 1,
v2 = 0.
We then compute a and b. We look for the non-zero partial derivatives of f at DFE. Since
v2 = 0, then the partial derivatives of f2 will cancel out after substitution. The non-zero
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partial derivatives of f1 are:
∂2f1
∂x2∂x1
= −e1βT +
e1βTµ
B
,
∂2f1
(∂x2)2
=
2e1µβT
B
.
For the computation of b, we look for the non-zero partial derivatives of f at DFE. We
neglect the partial derivatives of f1 since v1 = 0. Thus the non-zero partial derivatives are
given by:
∂2f2
∂x2∂β∗T
=
e1µ
B
.
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Appendix B
HTMP Model Equations
In this section, we present the model equations for the age-structured model of HIV, TB,
malaria and pneumonia.
dSc
dt
= B − b
f
+ r
Pc
Pc + rMcMc + zrPMcPMc + rTc Ic − (λTc e
′
c + νec)Sc (B.1a)
−(λ
Pc
p′c + ωpc + λvhcm
′
c + ϑmc + µSc + η1)Sc ,
dS
b
dt
= η1Sc + rP
b
P
b
+ r
M
b
M
b
+ zr
PM
b
PM
b
+ r
T
b
I
b
− (λ
T
b
e′b + νeb)Sb (B.1b)
−(λ
P
b
p′b + ωpb + λM
b
m′b + ϑmb + µS
b
+ η2)Sb
dSa
dt
= η2Sb − λHSa + rPaPa + rMaMa + zrPMaPMa + rTa Ia − λTa e
′
aSa (B.1c)
−(νea + λPa p
′
a + ωpa + λMam
′
a + ϑma + µSa + η3)Sa ,
dPc
dt
= (λ
Pc
p′c + ωpc)Sc + z2rMcPMc + θ1q1P˜Mc − (λvhcm
′
c + ϑmc)Pc (B.1d)
−(r
Pc
+ α
Pc
+ µ
Pc
+ η1)Pc ,
dP
j
dt
= ηiPj−1 + (λP
j
p′j + ωpj)Sj + z2rM
j
PMj + θ1q1P˜Mj − λvh
j
m′jPj (B.1e)
−(ϑmj + rP
j
+ α
P
j
+ µ
P
j
+ ηi+1)Pj , j = b, a, i = 1, 2
dMc
dt
= (λ
vhc
m′c + ϑmc)Sc + z1rPcPMc + θ2q2P˜Mc − (λPc p
′
c + ωpc)Mc (B.1f)
−(r
Mc
+ α
Mc
+ µ
Mc
+ η1)Mc ,
dM
j
dt
= ηiMj−1 + (λvh
j
m′j + ϑmj)Sj + z1rP
j
PM
j
+ θ2q2P˜Mj − λP
j
p′jMj (B.1g)
−(ωpj + rM
j
+ α
M
j
+ µ
M
j
+ ηi+1)Mj ,
dPMc
dt
= (λ
vhc
m′c + ϑmc)Pc + (λPc p
′
c + ωpc)Mc + θqP˜Mc − zrPMcPMc (B.1h)
−(z1rPc + z2rMc + αPMc + µPMc + η1)PMc ,
dPM
j
dt
= ηiPMj−1 + (λvh
j
m′j + ϑmj)Pj + (λP
j
p′j + ωpj)Mj + θqP˜Mj (B.1i)
−(zr
PM
j
+ z1rP
j
+ z2rM
j
+ α
PM
j
+ µ
PM
j
+ ηi+1)PMj ,
dP˜Mc
dt
= α
Pc
Pc + αMcMc + αPMcPMc − (θ + µP˜Mc
+ η1)P˜Mc . (B.1j)
dP˜M
j
dt
= ηiPMj−1 + αP
j
P
j
+ α
M
j
M
j
+ α
PM
j
PM
j
− (θ + µ
P˜M
j
+ ηj+1)P˜Mj . (B.1k)
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dIc
dt
= (λ
Tc
e′c + νec)Sc + rPc IPc + rMc IMc + zrPMc IPMc − rTc Ic (B.2a)
−(λ
Pc
p′c + ωpc + λvhcm
′
c + ϑmc + µIc + η1)Ic ,
dI
b
dt
= η1Ic + (λT
b
e′b + νeb)Sb + rP
b
IP
b
+ r
M
b
IM
b
+ zr
PM
b
IPM
b
− r
T
b
I
b
(B.2b)
−(λ
P
b
p′b + ωpb + λM
b
m′b + ϑmb + µI
b
+ η2)Ib ,
dIa
dt
= η2Ib + (λTa e
′
a + νea)Sa + rPa IPa + rMa IMa + zrPMa IPMa − rTa Ia (B.2c)
−(λ
H
+ λ
Pa
p′a + ωpa + λMam
′
a + ϑma + µIa + η3)Ia ,
dIPc
dt
= (λ
Pc
p′c + ωpc)Ic + z2rMc IPMc + θ1q1I˜PMc − (rPc + λvhcm
′
c)IPc (B.2d)
−(ϑmc + αIPc + µIPc + η1)IPc ,
dIP
j
dt
= ηiIPj−1 + (λP
j
p′j + ωpj)Ij + z2rM
j
IPM
j
+ θ1q1I˜PMj − rP
j
IP
j
(B.2e)
−(λ
vh
j
m′j + ϑmj + αIP
j
+ µ
IP
j
+ ηi+1)IPj ,
dIMc
dt
= (λ
vhc
m′c + ϑmc)Ic + z1rPc IPMc + θ2q2I˜PMc − (rMc + λPc p
′
c)IMc (B.2f)
−(ωpc + αIMc + µIMc + η1)IMc ,
dIM
j
dt
= ηiIMj−1 + (λvh
j
m′j + ϑmj)Ij + z1rP
j
IPMj + θ2q2I˜PMj − rM
j
IMc (B.2g)
−(λ
P
j
p′j + ωpj + αIM
j
+ µ
IM
j
+ ηi+1)IMj ,
dIPMc
dt
= (λ
vhc
m′c + ϑmc)IPc + (λPc p
′
c + ωpc)IMc + θqI˜PMc − zrPMc IPMc (B.2h)
−(z2rMc + z1rPc + αIPMc + µIPMc + η1)IPMc ,
dIPMj
dt
= ηiIPMj−1 + (λvh
j
m′j + ϑmj)IPj + (λP
j
p′j + ωpj)IMj + θqI˜PMj (B.2i)
−(zr
PM
j
IPM
j
+ z2rM
j
+ z1rP
j
+ α
IPM
j
+ µ
IPM
j
+ ηi+1)IPMj ,
dI˜PMc
dt
= α
IPc
IPc + αIMc IMc + αIPMc IPMc − (θ + µI˜PMc
+ η1)I˜PMc , (B.2j)
dI˜PMj
dt
= ηiIPMj−1 + αIP
j
IPj + αIM
j
IMj + αIPM
j
IPMj − θI˜PMj (B.2k)
−(µ
I˜PM
j
+ ηi+1)I˜PMj .
Stellenbosch University  http://scholar.sun.ac.za
Appendix B: HTMP Model Equations 166
dS1c
dt
= B1 + bf + fHcS2c + rP1c
S1Pc + rM1
c
S1Mc + zrPMc S1PMc + rTc I1c (B.3a)
−(λ
Pc
p′1c + ω1pc)S1c − (λvhcm
′
1c + ϑ1mc + λTc e
′
1c + ν1ec)S1c
−(r
Hc
+ (µ
0
(1− γps) + µ1γps) + η1)S1c ,
dS1
b
dt
= η1S1c + fHb
S2
b
+ r
P1
b
S1Pb + rM1
b
S1Mb + zrPM
b
S1PMb + rT
b
I1
b
(B.3b)
−(λ
P
b
p′1b + ω1pb)S1b − (λMb
m′1b + ϑ1mb + λT
b
e′1b + ν1eb)S1b
−(r
H
b
+ (µ
0
(1− γps) + µ1γps) + η2)S1b ,
dS1a
dt
= η2S1
b
+ λ
H
Sa + fHaS2a + rP1a
S1Pa + rM1
a
S1Ma + zrPMaS1PMa (B.3c)
+r
Ta
I1a − (λPa p
′
1a + ω1pa)S1a − (λMam
′
1a + ϑ1ma + λTa e
′
1a)S1a
−(ν1ea + rHa + (µ0(1− γps) + µ1γps) + η3)S1a ,
dS1Pc
dt
= (λ
Pc
p′1c + ω1pc)S1c + z2rM1
c
S1PMc + θ1q1S˜1PMc − rP1
c
S1Pc (B.3d)
−(λ
vhc
m′1c + ϑ1mc + αS1Pc + µS1Pc + η1)S1Pc ,
dS1Pj
dt
= ηiS1Pj−1 + (λP
j
p′1j + ω1pj)S1j + z2rM1
j
S1PMj + θ1q1S˜1PMj (B.3e)
−(r
P1
j
+ λ
vh
j
m′1j + ϑ1mj + αS1Pj
+ µ
S1Pj
+ ηi+1)S1Pj ,
dS1Mc
dt
= (λ
vhc
m′1c + ϑ1mc)S1c + z1rP1
c
S1PMc + θ2q2S˜1PMc − rM1
c
S1Mc (B.3f)
−(λ
Pc
p′1c + ω1pc + αS1Mc + µS1Mc + η1)S1Mc ,
dS1Mj
dt
= ηiS1Mj−1 + (λvh
j
m′1j + ϑ1mj)S1j + z1rP1
j
S1PMj + θ2q2S˜1PMj (B.3g)
−(r
M1
j
+ λ
P
j
p′1j + ω1pj + αS1Mj
+ µ
S1Mj
+ ηi+1)S1Mj ,
dS1PMc
dt
= (λ
vhc
m′1c + ϑ1mc)S1Pc + (λPc p
′
1c + ω1pc)S1Mc + θqS˜1PMc (B.3h)
−(zr
PMc
+ z1rP1
c
+ z2rM1
c
+ α
S1PMc
+ µ
S1PMc
+ η1)S1PMc ,
dS1PMj
dt
= ηiS1PMj−1 + (λvh
j
m′1j + ϑ1mj)S1Pj + (λP
j
p′1j + ω1pj)S1Mj (B.3i)
+θqS˜1PMj − (zrPM
j
+ z1rP1
j
+ z2rM1
j
+ α
S1PMj
+ µ
S1PMj
)S1PMj
−ηi+1S1PMj ,
dS˜1PMc
dt
= α
S1Pc
S1Pc + αS1Mc S1Mc + αS1PMcS1PMc − (θ + µ ˜S1PMc
)S˜1PMc (B.3j)
−η1S˜1PMc ,
dS˜1PMj
dt
= ηiS1PMj−1 + αS1Pj
S1Pj + αS1Mj
S1Mj + αS1PMj
S1PMj (B.3k)
−(θ + µ
˜S1PMj
+ ηi+1)S˜1PMj .
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dI1c
dt
= (λ
Tc
e′1c + ν1ec)S1c + fH2
c
I2c + rP1
c
I1Pc + rM1
c
I1Mc + zrPMc I1PMc (B.4a)
−(λ
Pc
p′1c + ω1pc + λvhcm
′
1c + ϑ1mc)I1c − (rHc + µI1c0
(1− γps))I1c
−(µ
I1c1
γps + rT1
c
+ η1)I1c ,
dI1
b
dt
= η1I1c + (λTb
e′1b + ν1eb)S1b + fH2
b
I2
b
+ r
P1
b
I1Pb + rM1
b
I1Mb (B.4b)
+zr
PM
b
I1PMb − (λP
b
p′1b + ω1pb + λM
b
m′1b + ϑ1mb)I1b − rHb
I1
b
−(µ
I1
b0
(1− γps) + µI1
b1
γps + rT1
b
+ η1)I1
b
,
dI1a
dt
= η2I1
b
+ λ
H
Ia + (λTa e
′
1a + ν1ea)S1a + fH2
a
I2a + rP1
a
I1Pa + rM1
a
I1Ma (B.4c)
+zr
PMa
I1PMa − (λPa p
′
1a + ω1pa + λMam
′
1a + ϑ1ma)I1a − rHa I1a
−(µ
I1a0
(1− γps) + µI1a1
γps + rT1
a
+ η1)I1a ,
dI1Pc
dt
= (λ
Pc
p′1c + ω1pc)I1c + rM1
c
I1PMc + θ1q1I˜1PMc − rP1
c
I1Pc (B.4d)
−(λ
vhc
m′1c + ϑ1mc + αI1Pc + µI1Pc + η1)I1Pc ,
dI1Pj
dt
= ηiI1Pj−1 + (λP
j
p′1j + ω1pj)I1j + z2rM1
j
I1PMj + θ1q1I˜1PMj (B.4e)
−(r
P1
j
+ λ
vh
j
m′1j + ϑ1mj + αI1Pj
+ µ
I1Pj
+ ηi+1)I1Pj ,
dI1Mc
dt
= (λ
vhc
m′1c + ϑ1mc)I1c + rP1
c
I1PMc + θ2q2I˜1PMc − rM1
c
I1Mc (B.4f)
−(λ
Pc
p′1c + ω1pc + αI1Mc + µI1Mc + η1)I1Mc ,
dI1Mj
dt
= ηiI1Mj−1 + (λvh
j
m′1j + ϑ1mj)I1j + z1rP1
j
I1PMj + θ2q2I˜1PMj (B.4g)
−(r
M1
j
+ λ
P
j
p′1j + ω1pj + αI1Mj
+ µ
I1Mj
+ ηi+1)I1Mj ,
dI1PMc
dt
= (λ
vhc
m′1c + ϑ1mc)I1Pc + (λPc p
′
1c + ω1pc)I1Mc + θqI˜1PMc (B.4h)
−(zr
PMc
+ z1rP1
c
+ z2rM1
c
+ α
I1PMc
+ µ
I1PMc
+ η1)I1PMc ,
dI1PMj
dt
= ηiI1PMj + (λvh
j
m′1j + ϑ1mj)I1Pj + (λP
j
p′1j + ω1pj)I1Mj (B.4i)
+θqI˜1PMj − (zrPM
j
+ z1r
P1
j
+ z2r
M1
j
+ α
I1PMj
+ µ
I1PMj
I1PMj
−ηi+1I1PMj ,
dI˜1PMc
dt
= α
I1Pc
I1Pc + αI1Mc I1Mc + αI1PMc I1PMc − (θ + µ ˜I1PMc
)I˜1PMc (B.4j)
−η1I˜1PMc ,
dI˜1PMj
dt
= ηi ˜I1PMj−1 + αI1Pc I1Pc + αI1Mc I1Mc + αI1PMc I1PMc − θI˜1PMc (B.4k)
−(µ
˜I1PMc
+ ηi+1)I˜1PMc .
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dS2c
dt
= r
Hc
S1c + rP2
c
S2Pc + rM2
c
S2Mc + zrPMc S2PMc + rTc I2c − fHcS2c (B.5a)
−(λ
Pc
p′2c + ω2pc + λvhcm
′
2c + ϑ2mc + λTc e
′
2c + ν2ec + µS2c
)S2c
−η1S2c ,
dS2
j
dt
= ηiS2
j−1
+ r
H
j
S1
j
+ r
P2
j
S2Pj + rM2
j
S2Mj + zrPM
j
S2PMj + rT
j
I2
j
(B.5b)
−(f
H
j
+ λ
P
j
p′2j + ω2pj + λvh
j
m′2j + ϑ2mj + λT
j
e′2j + ν2ej)S2j
−(µ
S2
j
+ ηi+1)S2
j
,
dS2Pc
dt
= (λ
Pc
p′2c + ω2pc)S2c + z2rM2
c
S2PMc + θ1q1S˜2PMc − rP2
c
S2Pc (B.5c)
−(λ
vhc
m′2c + ϑ2mc + αS2Pc + µS2Pc + η1)S2Pc ,
dS2Pj
dt
= ηiS2Pj−1 + (λP
j
p′2j + ω2pj)S2j + z2rM2
j
S2PMj + θ1q1S˜2PMj (B.5d)
−(r
P2
j
+ λ
vh
j
m′2j + ϑ2mj + αS2Pj
+ µ
S2Pj
+ ηi+1)S2Pj ,
dS2Mc
dt
= (λ
vhc
m′2c + ϑ2mc)S2c + z1rP2
c
S2PMc + θ2q2S˜2Mc − rM2
c
S2Mc (B.5e)
−(λ
Pc
p′2c + ω2pc + αS2Mc + µS2Mc + η1)S2Mc ,
dS2Mj
dt
= ηiS2Mj−1 + (λvh
j
m′2j + ϑ2mj)S2j + z1rP2
j
S2PMj + θ2q2S˜2Mj (B.5f)
−(r
M2
j
+ λ
P
j
p′2j + ω2pj + αS2Mj
+ µ
S2Mj
+ ηi+1)S2Mj ,
dS2PMc
dt
= (λ
vhc
m′2c + ϑ2mc)S2Pc + (λPc p
′
2c + ω2pc)S2Mc + θqS˜2PMc (B.5g)
−(zr
PMc
+ z1r
M2
c
+ z2r
P2
c
+ α
S2PMc
+ µ
S2PMc
+ η1)S2PMc ,
dS2PMj
dt
= ηiS2PMj−1 + (λvh
j
m′2j + ϑ2mj)S2Pj + (λP
j
p′2j + ω2pj)S2Mj (B.5h)
+θqS˜2PMj − (zrPM
j
+ z1rM2
j
+ z2rP2
j
+ α
S2PMj
+ µ
S2PMj
)S2PMj
−η1S2PMj ,
dS˜2PMc
dt
= α
S2Pc
S2Pc + αS2Mc S2Mc + αS2PMcS2PMc − (θ + µ ˜S2PMc
)S˜2PMc (B.5i)
−η1S˜2PMc .
dS˜2PMj
dt
= ηiS2PMj−1 + αS2Pj
S2Pj + αS2Mj
S2Mj + αS2PMj
S2PMj (B.5j)
−(θ + µ
˜S2PMj
+ ηi+1)S˜2PMj .
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dI2c
dt
= (λ
Tc
e′2c + ν2ec)S2c + rH2
c
I1c + rP2
c
I2Pc + rM2
c
I2Mc + zrPMc I2PMc (B.6a)
−(r
T2
c
+ f
H2
c
+ λ
Pc
p′2c + ω2pc + λvhcm
′
2c + ϑ2mc + µI2c
)I2c
−η1I2c ,
dI2j
dt
= ηiI2j−1 + (λTj
e′2j + ν2ej)S2j + rH2
j
I1j + rP2
j
I2Pj + rM2
j
I2Mj (B.6b)
+zr
PM
j
I2PMj − (rT2
j
+ f
H2
j
+ λ
P
j
p′2j + ω2pj + λvh
j
m′2j + ϑ2mj)I2j
−(µ
I2
j
+ ηi+1)I2
j
,
dI2Pc
dt
= (λ
Pc
p′2c + ω2pc)I2c + z2rM2
c
I2PMc + θq1I˜2PMc − rP2
c
I2Pc (B.6c)
−(λ
vhc
m′2c + ϑ2mc + αI2Pc + µI2Pc + η1)I2Pc ,
dI2Pj
dt
= ηiI2Pj−1 + (λP
j
p′2j + ω2pj)I2j + z2rM2
j
I2PMj + θq1I˜2PMj (B.6d)
−(r
P2
j
+ λ
vh
j
m′2j + ϑ2mj + αI2Pj
+ µ
I2Pj
+ ηi+1)I2Pj ,
dI2Mc
dt
= (λ
vhc
m′2c + ϑ2mc)I2c + z1rP2
c
I2PMc + θ2q2I˜2PMc − rM2
c
I2Mc (B.6e)
−(λ
Pc
p′2c + ω2pc + αI2Mc + µI2Mc + η1)I2Mc ,
dI2Mj
dt
= ηiI2Mj−1 + (λvh
j
m′2j + ϑ2mj)I2j + z1rP2
j
I2PMj + θ2q2I˜2PMj (B.6f)
−(r
M2
j
+ λ
P
j
p′2j + ω2pj + αI2Mj
+ µ
I2Mj
+ ηi+1)I2Mj ,
dI2PMc
dt
= (λ
vhc
m′2c + ϑ2mc)I2Pc + (λPc p
′
2c + ω2pc)I2Mc + θqI˜2PMc (B.6g)
−(zr
PMc
+ z1rP2
c
+ z2rM2
c
+ α
I2PMc
+ µ
I2PMc
+ η1)I2PMc ,
dI2PMj
dt
= ηiI2PMj−1 + (λvh
j
m′2j + ϑ2mj)I2Pj + (λP
j
p′2j + ω2pj)I2Mj (B.6h)
+θqI˜2PMj − (zrPM
j
+ z1rP2
j
+ z2rM2
j
+ α
I2PMj
+ µ
I2PMj
)I2PMj
−ηi+1I2PMj ,
dI˜2PMc
dt
= α
I2Pc
I2Pc + αI2Mc I2Mc + αI2PMc I2PMc − (θ + µ ˜I2PMc
)I˜2PMc (B.6i)
−η1I˜2PMc ,
dI˜2PMj
dt
= ηi ˜I2PMj−1 + αI2Pj
I2Pj + αI2Mj
I2Mj + αI2PMj
I2PMj − θI˜2PMj (B.6j)
−(µ
˜I2PMj
+ ηi+1)I˜2PMj .
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The mosquito dynamics are given by
dSv
dt
= bv − (λhvc + λhvb
+ λ
hva
)S
v
− µ
v
S
v
, (B.7a)
dIv
dt
= (λ
hvc
+ λ
hv
b
+ λ
hva
)Sv − µvIv . (B.7b)
With the system of equations (B.1a)–(B.1k), (B.2a)–(B.2k), (B.3a)–(B.3k), (B.4a)–(B.4k),
(B.5a)–(B.5j),(B.6a)–(B.6j) and (B.7a)–(B.7b), we have the following definitions:
p′1j = (γpsp1j + (1− γps)p0j), p1j = pp
1
2j + (1− p)p
1
1j , p0j = pp
0
2j + (1− p)p
0
1j.
m′1j = (γpsm1j + (1− γps)m0j), m1j = mm
1
2j + (1−m)m
1
1j , m0j = mm
0
2j + (1−m)m
0
1j .
e′1j = (γpse
′
1j + (1− γps)e
′
0j), e1j = ee
1
2j + (1− e)e
1
1j , e0j = ee
0
2j + (1− e)e
0
1j .
where j = c, b, a stands for the age groups [0, 5), [5, 14) and [14, 50) respectively. 0 rep-
resents not being on CTX and 1 represents being on CTX for the respective latent and
symptomatic classes. The other definitions are:
i p01j , m
0
1j , e
0
1j are the proportions of new infections of pneumonia, malaria and TB
respectively that become symptomatic for HIV infected individuals not on CTX.
ii p11j , m
1
1j , e
1
1j are the proportions of new infections of pneumonia, malaria and TB in
turn that become symptomatic for HIV infected individuals on CTX.
iii p02j , m
0
2j , e
0
2j are the proportions of reinfections of pneumonia, malaria and TB accord-
ingly that become symptomatic for HIV infected individuals not on CTX.
iv p12j ,m
1
2j , e
1
2j are the proportions of reinfections of pneumonia, malaria and TB respective
that become symptomatic for HIV infected individuals on CTX.
v λ
H
j
= β
H
j
IH/N . βH
j
is the infection rate for HIV. IH is the HIV infected human
population and N is the total human population. Note that β
Hc
= β
H
b
= 0 thus
λ
Hc
= λ
H
b
= 0.
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vi λ
T
j
= (β
T
j
I
T
+β
TH
j
I
TH
)/N . β
T
j
is the rate at which HIV negative active TB individuals
pass on infection for the respective age groups and β
TH
j
at which coinfected HIV-TB
individuals transmit the TB infection.
vii λ
vh
j
= β
vh
j
Iv/N . βvh
j
is the rate at which a vector (mosquito) infects a human, Iv is
the infected vector (mosquito) population and N is the human population.
viii λ
hv
j
= β
hv
j
(I
M
/N). β
hv
j
is the rate at which a vector (mosquito) becomes infected by
biting an infected human and IM is the human population infected with malaria.
ix λ
P
j
= β
P
j
I
P
/N . β
P
j
is the rate at which individuals acquire pneumonia infection and
I
P
is the infected pneumonia population.
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